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Scope of the thesis
All blood cells are derived from a self-renewing population of pluripotent 
hematopoietic stem cells (HSCs). Each HSC has the potential to progressively 
differentiate into more committed progenitors to generate the mature cells. 
Hematopoietic differentiation is characterized by a concomitant activation and 
repression of specific transcriptional programs, accompanied by changes at the 
chromatin structure level. The cellular environment including signaling molecules and 
growth factors and, ultimately, transcription factors regulate the complex balance of 
proliferation of HSCs and progenitors versus terminal differentiation and growth arrest. 
Transcription factors bind directly to regulatory elements to modulate gene expression 
in combination with additional ubiquitous or tissue-restricted transcription factors, 
and/or by tethering co-factors such as chromatin remodeling and/or modifying enzymes. 
Gene targeting and ectopic expression of transcription factors have highlighted their 
function, however such approaches do not not directly address their molecular basis. 
Identification of transcription factor-interacting partners and their molecular function 
will therefore provide a detailed characterization of the protein regulatory network, 
essential for a better understanding of the molecular mechanisms underlying their 
function in hematopoiesis. This has been the focus of the work of my thesis. 
Characterization of protein complexes from mammalian cells requires the 
availability of powerful technologies for protein purification. Chapter 2 describes a new 
technique based on the single step, high affinity pull-down of an in vivo biotin-tagged 
protein using streptavidin beads. Using this technique, it is shown in chapter 3 that 
the hematopoietic transcription factor GATA-1 is part of at least 5 distinct complexes in 
mature erythroid cells, including previously described as well as novel protein partners 
that are involved in gene activation and gene repression. In Chapter 4, chromatin 
immunoprecipitation (ChIP) analysis of gene targets shows that distinct GATA-1 
complexes are stably bound to different subsets of target genes. We also identified 
a mechanism for GATA-1-mediated repression of an early hematopoietic program. 
Finally, Chapter 5 describes the complementary characterization of protein complexes 
formed by Ldb1, a GATA-1 interacting partner, thus illustrating the importance of a 
cellular protein network. Our work provides evidence of a central role for GATA-1 
in erythroid differentiation. GATA-1 through its interacting partners is linked on the 
one hand to repression of early or alternative hematopoietic programs and of cell 
proliferation related genes, and on the other hand to activation of erythroid specific 
genes.
       Chapter 1: 
      Introduction
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1. Hematopoiesis/Erythropoiesis
1.1 Introduction 
Hematopoiesis is the generation of all the mature blood cells from a rare pool of 
hematopoietic stem cells (HSCs). Due to their limited life span, blood cells need to be continuously 
generated throughout life. Blood contains many types of cells executing different functions. These 
functions range from the transport of oxygen to all the cells, to the defence of the organism. 
Blood consists of red blood cells or erythrocytes, white blood cells, which include granulocytes 
(neutrophils, eosinophils and basophils), monocytes and lymphocytes, and platelets (Figure 1). 
Remarkably all classes of blood cell are derived from a single common multipotent progenitor, 
the so-called hematopoietic stem cell. In adults, HSCs are present primarily in the bone marrow 
at a very low incidence (1 to 10 cells in 100,000 cells). Specifically, HSCs have the capacity 
to self-renew and possess a high proliferative potential1. The hematopoietic system has been 
studied extensively and is a model of choice to study cellular and molecular mechanisms of 
differentiation. In addition, human diseases of the hematopoietic system, such as leukemias 
and hemoglobinopathies, are a serious health problem. 
Differentiation during normal hematopoiesis occurs through a stepwise process, each 
step generating increasingly restricted hematopoietic cells. The first division of the pluripotent 
stem cell leads to one daughter cell keeping the stem cell characteristics, and the other daughter 
cell proceeding a differentiation pathway. The first progenitors to be generated from HSCs are 
the so-called multilineage progenitors (MLPs). These cells have the capacity to differentiate into 
any type of blood cell but have lost the capacity to self-renew. MLPs can differentiate into either 
common lymphoid progenitor (CLP) or common myeloid progenitors (CMP)2. Once the decision 
for a cell fate is made, progenitors display a progressively more lineage-restricted potential 
at each branch point. In order to produce a sufficient number of mature blood cells, every 
progenitor at each step of differentiation goes through many rounds of cell division generating 
identical cells.
During lineage differentiation, the progressive restriction multipotency is underscored 
by the expression of unique combinations of transcription factors. These transcription factors 
act together with chromatin-remodeling and modifying co-factors to establish a particular 
lineage-specific gene expression program3,4. Commitment of a precursor cell to a specific 
lineage is accompanied by expression of the lineage-specific genetic program, as well as 
the concomitant suppression of programs associated with early multipotential states and of 
alternative lineages. While it has been generally accepted that commitment is an irreversible 
process, recent evidence has suggested it can actually be reversed5,6. Transcriptome analysis of 
HSC populations revealed co-expression of specific lineage affiliated genes such as erythroid, 
megakaryocytic and myeloid programs3, suggesting that these cells are “primed” for the different 
lineage-specific genetic programs. In addition, forced expression of a transcription factor such 
as GATA-1 in myeloid cells was shown to lead to the generation of erythroid cells, suggesting a 
reprogramming of the cells to a different hematopoietic program7.
In addition to lineage switches within the hematopoietic system, several lines of 
evidence have suggested that HSCs possess a remarkable plasticity for non-hematopoietic 
cell differentiation, called transdifferentiation8. For example, HSCs from bone marrow were 
suggested to give rise to neuronal cells9. Such phenomena have extraordinary consequences 
on the understanding of cell differentiation and ultimately on developing therapeutic treatments. 
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However, the basis of the transdifferentiation potential of HSCs is poorly understood and very 
controversial10. 
1.2 Hematopoiesis during Development
In mammals, the yolk sac (YS) is the first extraembryonic hematopoietic tissue to be 
formed. At around day 7 of gestation (E7) in mouse, blood islands emerge from the mesoderm. 
Within these islands, blood cells arise in close juxtaposition to endothelial cells. Endothelial 
and hematopoietic cells are thought to arise from a common progenitor, the hemangioblast11. In 
the early stage embryo, hematopoietic cells differentiate to give rise to primitive erythroblasts. 
These cells enter the circulation of the embryo proper and continue to divide for several days. 
Upon differentiation, they express embryonic globin genes. Primitive erythrocytes are large and 
nucleated12. Hematopoiesis in the yolk sac occurs until around E13 in mouse13.
Figure 1: Schematic representation of the hematopoietic hierarchy
The Hematopoietic Stem Cell (HSC) gives rise to all mature blood cells. During hematopoietic differentiation, 
multipotent progenitors (MLP) have similar progenitor potential than the HSC, but have lost their ability to 
self-renew. They differentiate into Common Myeloid Progenitor (CMP) and Common Lymphoid Progenitor 
(CLP). CMP are at the origin of Erythroid/Megakaryocytes Progenitors (EMP) and the Granulocyte/monocyte 
Progenitor (GMP). Recently, it was shown that a progenitor called CMLP had the potential to give rise 
to CLP and also GMP14. EMP will give rise to erythroid and megakaryocytes. GMP will differentiate into 
granulocytes, including eosinophils, macrophages and mast cells. In lymphoid lineage, CLP give rise to 
B- cells and T-cells.
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In contrast to primitive hematopoiesis, definitive hematopoiesis generates HSCs that 
give rise to all blood cells lineages, including the definitive erythrocytes. Definitive and primitive 
erythroid cells differ in that definitive red cells are smaller, enucleated cells that contain adult 
globin genes. However, transcription factors such as GATA-1, GATA-2, Lmo2 are expressed 
in both types of erythroblasts. The para-aortic splanchnopleura/aorta-gonad-mesonephros 
(PAS/AGM)15,16 is the first hematopoietic tissue to arise within the body of the embryo proper. 
The PAS represents the precursor tissue to the AGM region that produces the first HSC at 
E10/1117. By E11.5, these cells migrate and colonize the fetal liver, which is considered as 
the principle hematopoietic tissue in the developing foetus18,19. At E12, the fetal liver exhibits 
a large increase of the number of HSCs, suggesting a role in the specific expansion of those 
cells18,19. As the embryo develops, new hematopoietic reservoirs are formed in tissues such as 
the thymus and the spleen. After birth, HSCs migrate from the fetal liver to the bone marrow, 
which constitutes the main hematopoietic site throughout life. Recently, another source of HSCs 
was identified in the placenta20.
1.3 Regulation of Hematopoiesis
Hematopoiesis is often used as a model system to study the mechanisms involved 
in cell differentiation within a very tightly regulated environment. The production of all mature 
blood cells from one common progenitor is a stepwise process, influenced at different levels and 
at each branch point by the cellular microenvironment, signaling cues and the expression of a 
specific combination of tightly regulated transcription factors. The detailed roles of transcription 
factors during differentiation will be presented later in the introduction section. However the 
time, space and level of expression of such molecules are crucial factors in determining and 
executing cell fate. In addition to transcription factors, molecules from the environment such as 
cytokines and growth factors coupled to signaling pathways play a critical role, especially by 
regulating downstream transcription factors. 
The molecular mechanisms by which cell fate is determined remains poorly understood. 
Two hypotheses have suggested that the decision can be either instructive or stochastic21,22. In 
the first case, the decision for a specific cell fate is directly determined by extrinsic signals. In 
opposition, the stochastic model predicts that commitment to a particular hematopoietic lineage 
is independent of the extrinsic signals. Instead, extrinsic signals are required for survival and 
differentiation of the committed cell23. For example, the targeted mutation of the erythropoietin 
gene or of its receptor leads to embryonic lethality because of reduced primitive erythropoiesis 
and an absence of definitive erythropoiesis in vivo. However, the presence of BFU-E and CFU-E 
progenitors in homozygous knockout mice, demonstrated that these molecules are not essential 
for the erythroid lineage commitment “per se” 24. 
Cytokines are crucial for cellular survival and expansion. For example, interleukin 3 
(IL-3) and Granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulate proliferation 
of multipotential hematopoietic progenitors25-27. The latter also has a role in the proliferation 
of granulocytes and macrophages. Some other cytokines have a role in promoting cellular 
differentiation. For example, erythropoietin, IL-7 and IL-5 stimulate erythroblast, lymphoid and 
eosinophil differentiation, respectively28,29. In adult, most hematopoietic cytokines are produced 
by the bone marrow stroma cells30.
Developmental signaling pathways such as the Notch and Wnt pathways also play 
critical roles in the regulation of hematopoiesis31. Moreover, cell adhesion molecules such as 
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collagens and laminin appear to act as regulators of hematopoiesis, but their exact function 
remains to be elucidated32,33. 
1.4 Definitive Erythropoiesis
With a lifespan estimated at 120 days in human, billions of red blood cells need to 
be produced each day. Erythrocytes, or red blood cells, are by far the most abundant cells 
in the blood comprising about 45 % of its volume. They are very rich in hemoglobin, the 
molecule responsible for binding and transporting oxygen. The expression of the globin genes 
is differentially regulated during development since the various globin genes provide specific 
physiological needs of the developing organism. Definitive erythrocytes are tiny biconcave 
discs, a shape that increases the efficiency of oxygen diffusion.
 
Generation of mature red blood cells is a tightly regulated multistep process. Erythroid 
cells derive from HSCs as mentioned above. Erythroid and megakaryocytic progenitors 
(EMPs) coming from the common myeloid progenitor (CMP) are restricted to generate only 
the erythroid or the megakaryocytic cells. The first erythroid specific progenitor to be formed 
is referred as the Burst Forming Unit-Erythroid (BFU-E). The process of maturation from 
BFU-E to active circulating erythrocytes, the circulating red blood cells, is characterized by a 
progressive differentiation of several progenitors (Figure 2), in which the first morphologically 
recognizable differentiated erythroid progenitor is the proerythroblastic cell. Proerythroblasts 
correspond to large cells of 16 µm in mean diameter with a nucleus that occupies 80 % of the 
cell. Differentiation from the proerythroblastic stage to enucleated cells is referred to as terminal 
erythroid differentiation. It occurs in a defined structure, the so-called erythroblastic island 
(Figure 333), that was first identified by electron microscopy35. Terminal erythroid differentiation 
is characterized by the accumulation of high amounts of hemoglobin. In the final steps, the 
most differentiated erythroblastic cells, the orthochromatic erythroblasts, expel their nucleus 
to become reticulocytes, which represent the last stage of immature red cells that further lose 
specific organelles to generate the fully mature erythrocytes. 
1.5 Hematopoiesis as a Biological Model
1.5.1 Multi-lineage priming
One of the main questions in the process of generating all hematopoietic lineages 
from a single HSC is to understand how transcription of a lineage-specific program is 
initiated. One hypothesis is that precursors cells are transcriptionally “primed”, meaning that 
they promiscuously express lineage-specific genes, albeit at low levels, prior to commitment 
and differentiation36,37. Expression analysis and microarray data from purified HSCs have 
Figure 2: Schematic representation of different stages of erythropoiesis
The erythroid progenitor coming from the EMP differentiates into the first erythroid differentiated cell 
morphologically recognizable, the pro-erythroblast. Erythroid terminal differentiation leads to the production 
of mature red blood cells.
Erythroid 
progenitor
Pro-erythroblast Basophilic
erythroblast
Polychromatic
erythroblast
Orthochromatic
erythroblast
Reticulocyte erythrocyte
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demonstrated the presence of transcripts of multiple programs of hematopoietic lineages3. 
Analysis of MLPs shows co-expression of myeloid and lymphoid programs, and more restricted 
progenitors CMPs and CLPs express myeloid/erythroid genes and T and B lymphoid genes, 
respectively. Furthermore, expression analysis by Reverse Transcriptase PCR (RT-PCR) in a 
multipotential cell population has demonstrated that lineage-specific genes were co-expressed 
at the single cell level even before commitment38. For example, transcription factors such as 
GATA-1 and C/EBPα are expressed in the early progenitor cell CMP, GM and Meg/E related 
genes, respectively (Figure1). Presumably, this multilineage priming would allow progenitors 
to respond rapidly to changes in environmental signals and cues. An essential implication of 
such promiscuous expression is that chromatin would be in an “open structure”, thus allowing 
many key cis-regulatory elements of lineage-affiliated genes to be accessible for transcription 
prior to lineage commitment37. For example, erythroid specific DNase hypersensitive sites 
(HS) 1 and 2 of globin genes are sensitive in self-renewing multipotential FDCP cells (Factor 
Dependent Cell-Paterson mix cells)39. Similarly, in the same cells, enhancers of the T-lymphoid 
specific CD3 delta-chain and B-lymphoid specific immunoglobin heavy chain genes are also 
DNase I sensitive40. Collectively, these observations suggest that progenitors have a broadly open 
chromatin structure that allows transcription of several lineage specific programs supporting the 
model by which progenitors cells display promiscuous and simultaneous transcription of multiple 
hematopoietic differentiation programs. During hematopoietic differentiation, promiscuous 
expression of lineage-affiliated genes would become progressively more restricted as cells 
become more specialized. 
Main questions arising from these observations are how one program is selected and 
what is the role of the transcription factors in that process? 
1.5.2 Cell reprogramming
Cell commitment has been generally considered as an irreversible event. 
Instead, several recent lines of evidence have suggested that commitment of hematopoietic 
progenitors is more dynamic than previously thought. Cell reprogramming was shown 
to take place by the forced expression of oncogenes, cytokines and transcription factors in 
Figure 3: Erythroblastic island
The central macrophage is surrounded by erythroid cells. Distribution of erythroid cells depends on their 
stage of differentiation; the more immature cells are the closest to the centre. Adapted from reference 33. 
Proerythroblast
Basophilic erythroblast
Polychromatic erythroblast
Orthochromatic erythroblast
Reticulocyte
Pyknotic nucleus
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multipotential cell lines41-43. The forced expression of oncogenes, for example v-raf, reprogrammed 
a lymphoid cell line into a myeloid cell fate41. Similarly, chicken erythroid/megakaryocytic 
progenitors transformed with the Myb-Ets encoded by the E26 leukemia virus (Myb-Ets progenitor, 
MEPs) could be differentiated into myeloblasts and eosinophils8. Remarkably, the ectopic 
expression in MEPs of lineage-specific transcription factors such as C/EBPα, a member of the 
CCAAT/enhancer-binding protein (C/EBP), or GATA-1 leads to the generation of eosinophils and 
megakaryocytic cells, respectively. Similar to expression of C/EBPα, the ectopic expression of 
PU.1 converted MEPs into eosinophils44. Interestingly, PU.1 expression leads to the repression 
of GATA-1 activity. Conversely, GATA-1 was also shown to antagonize PU.1 function in MEPs45,46. 
These data suggest hematopoietic cells remain able to give rise to lineages different than the 
one they were initially programmed for. At the molecular level, cell reprogramming involves 
activation of a specific lineage as well as repression of alternative lineages. Similar experiments 
have also been carried out with primary mammalian progenitor cells. HSCs, CMPs and CLPs 
were reprogrammed through the ectopic expression of lineage-restricted transcription factor 
GATA-147. 
How GATA-1 is also able to reprogram lineage decisions will be detailed below.
2. Hematopoietic Transcription Factors 
2.1 Transcription: General Principles
2.1.1 Cis-regulatory elements for gene regulation
Proper spatial and temporal gene expression is dependent on the presence of cis-
regulatory DNA sequences, such as promoters, enhancer/silencers, Locus Control Regions and 
DNase I Hypersensitive sequences. These regions of DNA are characterized by their accessibility 
to regulatory factors. Such elements contain specific sequences that are recognized and bound 
by specific transcription factors that regulate gene expression. 
2.1.2 Basal machinery
Transcription in eukaryotic cells is achieved by three RNA polymerases regulating 
three classes of genes. RNA pol I and III transcribe ribosomal RNA and small nuclear 
RNAs, respectively, whereas the vast majority of protein coding genes are transcribed by 
RNA pol II48. Typically, RNA pol II transcription begins with the binding of gene specific regulators 
at the promoter, near the site of transcription initiation. These factors modulate the activity of the 
transcription machinery activity either indirectly by recruiting chromatin remodeling/modifying 
enzymes and/or directly by interacting with components of the basal transcription machinery. 
Both mechanisms result in the recruitment of the transcription machinery to a core promoter. 
This positions the pre-initiation complex49,50 (PIC), which consists of the RNA pol II enzyme and 
the well-characterized general transcription factor complex TFII (transcription factor for RNA pol 
II) consisting of the TFIIA to -H subunits, except the TFII E. However, transcription cannot yet 
start, as the machinery is still in an inactive state. The entry of TFII E into the complex causes 
a conformational change resulting in an open complex that allows transcription initiation to take 
place. After 30 bp of RNA synthesis, the RNA pol II C-terminal domain (CTD) is phosphorylated 
thus releasing the complex from the core promoter and allowing transcription elongation to 
proceed. 
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2.1.3 Transcription factors
Transcription factors are direct effectors as they recognize and bind to specific DNA 
sequence motifs located in regulatory sequences. Broadly speaking, tissue-specific transcription 
factors interact with ubiquitous transcription factors and (non DNA-binding) co-factors which 
can alter chromatin structure and/or tether the basal machinery to the gene, thus activating 
transcription. It is also important to note that such interactions can also result in repression 
through the recruitment of repressive complexes to gene targets acting at the chromatin level.
Transcription factors are classified into families based on their functional domains, 
such as the DNA binding domain. One of the first DNA binding domain to be discovered was the 
helix-loop-helix motif (HLH), composed of two α-helix domains separated by a stretch of amino 
acid forming a loop. Zinc-finger motifs represent another protein domain that can bind DNA with 
very high specificity and affinity. Additionally, the leucine zipper domain is another example of 
a DNA-binding motif48. This motif also mediates protein homodimerisation which inhibits the 
DNA binding activity. The specificity of DNA recognition and binding by a transcription factor 
is very high. Therefore, the smallest change in the DNA or the amino acid sequence of the 
DNA binding domain will modify the binding characteristic. Different outcome of target gene 
regulation resulting from such changes can lead to disease, for example.
These DNA binding domains are functionally critical as they mediate specific classes 
of proteins to interact and to form functional complexes that are important for proper gene 
regulation. Examples of such interactions include GATA-1 and Friend of GATA-1 (FOG-1) as 
well as GATA-1 and the pentameric complex formed between GATA-1 and the TAL-1/Ldb1/
Lmo2/E2A transcription factors51,52. The main focus of this thesis revolves around tissue specific, 
i.e. erythroid transcription factors and is described in greater detail below. 
2.2 Hematopoietic Transcription Factors 
Once HSCs differentiate to a multipotential progenitor (MLP), the genetic programs 
that specify a defined lineage are characterized by changes in the nature and the level of the 
transcription factor complement being expressed. Much evidence, mostly from gene knockout 
experiments but also from the analysis of hematological disorders such as leukemias, has 
accumulated showing that hematopoietic restricted transcription factors play a very important 
role in these processes. In addition, microarray expression analysis have provided large amount 
of information on the combinations of genes being switched on and off during differentiation 
and development. However, details of the molecular mechanisms at the chromatin level of 
how the regulation of these genes occurs remain scant. For example, gene knockouts have 
demonstrated an essential function in HSCs for GATA-2, TAL-1/SCL, AML1, Lmo253-56 (review57). 
Other factors such as PU.1, C/EBPα, Ikaros, GATA-1, FOG-1 and Gfi-1b have been shown to 
be essential for the differentiation of myeloid, eosinophilic, lymphoid and Meg/E lineages58-62. 
The analysis of the gene knockout phenotypes of transcription factors relevant to the 
scope of this thesis will be presented in greater detail later. However, it is important to note 
here that ablation of seemingly unrelated transcription factors can result in a similar phenotype. 
For example, the FOG-1, Gfi-1b and GATA-1 knockouts have very similar phenotypes in 
the megakaryocytic and erythroid lineages. In addition, the conditional knockout of TAL-1 in 
erythroid cells leads to a phenotype similar to that of GATA-1. Not surprisingly, FOG-1 and 
TAL-1 are indeed interacting partners of GATA-151,63. 
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2.3 GATA Factors
The GATA transcription factors form a family of 6 evolutionarily conserved members, 
all of which contain two characteristic zinc finger domains. GATA factors bind the consensus 
DNA sequence A/TGATAA/G via a conserved zinc-finger Cys-X2-Cys-X17-Cys-X2-Cys present 
in the carboxy terminal end of each protein (CF). A second GATA finger is more proximal to the 
amino-terminus of the protein (NF). 
The family is divided into two subgroups based on their expression pattern. The 
hematopoietic subfamily is composed of GATA-1, -2 and -3, each being an essential transcription 
factor at different stages and lineages in the generation of blood cells (see below) as their gene 
knockouts result in early embryonic lethality. 
GATA-2 is highly expressed in early hematopoietic progenitors but also in 
megakaryocytes and mast cells. GATA-2 null mice are characterized by a lack of definitive red 
blood cells and severely reduced yolk sac hematopoiesis that results in a severe anemia with 
embryonic lethality at E10-E1153. Furthermore, analysis of GATA-2 function has demonstrated 
GATA-2 as being essential in the expansion of multipotential hematopoietic progenitors64. It is 
also essential for expansion of HSCs in embryos and adults. Forced expression of GATA-2 in 
multipotential hematopoietic cells was shown to reduce erythroid differentiation65. These data 
suggest that during erythroid differentiation GATA-2 expression needs to be downregulated. 
In addition, GATA-1 null cells exhibit high level of GATA-2 expression, suggesting that 
GATA-1 represses GATA-266,67. Recent data have demonstrated a direct repression of GATA-2 by 
GATA-168-70. Taken together, these data suggest a close interplay between GATA-1 and GATA-2 
during hematopoiesis.
GATA-3 is expressed in T lymphoid cells in the hematopoietic system, but also in a 
number of additional tissues such as the nervous system, skin, liver and kidney. Loss of GATA-3 
function in mice shows a severe phenotype resulting in a early lethality due to internal bleeding 
and brain malformations71. GATA-3 is expressed in PSP and has been suggested to play a role 
in generation of the hematopoietic system in the embryo.
GATA-4, -5 and -6 are mainly expressed in other tissues such as the heart, lung and 
intestine72,73. The GATA-4 and GATA-6 knockouts result in embryonic lethality, due to defects 
in heart morphogenesis and endoderm lineage generation, respectively74-76. Among the GATA 
factors, only the GATA-5 knockout does not present any phenotype. Due to the topic of the 
thesis research, we will focus on GATA-1 protein and its partners.
2.3.1.1 GATA-1: gene and protein structure
GATA-1, the prototypic member of the GATA factor family, also known originally as 
NF-E1, NF-1, ery-1 and GF-1, is expressed in primitive and definitive erythroid76, 
megakaryocytic78,79, eosinophilic80 and mast cells78,81 and in the Sertoli cells of the testis82. 
GATA-1 was originally identified as a factor binding to conserved DNA sequences within the 
regulatory elements of globin genes83,84. It is now known that GATA-1 is a key regulator of gene 
expression of a very large number of genes in multiple cell types.
The GATA-1 transcriptional unit contains multiple cis-regulatory elements essential for 
its expression. The GATA-1 gene is X-linked and is composed of 7 exons, two promoters located 
in the two alternative non-coding first exons IE (erythroid specific) and IT (testis specific)85 and 
five coding exons86 (Figure 4). Both promoters lack a TATA box86,87, but contain GATA binding 
sites which are required for the proper expression of the gene, thus suggesting an auto-
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regulatory loop85,86,88,89. Since the translational start is in the exon II, the two promoters generate 
a unique GATA-1 protein. Disruption in mice of the specific-erythroid promoter (IE) leads to an 
arrest in primitive erythropoiesis while not affecting GATA-1 expression in Sertoli cells90. 
Transgenic mice expressing a reporter gene under the control of the different 
presumptive elements of GATA-1 and specific knockout mice have demonstrated that 
the different elements are required for spatial and temporal expression of GATA-188,89,91. 
Importantly, the -3.9 kb upstream region of the IE promoter shown to be sufficient to recapitulate 
GATA-1 expression in primitive as well as definitive erythropoiesis contains a GATA site and an 
E-box88,89. 
The GATA-1 protein is composed of 413 amino acids with an apparent molecular 
weight of approximately 48 kDa (Figure 4). It contains at least three functional domains: 
the two characteristic GATA Zn fingers (NF= N-terminal zinc finger and CF= C-terminal zinc 
finger) as well as an activation domain specific to GATA-1 which encompasses the N-terminal 
80 amino acids of the protein. The activation domain was originally defined in in vitro transfection 
experiments using fibroblasts. Deletion of this domain failed to confer transcriptional activation 
of a reporter gene78. However, the function of the activation domain in hematopoiesis remains 
unclear since deletion of the first 63 amino acids of the GATA-1 protein were dispensable 
for erythroid and megakaryocytic differentiation92,93. Nevertheless, it is important to note that 
erythropoiesis is impaired in transgenic mice expressing a GATA-1 mutant (NT) that is deleted 
for the first 83 amino acids of GATA-194. Severity of the phenotype was directly linked to the 
level of expression. Mice expressing a comparable level of endogenous and NT mutant were 
impaired for definitive erythropoiesis. In contrast, when the NT mutant was expressed at higher 
level than the endogenous GATA-1, the phenotype was rescued, thus suggesting a role for 
the NT in hematopoiesis. Recently, the GATA-1 gene was engineered as to express GATA-1s 
(deletion of the first 63 aas). Expression of GATA-1s in mice led to hyperproliferation of a novel 
hematopoietic progenitor95.
Of the GATA-1 zinc fingers, the CF is essential for recognizing and binding to the 
consensus GATA DNA motifs78,96. It is of note that virtually all erythroid genes contain such 
motifs57. The CF is also involved in interactions with other transcription factors such as EKLF, 
Sp1 and PU.197,98. The NF does not bind directly to GATA DNA consensus sites. It is involved 
in the stabilization of DNA binding by the CF. However, it was shown in erythroid cells to bind 
to different consensus sequences than the GATA sequence recognized by the CF99. Trans-
activation experiments in fibroblasts have shown that the NF can mediate DNA binding to the 
non-consensus binding site GATC thus activating transcription100. The NF is mainly involved 
in mediating interactions with a number of transcription factors and co-factors: FOG-151, 
EKLF97, CBP/P300101, TAL-163, Lmo-263 and also in mediating GATA-1 homodimerization or 
multimerization102,103. 
Evidence for the requirements of the GATA-1 zinc fingers in hematopoiesis has been 
obtained from rescue experiments of the GATA-1 knockout phenotypes. Early studies in the 
GATA-1 deficient proerythroblastic G1E cell line have demonstrated that both Zinc fingers 
are crucial GATA-1’s ability to drive terminal erythroid differentiation92. More recently, in vivo 
evidence for the function(s) of each Zn finger in primitive and definitive erythropoiesis was 
obtained by expressing GATA-1 zinc finger mutants in GATA-1 knockdown mice, i.e. mice that 
expressed only a small percentage of wild type levels of GATA-1 protein94. In agreement with the 
data previously published, these experiments showed that both zinc fingers were essential for 
erythropoiesis since no live pups were obtained. However, deletion of the CF led to impairment 
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of both primitive and definitive erythropoiesis, whereas deletion of the NF led to normal primitive 
erythropoiesis only. These observations suggest differential requirements for the GATA-1 zinc 
fingers in primitive and definitive erythropoiesis94. 
Taken together, these data suggest a very important role for GATA-1 in definitive 
erythropoiesis and that all of its domains are required at this stage.
2.3.1.2 GATA-1 posttranslational modifications (PTMs)
Like many other factors, GATA-1 is posttranslationally modified in several ways. 
However, the functions of GATA-1 PTMs remain largely unclear.
GATA-1 can be acetylated in vitro and in vivo in erythroid cells by the two ubiquitously 
expressed histone acetyltransferases (HATs) P300/CPB104,105. Acetylation occurs on two 
highly conserved lysine residues present in the C-terminal part of each zinc-finger (Figure 4). 
GATA-1 acetylation in transfected fibroblasts was shown to increase its binding to DNA as well 
as GATA-1-mediated transcriptional activation of a reporter gene, when co-expressed with 
p300104. However, in another study in erythroid cells, GATA-1 acetylation did not result in any 
changes in DNA binding. Nevertheless, the same study using the GATA-1 null proerythroblastic 
G1E cells showed that GATA-1 acetylation was required for terminal erythroid differentiation105. 
Phosphorylation of GATA-1 can occur at seven serine residues103. Of these, six 
serines are phosphorylated in non-differentiated MEL cells. Phosphorylation of S310, which is 
in proximity to the DNA binding domain, appears only during the erythroid MEL differentiation. 
Phosphorylation of GATA-1 in K562 cells has been associated with an increase of its binding 
to DNA106. However, specific mutations of all serines to alanines of the murine GATA-1 did 
not influence GATA-1 binding or transcriptional activity in vitro107. Signaling pathways such as 
mitogen-Activated Protein Kinase (MAPK) activated by IL-3 or EGF, and phosphatidylinositol 3-
kinase/Akt (PI3K) were shown to lead to specific GATA-1 phosphorylation108-110. In addition these 
reports show a function of phosphorylated GATA-1 in gene regulation. For example, transfection 
of GATA-1 in COS cells have shown that GATA-1 phosphorylation transactivates the survival 
gene E4bp4 and the tissue inhibitor of matrix metalloproteinase (TIMP-1)109,110. Mutation of 
serine 26 inhibits the induction of the anti-apoptotic gene Bcl-XL
109. Mutation of the two serines 
(Ser 26 and 178) in GATA-1 compromises interactions with its partner Lmo2 potentially affecting 
GATA-1 functions108. Despite these data, the precise function of GATA-1 phosphorylation in 
erythroid cells remains to be elucidated.
Figure 4: GATA-1 protein
The first 83 amino-acids correspond to the activation domain (AD). N-terminal zinc-finger (NF) is mainly 
involved in protein-protein interactions, whereas the C-terminal zinc finger mediates DNA binding to GATA 
sites.
On the top of GATA-1 protein are shown post-translational modifications. P: Phosphorylation;  
A: acetylation; S: Sumoylation.
- 21 -
Introduction
Recently, GATA-1 was also shown to be sumoylated in vitro and in vivo111 (and personal 
unpublished observations). The small ubiquitin-related modifier (SUMO) is covalently ligated to 
a lysine residue within the consensus sequence LKXE (for review112). The modification process 
is similar to the ubiquitin modification pathway and includes three enzymatic steps. The GATA-1 
consensus site for SUMOylation LKTE is located at position K137. Several functions have been 
associated with SUMOylation of transcription factors, such as gene repression or activation 
for Sp3 and p53, respectively113,114, protein localization of the promyelocytic leukemia protein 
(PML)115, protection from ubiquitin-mediated protein degradation116. However, any function(s) 
associated with GATA-1 sumoylation remain to be defined.
2.3.1.3 GATA-1 functions in hematopoiesis
In the hematopoietic system, GATA-1 is expressed at high levels in erythroid, 
megakaryocytic, eosinophilic and mast cells. GATA-1 expression is also detected in 
hematopoietic progenitors at lower levels. The levels of GATA-1 protein are dynamic during 
erythroid differentiation. GATA-1 is thought to be activated in progenitors, reaches maximal 
levels in erythroblasts and decreases prior to the last stage of terminal differentiation117,118. Thus, 
regulation of GATA-1 levels appears to be very tight.
GATA-1 is an essential transcription factor for normal erythropoiesis. Chimeric mice 
obtained from GATA-1 null embryonic stem (ES) cells are able to generate many hematopoietic 
lineages but not mature red blood cells60. More detailed genetic analysis has shown that 
GATA-1 null erythroid cells are not able to differentiate beyond the proerythroblastic stage due 
to apoptotic cell death119,120. Deletion of the GATA-1 gene in mice results in a lethal phenotype 
between E10.5-E11.5 due to severe anemia121. GATA-1 knockdown mice, in which the level 
of GATA-1 is 5 % of the physiological level (GATA-1.05 mice), lack primitive erythropoiesis 
and die from anemia between E11.5-E12.590. These studies showed that a very low amount of 
GATA-1 in erythroid cells is sufficient to prevent apoptosis but is unable to promote erythroid 
differentiation122.  
Intriguingly, the overexpression of GATA-1 in vitro and in vivo also inhibits erythroid 
differentiation123,124. The block in terminal erythroid differentiation resulting from the overexpression 
of GATA-1 is different to that resulting from the GATA-1 knockout. Overexpressing erythroid 
cells differentiate past the proerythroblastic stage but fail to activate late differentiation markers, 
such as globins, and do not undergo cell cycle arrest at the G1 phase123-125. This leads to 
a failure in generating mature erythroid cells resulting in lethal anemia at E13.5 in mice124. 
The defect generated in erythroid cells by Gata1 overexpression is non-autonomous. It was 
shown that in the presence of wild type cells, Gata1 overexpressing erythroid cells are able 
to contribute to the erythroid differentiated pool of cells, as shown in heterozygous GATA-1 
overexpressing females and chimeric mice124. This phenomenon involves a signaling molecule 
named Red Cell Differentiation Signal (REDS). REDS was shown to involve cells of the same 
type, characteristic of a homotypic mechanism, i.e. erythroid cells themselves communicate 
with each other126. REDS emerging from matured erythroid cells is thought to signal adjacent 
Gata1 overexpressing cells via a receptor-ligand interaction, leading to the degradation of 
proteins, including GATA-1 transcription factor. Thus, downregulation of GATA-1 allows the 
intrinsically GATA-1 overexpressing cells to differentiate properly. The degradation of GATA-1 
through cleavage by caspases has been reported in primary erythroid cells127. Significantly, 
activation of caspases through death receptors blocked terminal erythroid differentiation at the 
basophilic erythroblast stage, concomitant with the down-regulation of GATA-1. These results 
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are not necessarily contradictory to the REDS model proposed for late stages of terminal 
differentiation, as GATA-1 degradation induced by caspases was studied in immature erythroid 
cells. This difference suggests that a high level of GATA-1 protein is required at earlier stages 
of erythroid maturation.
GATA-1 in vivo functions have also been addressed in other hematopoietic lineages. 
Generation of a specific megakaryocytic knockdown has underlined an essential role for 
GATA-1 in this lineage128. Mutant mice are characterized by an increase of the proliferation of 
the megakaryocytic progenitors and a defect in their maturation, thus leading to a dramatic 
reduction in the number of platelets89. 
GATA-1 is also expressed at high levels in eosinophils80. GATA-1 null cells fail to 
generate eosinophil progenitors in the fetal liver129. In addition, deletion of a positive regulatory 
element in the GATA-1 promoter blocks eosinophil development130. These two studies show that 
GATA-1 plays an essential role in eosinophilic differentiation. In mature cells, GATA-1 plays a 
role in the activation of eosinophilic genes, such as the granule major basic protein (MBP)131. 
Lastly, mast cell differentiation appears to be impaired in GATA-1low mice. Even though 
mast cells were generated in these mice, an increase in the number of precursors was observed, 
in addition to an increase in apoptotic rates and defective maturation132. 
Taken together, these studies demonstrate an essential function of GATA-1 in several 
hematopoietic lineages. By contrast, the analysis of a testis-specific GATA-1 knockout has not 
demonstrated any apparent phenotype133.
2.3.1.4 An instructive role for GATA-1 in Meg/E differentiation
In addition to gene targeting experiments that have documented an essential function 
for GATA-1 in several hematopoietic tissues, the enforced expression of GATA-1 in lineages 
where it is not normally expressed has provided evidence for an instructive role for GATA-1 
in cell differentiation. An instructive role for GATA-1 can be defined as its ability to impose an 
expression program that promotes uni-lineage differentiation in a cell that had the potential to 
give rise to different cell types. 
The first observations of GATA-1 being capable of driving a multipotent progenitor cell 
to express a unique transcription program was obtained using the early myeloid cell line 416B43. 
This cell line can differentiate into the megakaryocytic or granulocytic lineages. The ectopic 
expression of GATA-1 in these cells led to their differentiation specifically to megakaryocytes43. 
The expression of the unrelated SCL/TAL-1 transcription factor in the same cells did not result 
in differentiation. Along the same lines, ectopic GATA-1 expression in avian multipotential 
progenitors led to the transdifferentiation of myeloblasts into eosinophilic or megakaryocytic 
cells. The observed upregulation of megakaryocytic and the suppression of myelomonocytic 
markers suggests that the activation of specific transcription programs (e.g. megakaryocytic) 
occurs concomitantly with the suppression of alternative (e.g. myeloid) lineage programs134. 
Furthermore, the induced expression of GATA-1 in Granulocyte/Macrophage (GM) progenitors 
in vitro directs differentiation towards cells resembling erythroid and eosinophilic cells7. 
In addition to studies in the cell lines above, the instructive role of GATA-1 was also 
demonstrated in highly purified progenitor cells such as HSCs, CMP, CLP and Granulocytes/
monocytes Progenitors (GMP)47. The enforced expression of GATA-1 “instructed” the 
differentiation of all these progenitors to the megakaryocytic and erythroid (Meg/E) lineages. 
Even progenitors committed to the lymphoid lineage (CLP) were reprogrammed into 
Meg/E fates by the ectopic expression of GATA-1, with the concomitant repression of 
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lymphoid-specific marker genes7,47.
Together, all these observations suggest that GATA-1 is a key regulator in cell fate 
execution, with its functions involving both gene activation and repression. In Chapters 3 and 
4 we provide molecular evidence of how GATA-1 can execute both repressive and activating 
functions. 
2.3.1.5 GATA-1 protein interactions
Regulation of gene expression does not involve a single transcription factor at once, 
but rather a combination of transcription factors and co-factors, forming networks that change 
during cell specification. Accordingly, GATA-1 has been reported to undergo several interactions 
with other transcription factors and co-factors57,135 (Figure 5). GATA-1 protein interactions are 
described below.
Figure 5: Protein partners of GATA-1
GATA-1 protein has been reported to bind to a number of transcription factors or co-factors. Evidence for 
interactions are based on different methods. Black arrows: immunoprecipitation; Grey arrow: GST pull-
down; Dashed black arrow: EMSA.
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FOG-1
The most prominent of the GATA-1 interacting proteins was identified from a MEL 
cell library using the yeast two-hybrid system. One of the isolated cDNA clones encodes a 
novel Zinc-finger protein of 998 amino-acids length, designated Friend of GATA (FOG-1)51. 
FOG-1 contains nine zinc-fingers, four of which can individually bind the N-finger of GATA-1136. 
Expression analysis of FOG-1 has revealed a tissue specific expression pattern similar to that of 
GATA-1. In hematopoiesis, FOG-1 is expressed strongly in erythroid and megakaryocytic cells51. 
However, FOG-1 expression could not be detected in eosinophils or in mast cells, both of which 
express GATA-1. FOG-1 is an essential hematopoietic factor, as the FOG-1 gene knockout is 
embryonic lethal at approximately E10.5−11.5 of gestation due to severe anemia. FOG-1 null 
embryos have a defect in primitive and definitive erythropoiesis with a block of cell maturation at 
the proerythroblastic stage, similar to that observed in the GATA-1 null mice51. FOG-1 mutants 
fail to express any globin genes and lack completely the megakaryocytic lineage. Analysis of 
megakaryocytic specific markers demonstrates an early block in megakaryocytic development137. 
Thus, FOG-1 plays an essential role in the megakaryocytic/erythroid lineages. 
The phenotypic similarities observed in GATA-1 and FOG-1 null mice suggest that these 
two factors act in common pathways in the two hematopoietic cell lineages137. However, a more 
detailed analysis of the GATA-1 and FOG-1 knockout phenotypes revealed some differences. 
Whereas FOG null mice exhibit a complete failure of megakaryopoiesis, GATA-1 null mice 
have a block in megakaryocytic differentiation at mid-maturation, suggesting a broader, critical 
role for FOG-1 in the early stages of megakaryopoiesis. In the erythroid lineage, ablation of 
GATA-1 or FOG-1 leads to a differentiation block at the proerythroblast stage. Erythroid 
precursors survive longer in FOG-1 null mice than in GATA-1 null mice, suggesting that some 
GATA-1 functions are FOG-1-independent. 
Early clues for the requirement of a co-factor in GATA-1 function emerged from the 
indispensability of the N-terminal zinc finger for GATA-1 functions92. Co-expression of FOG-1 
and GATA-1 in G1E cells increases the expression of globin genes51. Similarly, co-transfection 
of FOG-1 and GATA-1 in progenitor 416B cells favored the generation of megakaryocytic cells, 
compared to cells transfected only with GATA-1. These data suggest that FOG-1 enhances the 
ability of GATA-1 to induce erythroid terminal differentiation and megakaryocytic differentiation, 
respectively. Furthermore, to address to what extent the requirement of GATA-1 in erythroid 
development is dependent on its association with FOG-1, a GATA-1 mutant was created. This 
GATA-1 mutant bears a single V205M amino acid change in the N-terminal zinc finger which 
abolishes the specific interaction with FOG-1, while not affecting DNA binding. When expressed 
in the GATA-1 null proerythroblastic G1E cell line, the V205M GATA-1 mutant failed to rescue 
terminal differentiation, in contrast to expression of the wild-type GATA-1 protein67,138. These 
results show that FOG-1 is an essential co-factor of GATA-1 in the terminal differentiation of 
erythroid cells. GATA-1/FOG-1 interactions have been linked to activation of genes such as 
globin, DC11 and HD2. Recently, ChIP data have demonstrated that FOG-1 facilitates binding 
of GATA-1 to β-globin genes, but also to the activated erythroid specific EKLF gene69. Similar 
observations have been made in the α-globin locus68. Importantly, the FOG-1-dependent 
function of GATA-1 has also been linked to gene repression. Expression of the GATA-1V205M 
in G1E cells leads to a lack of the down-regulation of GATA-2 and c-myc genes expression 
normally observed in terminal erythroid differentiation67,138. Whereas FOG-1 is dispensable for 
GATA-1 occupancy of the GATA-2 gene locus, FOG-1 was shown to be required for GATA-2 
repression70,139.
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The GATA-1/FOG-1 interaction has also been linked to hematopoietic disorders in vivo. 
GATA-1 deficient mice rescued with a GATA-1 mutant unable to bind FOG-1 (V205G) exhibit 
X-linked thrombocytopenia at the adult stage, suggesting an essential role of the interaction of 
GATA-1/FOG-1 in late differentiation of megakaryocytes140. 
Importantly, the enforced expression of FOG-1 in hematopoietic cells has highlighted 
some additional functions in the regulation of cell fate. Constitutive expression of FOG-1 in MLPs 
leads to a block of C/EBPβ-mediated eosinophilic differentiation141. Expression of FOG-1 in an 
avian eosinophilic cell line, where it is not normally expressed, resulted in the dedifferentiation 
of the cells to a multipotential state141. This reprogramming function of FOG-1 is characterized 
by the suppression of eosinophilic markers such as EOS47 (which was shown to be activated 
by GATA-1 in eosinophils), suggesting that FOG-1 is a repressor of the eosinophilic lineage. 
Furthermore, deletion of the N-terminal zinc finger of GATA-1 abrogates the FOG-1-mediated 
repressing function. Recruitment of FOG-1 by GATA-1 to the target gene is then essential. 
Taken together, these data suggest that GATA-1 acts in complex with FOG-1 to mediate gene 
repression of alternative lineage programs. In Chapters 3 and 4, we show that GATA-1 forms 
distinct activating and repressive complexes in erythroid cells. We provide a mechanism for the 
GATA-2 repression mediated by GATA-1 in a FOG-1 dependent manner. In addition, we show 
that GATA-1 and FOG-1 bind to a repressed eosinophilic gene in erythroid cells.
SCL/TAL-1
Many of the genes that encode critical hematopoietic transcription factors are also 
implicated in leukemias, supporting the hypothesis that the appropriate regulation of transcription 
factor networks is essential for maintaining proper tissue homeostasis within the hematopoietic 
compartment. Chromosomal rearrangements in leukemia are of particular interest. The 
gene encoding SCL/TAL-1 was first identified as a chromosomal translocation in T-cell acute 
lymphoblastic leukemia (T-ALL)142-145. The translocation fused the SCL/TAL-1 gene with the 
T-cell  receptor δ-locus, thus causing the misregulated expression of an aberrant TAL-1 fusion 
protein in the T-cell lineage, where TAL-1 is not normally expressed. 
The TAL-1 gene encodes for a transcription factor belonging to the basic helix-loop-
helix (bHLH) family. The activity of TAL-1 relies on two important domains of the protein. First, 
the HLH domain promotes homo- or hetero-dimerization of the protein with the ubiquitously 
expressed bHLH E2A proteins (E47, E12 and HEB). Second, the basic domain mediates DNA 
binding to the CANNTG consensus sequence, referred to as the E-box.
During embryogenesis, TAL-1 is expressed in hemogenic sites (YS and AGM), as 
well as in neural tissues and the vascular system146. The gene knockout of TAL-1 has shown 
that it is essential for the development of all hematopoietic lineages54. TAL-1 mutant ES cells in 
chimeric mice do not contribute to the development of any hematopoietic lineage. Importantly, 
expression of TAL-1 cDNA in TAL-1-/- cells rescues the hematopoietic defects demonstrating 
that TAL-1 is essential in ES cells for hematopoietic development. Thus, these studies implicate 
TAL-1 as one of the earliest expressed transcription factors required for hematopoiesis. 
Within the hematopoietic system, the expression pattern of TAL-1 is very similar to 
that of GATA-1, namely, it is expressed in erythroid, megakaryocytic and mast cells147. It is 
also highly expressed in HSCs. Shivadasani and colleagues have shown by targeted gene 
disruption that TAL-1 is necessary for the production of embryonic blood cells. Tal-1 null 
embryos die at E9-10.5 due to anemia148. A functional inter-connection between GATA-1 and 
TAL-1 in erythropoiesis is supported by the fact that GATA binding sites in the TAL-1 promoter 
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are required for its transcription activation149. More recently, the role of TAL-1 specifically in the 
erythroid and megakaryocytic lineages was addressed using a TAL-1 conditional knockout. The 
loss of TAL-1 in these animals resulted in defects in both lineages, with a loss of progenitors, 
leading to anemia and thrombocytopenia. However, myeloid progenitors remained unaffected150. 
These observations suggest a crucial role for TAL-1 in the erythroid and megakaryocytic 
lineages150,151, and parallel those of the GATA-1 knockout which also results in defects in the 
Meg/E lineages66,119,128.
TAL-1 has been shown to be part of a large, so-called pentameric, protein complex that 
includes E47, Lmo2, Ldb1 and GATA-1. In vitro this complex acts as a transcriptional activator52. 
Lmo2 contains a LIM-domain which is involved in protein-protein interactions by acting as 
the bridging molecule between DNA binding proteins. Lmo2 null mice are characterized by 
a complete absence of hematopoietic cells, a phenotype which is very similar to that of the 
TAL-1 knockout55,152. The TAL-1 partner LIM-domain binding protein (Ldb1) is a ubiquitously 
expressed protein which is extremely conserved between human and mouse153. Loss of function 
of Ldb1 results in a severe developmental patterning defect154 (A. Hostert, unpublished data). 
Interestingly, the hematopoietic system was also impaired, characterized by an absence of yolk 
sac blood islands in Ldb1 null embryos. This observation supports a role of Ldb1 in erythropoiesis, 
probably through interaction with proteins such as GATA-1 and TAL-1. Interestingly, Lmo2 was 
shown by immunoprecipitations to interact directly with GATA-1 in MEL cells, and to serve as 
a bridging factor between GATA-1 and TAL-163. Thus, Lmo2 could serve as a bridge between 
GATA-1 and TAL-1/Ldb1 in the pentameric complex52.
The function of the pentameric complex has been linked to the regulation of a number 
of target genes The complex binds to DNA through GATA/E-box motifs, with both DNA binding 
motifs spaced within 9-11bp to each other. The GATA/E-box motif was identified in a number of 
genes by ChIP assays using TAL-1 specific antibodies in MEL cell chromatin155, and in the DNase 
Hypersensitive Site 1 (HS I) of the GATA-1 gene89. The TAL-1 complex in association with SP1 
binds to the promoter of the c-kit gene, which codes for a kinase essential for hematopoietic 
development156. In addition, the erythroid specific EKLF gene contains upstream of the 
promoter a GATA-E-box and a GATA motif. In transcriptional assays, these motifs were shown 
to be sufficient to drive a level of expression comparable to the minimal promoter157. Recently, 
TAL-1 was shown to form a complex including GATA-1, E2A, Lmo2 that binds and activates 
the promoter of the GlycophorinA (GPA) gene, coding for one of the most abundant erythroid 
surface proteins158. Transcriptional activation of the GPA gene was shown to be dependent on 
the GATA-E-box and Sp1 motifs.
Lastly, TAL-1 has also been shown to interact in erythroid cells with both activating and 
repressing co-factors. Using immunoprecipitation experiments, P300 was found to interact with 
TAL-1 in differentiated MEL cells, and co-transfection assays showed that this interaction led to 
gene activation159. In MEL cells, TAL-1 also co-immunoprecipitated with the Sin3A transcriptional 
co-repressor and with HDAC1160. These observations suggest that TAL-1 can be involved in 
gene repression as well as gene activation.
EKLF 
EKLF was identified as an erythroid specific transcription factor161. It belongs to the 
SP/XKLF (specificity protein/krüppel-like factor) family based on its three conserved Cys2His2 
type zinc-fingers. This domain, located at the C-terminal end of the protein, mediates DNA 
binding to GC-rich sequences, such as CACC boxes found in many erythroid genes161,162. The 
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zinc-fingers overlap with a nuclear localization domain. In the N-terminal of the protein, two 
proline-rich domains have been defined as transactivation domains since in vitro they were 
shown to mediate transcriptional activation163,164. 
EKLF expression is restricted to the erythroid lineage only165. Hence, it is not surprising 
to find a GATA functional binding site in the promoter of EKLF, suggesting that EKLF is 
downstream of GATA-1 in erythropoiesis166. The regulatory sequences located 1kb 5’ to the 
start of transcription are sufficient to drive erythroid-specific expression in mice157. Analysis of 
this sequence revealed a GATA/E-box/GATA motif that was shown to be essential for EKLF 
expression in vitro. In addition, these sequences are essential in transgenic mice167.
As shown in EKLF gene knockout studies, the complete lack of erythropoiesis results 
in embryonic lethality at around day 14. Heterozygous knockout mice do not present with any 
defects168,169. EKLF-/- embryos have normal primitive yolk sac hematopoiesis up to E12, and 
die from anemia in early fetal life following shift of after the switch of hematopoiesis to the fetal 
liver168. The EKLF phenotype can be related to its role in regulating globin gene expression. The 
β-globin gene contains a CACC box in the promoter to which EKLF can bind with a very high 
affinity169-172. When crossed with mice containing a human β-globin locus, EKLF-/- null embryos 
express no β-globin, however they do exhibit elevated expression of γ-globin173. In addition, 
DNase hypersensitivity of the β-globin Locus Control Region (LCR) in EKLF mutants showed 
that HS3 became less sensitive to DNase digestion, suggesting that loss of EKLF affects 
chromatin structure at the LCR173. More direct evidence in a recent study further reinforced the 
important role of EKLF in β-globin locus regulation by showing it is required for the formation 
of the three-dimensional Active Chromatin Hub (ACH) and for the expression of the β-globin 
gene174. In addition, recent microarray analysis revealed that the Alpha Hemoglobin Stabilizing 
Protein (AHSP) gene, a protein that stabilizes free α-globin chains, was downregulated in 
EKLF knockout erythroid cells175. Importantly, a number of other target genes were found to be 
commonly affected in both the GATA-1 and EKLF knockouts175,176.
EKLF interacts with a number of other proteins in exerting its functions. EKLF binds 
through its DNA binding domain to the mSin3a and HDAC1 repressors, thus preventing DNA 
binding177. Whereas this interaction suggests a role for EKLF in gene repression, such a function 
has not yet been described in vivo. EKLF has also been shown to bind proteins involved in 
gene activation, such as CBP/P300, which acetylates EKLF on conserved lysine residues thus 
enhancing the activation of the β-globin promoter178. It was also shown to require a chromatin 
remodeling complex related to SWI/SNF to induce the active conformation of the β-globin 
gene179. In order to gain further insight into the functions of EKLF in vivo, a strategy to tag the 
protein is presented in Chapter 2.
PU.1
PU.1 is a key transcription factor in hematopoiesis180. It is required for myeloid lineage 
differentiation58,181. PU.1 overexpression in MEL cells blocks erythroid differentiation and this 
block can be relieved by overexpression of GATA-145,182. The Ets DNA binding domain of PU.1 
has been shown to physically interact with the C-terminal domain of GATA-1 thus inhibiting 
DNA binding and GATA-1-mediated transcriptional activation in erythroid cells45,182. Conversely, 
GATA-1 interacts with PU.1 in myeloblasts leading to PU.1-dependent transcription repression, 
without affecting the PU.1 gene expression46. Whereas the GATA-1 interaction with PU.1 
prevents recruitment of c-jun by PU.1. for transcriptional activation, the molecular mechanism 
by which the PU.1 interaction with GATA-1 represses GATA-1 activity in erythroid cells remains 
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to be elucidated183,184. These observations suggest that the two hematopoietic transcription 
factors GATA-1 and PU.1 are functionally antagonistic in cell lineage decisions between the 
myeloid and erythroid lineages. In agreement with this model, recent knockdown experiments 
in zebrafish have shown that expression levels of PU.1 versus GATA-1 represent an essential 
aspect of the balance of myeloid versus erythroid commitment185.
CBP/P300
The two highly related, ubiquitously expressed histone acetyltransferases (HAT), CBP 
and P300, have been reported to interact with a number of transcription factors (Reviewed by 
Goodman and Smolik186). Immunoprecipitation experiments in MEL cells have shown that CBP 
can bind to GATA-1 and acetylation of GATA-1 correlates with the enhancement of GATA-1 
transcriptional activity in murine fibroblasts101. Since histone acetylation is essentially linked to 
gene activation, one model suggests that GATA-1 tethers such chromatin modifiers to target 
genes to facilitate transcription, as was described for example for the β-globin locus69. Another 
model would suggest that transcriptional activation may be mediated by acetylated GATA-1, 
since GATA-1 acetylation by P300 was linked to an increase of its transcriptional activity104. 
However, the role of GATA-1 acetylation in enhancing transcriptional activation remains a 
somewhat controversial issue as two reports previously published on GATA-1 acetylation do not 
agree on this aspect104,105. 
 
Rb
Retinoblastoma is a tumor suppressor with a critical function in cell cycle progression 
from G1 to S phase187. The Rb null mutation leads to embryonic lethality characterized by 
neuronal defects and anemia due to erythropoietic impairment188,189. Importantly, erythroid cells 
in GATA-1 overexpressing mice fail to arrest at the G1 phase of the cell cycle. This defect is 
characterized by a decrease of the active hypophosphorylated form of Rb that interacts with the 
transcription factor E2F to stop cell cycle progression123. In addition, GATA-1 has been shown 
to interact directly with Rb123. These observations suggest a common pathway between Rb and 
GATA-1 in erythropoiesis.
2.3.1.6 GATA-1 Target genes
GATA sequences occur frequently in the genome and virtually all erythroid genes 
contain GATA binding sites in their regulatory elements57. The number of GATA-1 target genes 
is ever increasing since GATA-1 is also involved in regulating gene expression in lineages 
other than the erythroid lineages (i.e eosinophils, megakaryocytes). GATA-1 has been reported 
to regulate genes involved in many pathways, such as anti-apoptotic regulation, hemoglobin 
synthesis, cell signaling and also the cell cycle176. Direct binding of GATA-1 to target genes has 
been addressed primarily by Electro Mobility Shift Assays (EMSA) and by Chromatin Immuno 
Precipitation assays (ChIP). The latter consists of using an antibody to precipitate the protein of 
interest from formaldehyde crosslinked chromatin and to assay the specific in vivo bound DNA 
sequences by Polymerase Chain Reaction (PCR). 
 
Globin genes
The β-globin gene was the first GATA-1 target gene to be identified. GATA-1 was 
found to bind to the β-globin gene enhancer83,84. It can also bind the α-globin gene78. Recent 
studies of the α-globin gene cluster have shown that in committed erythroid cells, GATA-1 binds 
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to the promoter and to an upstream HS68. However, GATA-1 null mice can still produce some 
hemoglobin suggesting that GATA-1 might not be absolutely essential for globin expression. 
In addition, the GATA-1 null cells express GATA-2 at an abnormally high level, suggesting that 
GATA-2 can partially replace GATA-1 in activating globin expression66.
ChIP-on-Chip analysis has identified GATA in vivo binding sites across the β-globin 
LCR190. Recently, using the 3C (Chromosomal Conformation Capture) approach in erythroid 
cells, GATA-1 and its FOG-1 cofactor were shown to mediate spatial interactions between 
β-globin gene and the LCR191. 3C technology enables the in vivo mapping of interactions 
between chromosomal regions independent of their transcriptional status192. 
 
Cell cycle
Cell cycle-related genes are affected in GATA-1 overexpressing erythroid cells. For 
example, the decrease in cyclin E expression normally observed during erythroid differentiation 
was not observed upon GATA-1 overexpression123. These observation suggested a role for 
GATA-1 in the regulation of the cell cycle, and more precisely in the G1 to S transition. Microarray 
data, obtained from the GATA-1 null G1E proerythroblastic cell line expressing an inducible form 
of GATA-1, showed that a number of cell cycle genes, such as p27kip1, were activated, while 
some others, such as Cyclin D2, were repressed193. However, this study did not systematically 
investigate whether these genes were direct or indirect targets of GATA-1. Nevertheless, in 
the same study it was shown that GATA-1 could bind directly to the repressed promoter of 
c-myc, a known oncogene involved in cell proliferation193. These observations suggest that in 
differentiating erythroid cells, c-myc repression, and hence repression of cell proliferation, is 
GATA-1 dependent. As we mentioned, GATA-1 plays a role in cell cycle as it was shown to 
interact with the Rb protein123. Chapter 4 describes that GATA-1 binds to the c-myc promoter 
in association with the essential hematopoietic transcription factor Gfi-1b, which acts as a 
repressor.
Signaling pathways
Cell surface receptors are essential molecules that are part of the signaling pathways 
that respond to a stimuli at the cell/environment interface and trigger intracellular responses. 
During erythroid differentiation the activation of glycophorin A (GPA, a membrane protein 
associated with the erythroid marker Ter119) and the erythopoietin receptor (EpoR, receptor 
to the Epo growth factor that promotes differentiation of erythroid cells) were shown to be 
GATA-1-dependent158,81. EpoR is present at the surface of erythroid, megakaryocytes and mast 
cells. Binding of Epo to its receptor triggers signaling cascade, which leads to the proliferation, 
differentiation and survival of erythroid progenitors194. However, in GATA-1 null proerythroblasts 
EpoR transcription appeared unaffected, suggesting a potential redundancy with GATA-266.
 
Transcription factors
Transcription factors constitute an important group of GATA-1 target genes. Thus 
GATA-1 play a pivotal role in broad transcriptional regulation. As described earlier in the 
introduction, GATA-2 is an essential factor in early hematopoiesis. Erythroid cells lacking 
GATA-1 exhibit higher GATA-2 expression levels66. GATA-2 gene analysis has revealed 
multiple GATA binding sites in regulatory elements. Using ChIP assays, Bresnick and 
colleagues investigated GATA-1 binding to the GATA-2 locus139,195. In progenitor cells, the active 
GATA-2 locus is occupied by GATA-2 and CBP. Upon erythroid commitment, differentiation and 
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increased GATA-1 expression, GATA-1 replaces GATA-2 binding in the GATA-2 locus, CBP is 
displaced and a wave of deacetylation occurs concomitant with the GATA-2 repression. Using 
the G1E GATA-1 null cell line expressing an inducible form of GATA-1, it was clearly shown that 
GATA-2 repression required the expression and binding of GATA-1 to the locus. Data presented 
in Chapters 3 and 4 of this thesis provide further molecular insight as to how GATA-1 and FOG-1 
repress the GATA-2 locus.
TAL-1 also plays an essential role during hematopoiesis where it is expressed early 
in the hematopoietic stem cells and later in the erythroid, megakaryocytic lineages and in 
mast cells147. Detailed studies of the TAL-1 promoter revealed the presence of GATA sites. 
GATA-1 was shown to bind directly to the TAL-1 promoter, in cooperation with the ubiquitously 
expressed SP1 transcription factor149. In vitro data suggested that GATA-1 promoted activation 
of the erythroid-specific expression of the TAL-1 gene.
EKLF, an erythroid specific transcription factor, has also been reported to be a direct 
target of GATA-1. The EKLF promoter region contains two GATA binding sites, and importantly, 
one was shown to be crucial for its transcriptional activation107. The motif GATA/E-box/GATA 
present in an upstream enhancer element was shown to be essential for in vivo erythroid 
expression of an EKLF transgene167. More recently, and consistent with previous data, the 
expression of GATA-1 in the GATA-1 null G1E cells was correlated with the upregulation of 
EKLF gene transcription193. In Chapter 4, we show GATA-1 binding in association with the TAL-1/ 
Ldb1 complex to the upstream enhancer of the EKLF gene in differentiated erythroid cells157. 
In human eosinophilic cells, GATA-1 protein was also shown to regulate the expression 
of an eosinophil/granulocyte gene, the major basic protein (MBP)131. In the mouse hematopoietic 
system, Mbp gene is highly expressed in eosinophils and less so in basophils196,197. The 
MBP protein is one of the principal mediators in the inflammatory response. A more detailed 
analysis of the MBP gene has revealed functional binding sites for GATA-1 in the promoter and 
GATA-1 binding to the MBP promoter in eosinophils was associated with modulation of the 
gene’s expression198.
2.4 GATA-1 and Diseases 
Down’s syndrome patients present a high incidence of hematopoietic malignancies 
such as transient myeloproliferative disorder (TMD) or acute megakaryoblastic leukemia 
(AMKL). AMKL patients express a truncated GATA-1 protein in which the N-terminal 
83 amino acid activation domain has been deleted because of a premature stop codon; the 
full-length GATA-1 protein is absent199-201. These observations suggest that the loss of full length 
GATA-1 is an essential step in leukemogenesis in these patients. But the mechanism by which 
the mutations contribute to leukemia remains unclear. Indeed, even in normal hematopoietic 
cells, a second isoform of GATA-1 is expressed from an alternative translational initiation site 
located at methionine 84, thus omitting the N-terminal activation domain. Despite a lower level 
of expression, the shorter isoform can be detected in erythroid cell lines such as the murine MEL 
and the human K562 erythroleukemic cells as well as in the mouse tissues. The shorter protein 
shows normal DNA binding capacity, as it contains the two characteristic zinc-fingers202. 
In addition, missense mutations have been identified in families presenting with anemia 
and thrombocytopenia, though these disorders remain rare. Strikingly, all mutations associated 
with these disorders reside in the N-terminal zinc finger of GATA-1. The first mutation that was 
found in patients suffering from severe anemia and thrombocytopenia, was a substitution of a 
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valine to a methionine at position 205 (V205M). This mutation leads to a dramatic decrease of 
GATA-1 binding to FOG-1, as was also shown in vitro138,201. Other mutations in the GATA-1 protein 
such as R216Q, were shown to be present in patients suffering from macrothrombocytopenia 
with β-thalassemia. This mutation in the N-terminal zinc finger does not affect the interaction 
with FOG-1, but affects the binding to palindromic GATA sequences130.
3. Chromatin and Transcription
The length of the DNA contained in the nucleus when fully stretched is about 2 meters. 
To fit into the nucleus, DNA is compacted into chromatin. Despite the enormous degree of 
compaction that the DNA undergoes, the DNA in chromatin must be rapidly accessible for 
interactions with protein complex that regulate many DNA functions (replication, transcription, 
repair and recombination). The dynamic organization of DNA in chromatin is therefore an 
essential aspect of gene regulation.
3.1 Definition-Structure
To form the so-called chromatin, DNA is in complex with proteins, mostly histones. 
The fundamental unit of chromatin is the nucleosome. It is composed of a histone (H) octamer 
around which 146 bp of DNA are wrapped. The octamer consists of two copies of each of the 
histones H2A, H2B, H3 and H4. Structurally, histone proteins contain two domains: a globular 
domain involved in histone-histone and histone-DNA interactions, and a N-terminal tail of 
variable length that is the site of many posttranslational modifications, involved in activation, 
silencing, chromatin assembly and DNA repair203. Nucleosome arrays assembled on DNA are 
separated by short (10-80bp) segments of DNA (the linker DNA) to form a beads-on-a-string-
like structure, which can fold into a helical compacted structure, the so-called 30 nm fibre. This 
structure is found in both interphase chromatin and mitotic chromosomes. Histone H1, a fifth 
class of histones, binds to the nucleosomes and to linker DNA thus compacting the nucleosomal 
array into forming higher order chromatin structures such as the 30nm fiber and beyond. The 
overall compaction ratio estimated in mitotic chromosomes is about 10,000204. However the 
precise structure of higher order chromatin in chromosomes in vivo, beyond the 30nm fiber, 
remains unclear.
In the nucleus, two forms of chromatin can be distinguished: euchromatin and 
heterochromatin. Heterochromatin represents around 10% of the genome and remains 
condensed throughout the cell cycle. It is primarily associated with the gene-poor telomeric and 
pericentromeric regions and is thus considered to be a transcriptionally inactive form of chromatin. 
Further studies have described two subtypes of heterochromatin. Constitutive heterochromatin 
contains very few genes and is composed of a high content of repetitive sequences located in 
large regions such as centromeres and telomeres. Facultative heterochromatin corresponds 
to regions that condense into heterochromatin-like structures as a result of developmental 
changes. One of the best-studied examples of facultative heterochromatin is the X chromosome 
of mammals, that is subject to compaction in the X-inactivation process.
In contrast, euchromatin decondenses after metaphase, is nuclease sensitive and 
contains a high density of genes. In addition, the distinctions between heterochromatin and 
euchromatin are also reflected in the types and combinations of posttranslational modifications 
in histone tails (see below).
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3.2 Chromatin and Gene Expression
Nucleosomes associated with active genes were shown to be more accessible to 
nucleases than those associated with inactive genes205. Clues on the dynamic aspect of chromatin 
came from the isolation of proteins that are able to modify chromatin. In studying modification of 
chromatin structure, the best-studied level is that of the nucleosome. Generally, there are three 
ways in which chromatin structure can be modulated (i) by nucleosome remodeling catalyzed 
by specific large protein complexes containing specific enzymes that hydrolyze ATP, (ii) by 
covalent posttranslational modification of histone tails, (iii) by histone variants with specialized 
properties. 
3.2.1 Histone modifications
The N-terminal tails are not required for the structural integrity of the nucleosome206. 
However, they are essential for the regulation of chromatin structure in vivo as they are the 
sites of a very complex combination of post-translational modifications. The size of the tails 
varies from 16 to 44 amino acids, depending on the histone. In addition to the modifications 
presented below, we can mention that other modifications such as ubiquitination, sumoylation 
and PARylation can also occur203.
Histone acetylation/deacetylation
One of the best-described histone modifications is acetylation. Acetylation disrupts 
higher order chromatin folding and facilitates recruitment of transcription factors207. For these 
reasons, histone tail acetylation is generally correlated with transcription208. Histone tail 
acetylation occurs on specific lysine residues and is reversible, thus resulting in a dynamic 
state of acetylation and deacetylation. The acetylation status of histone tails is catalyzed by the 
enzymes Histone Acetyl Transferases (HAT) and Histone Deacetylases (HDAC). 
CBP (CREB Binding Protein) and p300, two closely related mammalian proteins, were 
identified as co-activators of transcription186,209 and possess HAT activity. These co-factors are 
thought to be tethered by specific transcription factors to gene targets, for example, by their 
interaction with transcription factors, such as GATA-1 or EKLF101.
Interestingly, yeast Gcn5 and its human homologue p300/CBP-associated factor 
(PCAF) are transcription factors that carry their own intrinsic HAT activity. Human TAF250, 
which is part of the basal transcriptional machinery, has also been shown to possess intrinsic 
HAT activity210. Finally, transcriptional effectors such as PCAF bind preferentially to specific 
acetylated lysines on histone tails through the bromodomain211.
HDACs work antagonistically to HATs in that they are associated with gene 
repression212. Based on their homology to yeast HDACs RPD3 and HDA1, mammalian HDACs 
are grouped respectively into class I and II. Activity of class I and II HDACs can be inhibited 
using the deacetylase inhibitor trichostatin A (TSA). HDAC1 and HDAC2 belong to the HDAC 
class I and share 84 % homology. Most HDACs do not contain DNA-binding activities, hence 
transcription factors recruit them to specific target genes. For example, the repression of the 
cyclinE expression resulting from Rb protein binding to E2F was shown to involve recruitment 
of HDAC1 protein binding to the promoter of cyclinE gene213. 
Importantly, HDAC inhibitors are important molecules in cancer research, as they are 
effectors of many pathways, such as growth arrest and apoptosis of transformed cells. They are 
already being used as therapeutic agents for the treatment of certain forms of cancer214.
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Histone methylation
Methylation of histones was first described in 1964215, however, the histone-
methyltransferases (HMT) responsible for catalyzing the histone methylation reaction were 
only recently discovered216. Since then, other HMTs have been described and classified based 
on the specificity of lysine residue methylation. Unlike histone acetylation, methylation can 
occur on lysine and arginine residues, catalyzed respectively by the SET domain-containing 
family of HMTs and the protein arginine methyltransferases (PRMTs). Methylation of histones 
plays an important role in chromatin regulation and is linked to both transcriptional activation 
and repression217. Methylation of histone H3 on lysine residue 9 (H3-K9) is associated with 
heterochromatin formation218 and gene repression. In heterochromatic regions, the Suv39H 
HMT methylates H3-K9, which is then recognized by the heterochromatin-associated protein 
HP1219. In contrast, methylation of H3-K4 is linked to gene activation220.
While regulation of histone acetylation is highly dynamic, histone methylation has been 
considered as very stable mark of the chromatin221. It is only very recently that an enzyme, 
referred to as LSD1 (Lysine Specific Demethylase1), has been identified that can demethylate 
histones. This enzyme has been previously shown to be part of repressor complexes, such as 
CtBP or Co-REST222,223.
Histone phosphorylation
Phosphorylation of serines is not as well characterized as other histone modifications; 
nevertheless the function of phosphorylation is linked to chromatin regulation during the cell 
cycle. Specific phosphorylation of H3-S10 is required for chromosomal condensation, whereas 
the level of the phosphorylated form rapidly decreases after mitosis. Moreover, the Snf1 kinase 
that phosphorylates specifically H3-S10 cooperates with the activating co-factor GCN5 HAT, 
suggesting that phosphorylation of H3-S10 is associated with gene activation224. In addition, the 
level of phosphorylated H1 increases during the cell cycle from the G2 to the S phase225.
The “histone code”
The number of reported histone modifications and their biological relevance is ever 
increasing. The brief introduction given in this thesis is highlighting some of the main concepts, 
but does not address them all exhaustively. Nonetheless, histones are modified in several ways 
leading to a concept of a complex interplay between all modifications, referred as the “histone 
code” 226. Histone modifications on the one hand have a structural function that influences 
interactions with DNA, and on the other hand affect binding and recruitment of effectors 
molecules227. Bromo- and chromodomains have been demonstrated to bind with high specificity 
to specific acetylated and methylated lysine residues, respectively228,229. Furthermore, histone 
modifications were shown to prevent or facilitate binding of effectors. For example, acetylation 
of H3-K9/K14 abrogates affinity of the co-repressor complex INHAT230. In addition, the NuRD 
complex is displaced from histone H3 if the latter is methylated on K4231. The binding of HP1 
to methylated H3 can recruit SUV39H, that can methylate H3 tail of neighboring histones, 
therefore spreading the modification and providing an example of how heterochromatin can 
spread232. In addition, specific histone modifications can modulate additional modifications 
in nearby residues. For example, methylation of H3-K9 for instance is inhibited if H3-S10 is 
phosphorylated233, and by contrast, phosphorylation of H3-S10 facilitates the acetylation of 
H3-K14234. These observations suggest that histone modifications can influence each other.
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3.2.2 Histone variants
In addition to the major histones contained in nucleosomes, some different histones 
have been described, the so-called histone “variants”. They are associated with all histones 
except H4, and differ structurally from the main histones by changes in amino acid sequences. 
However, their functions are as yet undetermined but they are thought to be involved in 
epigenetics changes. They are assembled in alternative chromatin structures that can be 
transmitted to the next generation235. In chromatin, they replace corresponding major histones. 
The majority of nucleosome assembly involving canonical histones occurs during the replication 
phase. In contrast to the major class of histones, some histones variants, such as the H3.3 can 
be incorporated throughout the cell cycle236. Interestingly, H3.3 has also shown to play a role in 
transcriptionally active chromatin of the chromosome236,237.
 3.2.3 Chromatin remodeling complexes
Large ATP-dependent chromatin remodeling complexes increase accessibility of the 
nucleosomal DNA during regulation of transcription. Enzymes possessing ATPase activity 
constitute the “heart” of the remodeling complexes. Based on homology of sequences, three 
classes of ATP-dependent chromatin remodeling complexes are distinguished: the SWI2/SNF, 
the ISWI and Mi-2 families238. Recently, a fourth class of complexes, INO80/SWR, was described 
in S. cerevisiae239 (Figure 6). In addition to the ATPase domain, these enzymes contain other 
functional domains such as bromodomains and PHD domains. Importantly, whereas SWI/SNF 
and ISWI complexes have a unique ATPase activity, the Mi-2 complex family has the particularity 
to possess ATPase and HDAC activities. These complexes are expressed ubiquitously.
SWI/SNF and ISWI
hSWI/SNF and ISWI, which are the two best-studied families of chromatin remodeling 
complexes, are conserved from yeast through to Drosophila and man. The first chromatin-
remodeling complex to be discovered in yeast was a 2 MDa complex containing the 
SWI2/SNF2 subunit responsible for nucleosome disruption240. Similar complexes were also 
identified in Drosophila and in human. In mammals there are two SWI/SNF2 homologues, Brm 
and Brg1241,242. 
Whereas early evidence suggested that the SWI/SNF complex was recruited to 
promoters by RNA pol II, subsequent data suggested that this is not the case. Instead, 
SWI/WNF is tethered to DNA by gene-specific transcription factors, eventually recruiting 
RNA pol II for transcription243,244. In addition, recruitment of SWI/SNF by an activator on a gene 
target has been shown in vivo by ChIP assays245. In mammals, the SWI/SNF is recruited to the 
β-globin locus by the essential erythroid specific transcription factor EKLF246, and to myeloid 
genes by C/EBPβ247. In vitro data have also indicated that GATA-zinc fingers are able to interact 
with SWI/SNF248 but no in vivo function has been described. Targeted inactivation of the Brg1 
gene in mice also resulted in an increase in expression of a number of genes, thus suggesting 
that the complex may also be linked to gene repression249.
ISWI chromatin remodeling complexes contain SNF2h as the ATPase subunit. In 
human, SNF2h forms three distinct complexes: RSF, ACF/WCRF and CHRAC. The ACF/WCRF 
complex is composed of 2 subunits: SNF2h and ACF, while the CHRAC complex contains in 
addition two subunits P15 and P17. 
Studies in vitro in Drosophila have linked ISWI to gene activation, but an increasing 
number of reports have also described a strong link between SNF2h and gene repression250. 
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NCoR, a SNF2h-containing chromatin remodeling complex, has also been shown to repress 
ribosomal gene transcription by recruiting histone deacetylases on rDNA promoters251. In 
addition, SNF2h was shown to localize with heterochromatin through its interaction with ACF1 
during replication252. Gene targeting of Brg1 and SNF2h have revealed that they are both 
essential for embryonic development. Brg1-/- mice die very early in embryogenesis, before the 
preimplantation stage (E3.5-E6.5)253. The SNF2h null phenotype in mice is also embryonic 
lethal. However, SNF2h null embryos undergo implantation254. Importantly, SNF2h knockdown 
experiments in primary erythroid progenitors were shown to lead to a marked reduction of 
GlyA+ cells and a decrease of β-globin mRNA accumulation, suggesting an essential role in 
erythropoiesis254. In Chapter 3, we describe a specific interaction of GATA-1 with SNF2h in the 
context of the ACF/WCRF complex, suggesting a possible function in a common pathway in 
erythropoiesis.
At the molecular level, Brg1 functions on both naked and nucleosomal DNA, and 
SNF2h is stimulated preferentially by nucleosomal DNA255,256. All chromatin complexes are able 
to remodel nucleosomes according to the “sliding model”, in which the amount of DNA exposed 
and nucleosome spacing remain unchanged238. However, the remodeling function of SWI/SNF 
induces topological changes in the nucleosomal structure that lead to an increase in the amount 
of DNA being exposed, and is referred to as “conformational change”.
NuRD/MeCP1
Purification of the NuRD/Mi-2 complex from HeLa cells and Xenopus eggs led to the 
characterization of the only type of chromatin remodeling complex that contains both ATPase 
Figure 6: Chromatin remodeling complexes.
Chromatin remodeling complexes in different species are classified based on their ATPase domain: CHD, 
ISWI, INO80 and Swi2P. Adapted from reference 239.
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and HDAC activities257,258. The purified MeCP1 protein complex is composed of 10 subunits, 
including all subunits of the NuRD complex and in addition the MBD2 subunit259. The latter was 
shown to bind methylated DNA259,260. This complex was shown to preferentially bind, remodel 
and deacetylate methylated nucleosomes over naked DNA259. 
In HeLa cells, characterization of the NuRD complex has revealed the presence of 
7 components, including the ATPase/helicase Mi-2, HDAC1 and 2, Metastasis Associated 
Protein 2 (Mta2), Methyl Binding Protein 3 (MBD3), Retinoblastoma Associated Protein 46 and 
48 (RbAp46/48). The core complex composed of HDAC1, HDAC2 and RbAp46/48 is shared 
between the NuRD complex and the chromatin-remodeling complex Sin3a. Within the NuRD 
complex, the MTA2 subunit plays an important role in modulating the activity of the HDACs261. 
The MBD3 subunit of the complex is a methyl-CpG-binding domain-containing protein262. 
Further studies have shown that the NuRD complex is itself part of a larger protein complex of 
10 subunits, the so-called MeCP1 complex. It contains in addition to the NuRD complex, MBD2, 
P66 and P68259,263,264. MBD2 is a methyl DNA binding domain-containing protein that is related 
to MBD3. However, unlike MBD3, MBD2 can bind to methylated DNA in vivo and in vitro in 
mammalian cells.
The NuRD/MeCP1 complexes have been associated with gene repression during 
development265-267. As with other remodeling complexes, NuRD/MeCP1 are recruited to target 
genes through interactions with DNA binding transcription factors. For example, Ikaros, an 
essential transcription factor for B and T cell development268, was shown to recruit NuRD 
complex to a heterochromatic region upon T-cell activation, suggesting that recruitment of 
NuRD is associated with alternative lineage suppression269. Interestingly, interaction of GATA-3 
with NuRD in differentiating Th2 cells was shown to activate transcription of the IL-4 gene after 
displacing MBD2 from the chromatin266. Expression of Mi2 defective for the ATPase activity 
relieved transcriptional repression, suggesting that the Mi2 protein is essential in the repression 
activity of the complex259. 
In addition, the presence of the MBD2/3 subunits in the complex suggests that it might 
be recruited to methylated DNA, thus mediating transcriptional silencing270. Importantly, the 
function of MBD2 and MBD3 differs between organisms. Whereas mammalian MBD3, either 
by itself or interacting with NuRD, does not show any affinity for methylated DNA, recombinant 
MBD3 isolated from Xenopus binds methylated DNA260,261. Further, in mammalian cells, MBD2 
can mediate the interaction between NuRD and methylated DNA in vitro261. 
Genetic studies of Mi2 have given some insight as to the function of the NuRD/MeCP1 
complexes in vivo. The Mi-2β conditional knockout in thymocytes showed that Mi2 is required 
at different stages of T cell maturation271. Despite its interaction with the repressive NuRD 
complex, Mi-2β was unexpectedly shown to promote expression of CD4 by association with 
HAT271. Recently, the function of MBD3L2, a homologue of MBD2 and MBD3 lacking the methyl 
CpG binding domain, was shown to be interchangeable with MBD2 in the MeCP1 complex 
in vitro. MBD3L2 mediates gene repression, but could displace MeCP1 from methylated DNA272. 
These observations suggest that Mbd related proteins could regulate function of MeCP1.
In Chapter 3, we report that GATA-1 interacts in erythroid cells with MeCP1 through its 
interaction with FOG-1. This complex is stably bound to repressed genes during erythropoiesis. 
In addition, it was shown recently that FOG-1 mediates the interaction of NuRD with GATA-1 by 
directly binding to MTA proteins273.
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Proteomic approaches require simple and efficient protein purifi-
cation methodologies that are amenable to high throughput.
Biotinylation is an attractive approach for protein complex purifi-
cation due to the very high affinity of avidin�streptavidin for
biotinylated templates. Here, we describe an approach for the
single-step purification of transcription factor complex(es) based
on specific in vivo biotinylation. We expressed the bacterial BirA
biotin ligase in mammalian cells and demonstrated very efficient
biotinylation of a hematopoietic transcription factor bearing a
small (23-aa) artificial peptide tag. Biotinylation of the tagged
transcription factor altered neither the factor’s protein interactions
or DNA binding properties in vivo nor its subnuclear distribution.
Using this approach, we isolated the biotin-tagged transcription
factor and at least one other known interacting protein from crude
nuclear extracts by direct binding to streptavidin beads. Finally,
this method works efficiently in transgenic mice, thus raising the
prospect of using biotinylation tagging in protein complex purifi-
cation directly from animal tissues. Therefore, BirA-mediated bio-
tinylation of tagged proteins provides the basis for the single-step
purification of proteins from mammalian cells.
In the postgenome-sequencing era, focus has shifted toward theidentification and characterization of the protein complement of
cells, the proteome. A crucial aspect of this effort is the utilization
of simple and efficient methodologies that are amenable to high-
throughput approaches for the purification of proteins and protein
complexes (1, 2). As a result, a number of generic affinity-based
methodologies have been developed for these purposes, based
primarily on the use of specific antibodies or affinity tags that are
fused to the protein of interest (3, 4).
Prominent among the affinity-based purification methodologies
is the biotin�avidin system. Biotin is a naturally occurring cofactor
for metabolic enzymes, which is active only when covalently at-
tached to the enzymes through the action of specific protein–biotin
ligases (5). Any biotinylated substrate can be bound very tightly by
the proteins avidin and streptavidin. Biotin�avidin binding is the
strongest noncovalent interaction known in nature (Kd� 10�15 M),
several orders higher than that of commonly used antibodies or
other affinity tags. As a result, the biotin�avidin affinity system has
numerous applications inmodern biological techniques (6). For the
purposes of protein purification, in particular, biotinylation offers a
number of advantages. For example, the high affinity of biotin for
avidin�streptavidin allows purification of the biotinylated protein
under high stringency conditions, thus reducing background bind-
ing often observed with other affinity tags that elute more easily. In
addition, there are very few naturally biotinylated proteins, thus
reducing the chance for crossreaction when using biotinylation in
protein purification, as opposed to antibodies that may crossreact
with several species.
The potential advantages of biotinylation tagging in protein
purification have not gone unnoticed (7). The characterization of
the minimal amino acid sequence requirements of naturally bio-
tinylated proteins has led to the development of sequence tags that
can be biotinylated in bacterial, yeast, insect, and mammalian cells
(7–11). Biotinylation can occur either by the cell’s endogenous
protein–biotin ligases or through the coexpression of an exogenous
biotin ligase, in most cases that of the bacterial BirA enzyme. These
tags, however, are large in size (at least 63 aa) and may thus affect
the structure of the proteins they are fused to. In addition, that these
tags can be recognized by endogenous enzymes excludes applica-
tions where biotinylation of the tagged protein may need to be
regulated. Furthermore, biotinylation using these tags is not very
efficient, particularly in mammalian cells (10, 11). Another ap-
proach, so far only demonstrated in bacteria (12–15), utilizes small
(�23-aa) artificial tags that have been selected through multiple
rounds of screening combinatorial peptide libraries for specific
biotinylation by BirA biotin ligase (16). These tags have been shown
to be biotinylated in vitro with kinetics comparable to those of
natural biotin acceptor sequences (17) and may thus serve as
excellent substrates for efficient biotinylation in cells by coexpressed
biotin ligases.
Simple generic affinity purification methodologies have been
increasingly applied for the purposes of large-scale proteomic
studies, particularly in yeast (18, 19). However, these often use
reagents of variable affinities (e.g., antibodies) that increase back-
ground and�or intermediate steps (e.g., prepurification or affinity
tag removal) that restrict their simple application in more complex
protein sources such as mammalian cells. Considering the advan-
tages of biotinylation, we explored the feasibility of using it for the
simple high-affinity one-step purification of tagged proteins from
mammalian cells. To these ends, we coexpressed bacterial BirA
biotin ligase and hematopoietic transcription factors tagged by an
N-terminal fusion of a small artificial peptide previously shown to
be biotinylated by BirA (15–17). We show that tagged proteins can
be very efficiently and specifically biotinylated in mammalian cells
and transgenic mice and can be efficiently purified in a single step
by binding to streptavidin beads.
Experimental Procedures
Constructs. The coding region of the Escherichia coli birA biotin–
protein ligase gene (20) was cloned from genomic DNA by PCR as
an �1-kb fragment by using Deep-VENT DNA polymerase (New
England Biolabs) and verified by sequencing. The birA gene was
recloned into the BglII site of the erythroid expression vector
pEV-puromycin, which consists of the human �-globin Locus
Control Region (miniLCR), the human �-globin promoter, and the
�-globin second intron (21). GATA-1 cDNA cloned in pEV-
NeomycinwasN-terminally tagged by introducing into theNcoI site
at the start codon, an oligonucleotide linker with NcoI overhangs
Abbreviations:MEL,mouse erythroleukemic; HRP, horseradish peroxidase; EKLF, erythroid
Kru¨ppel-like factor.
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coding for the 23-aa biotinylation tag (16). Tagged erythroid
Kru¨ppel-like factor (EKLF) cDNA was constructed in pBluescript
by cloning sequentially into the NcoI site start codon firstly an
oligonucleotide coding for three copies of the hemagglutinin tag,
followed by an oligonucleotide coding for the 23-aa biotinylation
tag. Tagged EKLF was then subcloned into pEV-Neomycin.
Mouse Erythroleukemic (MEL) Cell Transfections.MELcells (22)were
initially electroporated with linearized BirA�pEV, and stable
clones were selected under puromycin. Clones were screened for
BirA RNA expression by Northern blot analysis. A selected BirA�
pEV MEL clone was transfected with tagged GATA-1�pEV, and
stable clones were double selected for puromycin and neomycin
(Invitrogen).
Nuclear Extract Preparation. MEL cells cultured in DMEM supple-
mented with 10% FCS at 37°C were induced to differentiate into
mature erythroblasts with 2%DMSO for at least 3 days (22). Cells
were harvested by centrifugation at 640 � g and washed once with
cold PBS. The cell pellet was resuspended in 2.2 M sucrose in 10
mM Hepes, pH 7.9�25 mM KCl�0.15 mM Spermine�0.5 mM
Spermidine�1 mM EDTA and incubated for 20 min. Cells were
lysed with a blender, and lysis was checked under a lightmicroscope
by staining nuclei with Unna (Methylgreen-Pyronin). Nuclei were
pelleted by ultracentrifugation at 141,000 � g for 2 h at 4°C,
resuspended in lysis buffer (10 mM Hepes, pH 7.9�100 mM KCl�
3 mM MgCl2�0.1 mM EDTA�20% glycerol), and extracted by
dropwise addition of 3.3 M KCl until the final concentration was
�400 mM. Insoluble material was removed by ultracentrifugation
at 300,000 � g for 1 h at 4°C. Nuclear extracts were aliquoted and
stored at �70°C.
Immunoblot Analysis.For analysis ofGATA-1 expression and in vivo
biotinylation, nuclear extracts (1–2.5 �g�lane) were resolved by
SDS�PAGE in an 8% gel and blotted onto ProTran nitrocellulose
membrane (Schleicher & Schuell) by using standard procedures.
Filters were blocked for 1 h in 5% BSA�1� TBS�0.2% Tween-20
and incubated for 1 h at room temperature with anti-GATA-1 N6
rat monoclonal antibody (Santa Cruz Biotechnology, dilution
1:5,000) or streptavidin–horseradish peroxidase conjugate (HRP)
(NEN, dilution 1:10,000). Filters were washed in 1� TBS�
0.5M NaCl�0.3% Triton X-100 and incubated in secondary rabbit
anti-rat antibody (DAKO, dilution 1:3,000), as above. No second-
ary antibody step was required after incubating the filters with
streptavidin–HRP. Filters were developed by using enhanced
chemiluminescence (Amersham Pharmacia).
Binding to Streptavidin Beads. Paramagnetic streptavidin beads
[Dynabeads M-280, Dynal (Great Neck, NY)] were blocked by
washing three times in TBS with 200 ng��l purified chicken serum
albumin (Sigma-Aldrich). We used �20 �l of beads per 1 mg of
nuclear extract. Binding was done in 1� TBS�0.3% Nonidet P-40
at 4°C for 1 h to overnight on a rocking platform, followed by six
washes in binding solution at room temperature. Bound material
was eluted by boiling for 5 min in Laemmli protein sample loading
buffer and analyzed by immunoblotting as above.
MS.Proteins eluted from the beads after binding of theBirAnuclear
extract were separated by SDS�PAGE electrophoresis on an 8%
polyacrylamide gel and stained with Colloidal blue (Invitrogen).
The entire lane was cut out and divided into at least 20 gel plugs,
which were each further reduced to 1 mm3 gel pieces and dried by
using 100% acetonitrile (Fluka) in 60% acetonitrile pretreated
tubes (Bioquote, York, U.K.). Proteins were in-gel-digested by
using modified trypsin (Roche Diagnostics) in 50 mM ammonium
bicarbonate. Digests were analyzed by nanoflow liquid chromatog-
raphy–tandem MS by using an electrospray ionization quadrupole
time-of-flight mass spectrometer (Q-Tof, Micromass, Manchester,
U.K.) operating in positive ion mode. A nanoLC system was
coupled to theQ-Tof essentially as described (23). Peptidemixtures
were delivered to the system by using a Famos autosampler (LC
Packings, Amsterdam) at 3�l�min and trapped on anAquaC18RP
column [Phenomenex (Belmont, CA); column dimensions 1 cm �
100�m ID, packed in-house]. After flow splitting down to 150–200
nl�min, peptides were transferred to the analytical column (Pep-
Map, LC Packings; column dimensions 25 cm� 50 �m ID, packed
in-house) in a gradient of acetonitrile (1%permin). Fragmentation
of eluting peptides was performed in data-dependent mode, and
mass spectra were acquired in full-scan mode. Database searches
were performed by using MASCOT (www.matrixscience.com).
Chromatin Pull-Down Assays. MEL cells were treated with 1%
formaldehyde in 40mMHepes, pH 7.9, at room temperature for 10
min, followed by quenching with 0.125 M glycine. Crosslinked
chromatin was fragmented by sonication [10 � 30-s bursts at
amplitude 5, followed by 10 � 30-s bursts at amplitude 8 by using
a Sanyo Soniprep (Loughborough, U.K.) 150 sonicator] and ali-
quots corresponding to 4–10 OD260 units were snap-frozen. Pull-
downs were carried out by incubating an aliquot of crosslinked
chromatin for at least 1 h at 4°C with 20 �l of streptavidin-coated
Dynabeads, preblocked with 1 mg�ml BSA and 0.4 mg�ml soni-
cated salmon sperm DNA. Washes were done according to stan-
dard protocols (www.upstate.com�misc�protocols.asp). Elution of
bound material and reversal of crosslinks was done in 1% SDS in
TE buffer (10 mM Tris�1 mM EDTA, pH 8.0) by overnight
incubation at 60°C with shaking. DNA was recovered after depro-
teinization, and aliquots of pulled-downDNAwere assayed by PCR
using primers against the erythroidmouse �maj globin promoter as
described in Supporting Materials and Methods, which is published
as supporting information on the PNAS web site, www.pnas.org.
Transgenic Mice.DNA fragments containing the tagged EKLF, and
BirA erythroid expression cassettes were released fromprokaryotic
vector sequences by double digestion with Aat II�Asp 718. The
DNA was gel-purified by using Gelase (Epicentre Technologies,
Madison, WI) and prepared for microinjection by using EluTip
(Schleicher & Schuell) according to the manufacturers’ instruc-
tions. Microinjection into mouse fertilized eggs was carried out
according to standard procedures (24). Screening of mice for
transgenics was carried out by Southern blot analysis by using the
BirA cDNA and the human �-globin intron II as probes.
Results
Efficient Biotinylation of Tagged GATA-1 in Transfected Cells. The
scheme for the specific in vivo biotinylation of tagged proteins in
mammalian cells is outlined in Fig. 1A. According to this procedure,
a small (23 aa) peptide tag is fused to the protein of interest and
coexpressed in cells together with BirA, a bacterial protein–biotin
ligase (20). The peptide tag used has been previously isolated from
a synthetic peptide library screened for BirA-mediated biotinyla-
tion, which occurs specifically at the lysine residue of the tag
(16). Protein database searches have identified no naturally occur-
ring proteins that possess a sequence motif similar to that of the
peptide tag.
The protein we tagged in testing this system was the essential
murine hematopoietic transcription factorGATA-1 (for review, see
ref. 25). The tag was fused N-terminally to GATA-1 and expressed
under the control of a human �-globin expression cassette in MEL
cells, which can be induced to undergo terminal erythroid cell
differentiation (22). BirA was also cloned and expressed in MEL
cells by using the human globin expression cassette. Clones corre-
sponding to single and double stable transfectants for tagged
GATA-1 and BirA were isolated and initially screened for expres-
sion of both constructs. In the case of GATA-1, Western blot
analysis using a GATA-1 antibody detects the slower-migrating
tagged protein as well as the endogenous GATA-1 in nuclear
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extracts from transfected cells (Fig. 1B, lanes 1 and 2). Expression
of BirA was analyzed at the RNA level (data not shown).
We next tested, on selected stable transfectants, whether the
taggedGATA-1 protein was biotinylated by BirA. Assaying nuclear
extracts fromMEL cell clones using a streptavidin–HRP conjugate
showed a robust signal corresponding to the tagged GATA-1
protein, detectable only in the lane of the tagged GATA-1�BirA
double transfectant (Fig. 1B, lane 5). No biotinylation of tagged
GATA-1 is visible in the absence of BirA (Fig. 1B, lane 6). These
findings confirm that BirA protein is synthesized in an active form
in transfected MEL cells. In addition, very little nonspecific back-
ground biotinylation is observed in MEL cell nuclear extracts
expressing only BirA (Fig. 1B, lane 7). We therefore conclude that
expression of bacterial BirA protein–biotin ligase in MEL cells can
specifically biotinylate a mammalian transcription factor bearing a
unique peptide tag.
We next tested the efficiency of biotinylation by binding tagged
GATA-1 in crude nuclear extracts to streptavidin paramagnetic
Dynabeads (Fig. 1C).Analysis of thematerial eluted from the beads
showed that almost all of the tagged GATA-1 protein was bound
(compare lane 2 to lanes 1 and 3, Fig. 1C). Reprobing the same filter
with streptavidin–HRP shows �100% efficiency in the biotinyla-
tion and capture of tagged GATA-1 by the beads (Fig. 1C, lanes 4
and 5). In addition, consistent with what was seen in Fig. 1B, there
is little background binding of endogenously biotinylated proteins
to the beads, as detected by streptavidin–HRP (Fig. 1C, lane 5).
These data demonstrate that tagged GATA-1 is very efficiently
biotinylated and recovered from extracts by streptavidin binding,
with negligible background biotinylation.
Single-Step Purification of Biotinylated GATA-1 from Crude Nuclear
Extracts by Streptavidin Binding.We also explored the feasibility of
a single-step purification in isolating biotinylated GATA-1 from
crude nuclear extracts by directly binding to streptavidin beads
undermoderate stringency (150mMNaCl�0.3%Nonidet P-40�200
ng��l chicken serumalbumin).We first tried a control binding from
5mg of crude nuclear extracts fromMEL cells expressing only BirA
(Fig. 2, lane 4). The eluted material consisted of approximately five
strongly stained bands against a backdrop of much fainter bands
(Fig. 2, lane 5). We identified the background binding proteins by
excising the whole lane from the gel and analyzing it by liquid
chromatography–tandem MS. The proteins thus identified are
classified in Table 1 according to biological function and cellular
compartment, as defined by the GeneOntology Consortium (www.
geneontology.org). The results showed that the most abundant
background proteins identified were the naturally biotinylated
carboxylases and associated enzymes, which largely coincided with
the intensely staining bands. We also found background binding of
abundant nuclear proteins involved in mRNA processing, such as
splicing factors, as well as of ribosomal proteins. Together, these
Fig. 1. (A) Scheme for the specific biotinylation of tagged GATA-1 by BirA biotin ligase in MEL cells. The sequence of the 23-aa peptide tag fused to the N
terminus of GATA-1 is shown. The asterisk indicates the lysine residue that becomes specifically biotinylated by BirA. Speckled boxes indicate the positions of
the two GATA-1 Zinc-fingers. Tagged GATA-1 and BirA were cloned separately in a mammalian erythroid expression cassette and coexpressed in MEL cells. (B)
Biotinylation of tagged GATA-1 in MEL cells. (Left) Western blot with an anti-GATA-1 antibody to detect endogenous and tagged GATA-1 proteins. (Right)
Western blot of the same extractswith streptavidin–HRP conjugate to detect biotinylatedGATA-1. Nuclear extracts (5�gper lane) from the double transfectants
(lanes 1 and 5) and single transfectants (lanes 2, 3, 6, and 7) for tagged GATA-1 and Bir A were tested. Lanes 4 and 8, nuclear extract from nontransfected MEL
cells. Biotinylated GATA-1 (asterisk) is clearly visible in only in the lane of the double transfected cells. Also indicated is the low background detected by
streptavidin inMEL nuclear extracts from cells expressing only BirA (Right, lane 7). (C) Efficiency of GATA-1 biotinylation and binding to streptavidin beads. (Left)
Western blot using anti-GATA-1 antibody to detect binding of tagged GATA-1 to streptavidin beads (lane 2; starting material for the binding was 2.5 times the
amount of nuclear extract shown in the input lane). Input and unboundmaterial are shown in lanes 1 and 3. (Right) The same filter stripped and reprobed with
streptavidin–HRP to detect the binding of biotinylated GATA-1 to streptavidin beads (lane 5). Lane 6 shows that very little tagged GATA-1 remains unbound by
streptavidin. In this binding experiment, the beads were washed under stringent conditions (0.5 M NaCl�0.3% Triton X-100 in PBS). In, input (nuclear extract);
El, eluted material; Un, unbound material.
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three classes of proteins accounted for �80% of background
binding under the conditions used (Table 1). It is notable that very
few peptides were identified as corresponding to factors involved in
transcriptional regulation (Table 1). We conclude that background
binding to streptavidin beads is mainly due to endogenous biotin-
ylated proteins as well as abundant nuclear factors involved in
mRNA processing and ribosome synthesis and assembly, with very
little nonspecific binding of factors involved in transcriptional
regulation�activation.
We next tried binding a similar amount of crude nuclear extract
(5 mg) from taggedGATA-1�BirA double transfectants, under the
same conditions (Fig. 2, lane 2). The staining pattern of the lane
with the eluted material (Fig. 2, lane 3) was significantly different
to that observed with the background binding in lane 5, indicating
a significant enrichment in proteins coeluting with tagged GATA-1
(Fig. 2, lane 3 vs. lane 5). Biotinylated GATA-1 and coeluting
proteins may dilute out or compete for binding with the nonspecific
proteins observed in lane 5. The protein enrichment visible in lane
3 may thus correspond to copurified GATA-1-interacting proteins.
In the eluted material, we also observed a strongly stained band
migrating with a size similar to that expected for tagged GATA-1
(Fig. 2, arrow, lane 3). We confirmed the presence of GATA-1 in
this band by gel excision and MS. The detailed analysis of all
proteins copurifying with tagged GATA-1 will be published else-
where (P.R., F.G., and J.S., unpublished results). Taken together,
these data demonstrate the quantitative biotinylation of tagged
GATA-1 in MEL cells and its efficient purification from crude
protein extracts in a single-step procedure by direct binding to
streptavidin beads, with few background binding bands correspond-
ing primarily to endogenously biotinylated proteins and easily
identifiable abundant nuclear�nucleolar proteins.
Biotinylation Does Not Affect the Protein-Interacting or DNA-Binding
Properties of GATA-1. Because it is possible that addition of the
peptide tag and�or biotinylation may affect the properties of the
Table 1. Summary of background binding proteins
Biological process
Cellular
component
Total no.
of peptides Remarks
Metabolism Mitochondrion �180 Carboxylases, acyltransferases, etc.
mRNA processing Nucleus 120 Splicing factors, hnRNPs, ATP-dependent RNA helicases, etc.
Protein biosynthesis Cytosol 93 Ribosomal proteins, etc.
Receptor activity? Unknown 17 Single protein: thyroid hormone receptor-associated
protein
RNA processing? Unknown 16 Four proteins with RNA-binding motifs
Cytoskeleton 13 Actin, lamin
Chromatin assembly Nucleosome 13 Histones
Apoptotic program Nucleolus 10 Single protein: apoptotic chromatin condensation inducer
in the nucleus
No information Unknown 10 Bcl-2-associated transcription factor
Ribosome biogenesis Nucleolus 9 SnoRNA-binding proteins, fibrillarin
Protein targeting Nucleus 5 Single protein: cdc5-like
Electron transport Microsomes 5 Single protein: oxidoreductase
No information Nucleolar 4 myb-binding protein 1a
Chromatin Nucleus 3 Single protein: SAP 18
Modification
DNA recombination Nucleus 2 Two proteins: pontin and reptin (RuvB-like)
Transcription
regulation
Nucleus 2 Two proteins: Y box transcription factor 1 (1 peptide);
thymocyte selection associated HMG box (1 peptide)
Total no. of peptides �500
Gel slices �21
Protein molecular
mass range, kDa
15–274
Proteins identified byMSwere classified according to biological function and cellular localization, with the criteria used by the Gene
Ontology Consortium. Also shown is the number of peptides identified for each class of proteins.
Fig. 2. Colloidal blue-stained gel of a binding experiment of crude nuclear
extracts to streptavidin beads. Lane 1, marker (M). Lane 2, input nuclear
extract from tagged GATA-1�BirA double transfected cells (�12 �g). Lane 3,
proteins eluted after direct binding to streptavidin beads of �5 mg of crude
nuclear extracts from tagged GATA-1�BirA transfected cells. Lane 4, input
nuclear extract from tagged GATA-1�BirA transfected cells. Lane 5, proteins
eluted after binding to streptavidin beads�5mg of nuclear extract from BirA
transfected cells. Arrow in lane 3 indicates protein band containing purified
biotinylated GATA-1, as determined by MS.
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tagged protein, we tested whether biotinylated GATA-1 could still
undergo protein–protein interactions with a known GATA-1 part-
ner, such as FOG-1 (26), and whether it could bind in vivo to known
GATA-1 gene targets such as themouse�maj globin promoter.We
carried out a pull-down experiment of biotinylated GATA-1 by
binding nuclear extracts to streptavidin beads and tested whether
FOG-1 was also copurified. We found FOG-1 to be pulled down
fromextracts expressing biotinylatedGATA-1 but not fromextracts
expressing BirA only (Fig. 3A, lanes 2 and 4). We have also found
FOG-1 to be copurifyingwith biotinylatedGATA-1 byMS.Wealso
carried out a chromatin pull-down (ChIP) experiment in which
sonicated chromatin from formaldehyde-crosslinked MEL cells
was incubated with streptavidin beads, followed by elution of the
bound material and recovery of the pulled-down DNA. Using
primers specific for the �maj promoter, we found enrichment for
these sequences in the DNA pulled down from the chromatin of
cells expressing biotinylated GATA-1 but not from cells expressing
BirA (Fig. 3B). We have also found that biotinylation does not
affect the subnuclear distribution normally observed with GATA-1
(Fig. 5, which is published as supporting information on the PNAS
web site; ref. 27) and that biotinylatedGATA-1 displays an identical
biochemical fractionation profile as endogenous GATA-1 in MEL
cell nuclear extracts (data not shown). Taken together, these results
provide strong evidence that the properties of GATA-1 are not
affected by biotinylation tagging. In addition, these data also
demonstrate the application of biotinylation tagging as an alterna-
tive to antibodies in methods involving an affinity purification step,
such as protein pull-downs or a ChIP assay.
Biotinylation Tagging in Transgenic Mice. The ability to directly
isolate the biotin-tagged protein from crude extracts in a single step
raises the prospect of using this approach in the purification of
tagged proteins from limiting sources such as mouse tissues. We
therefore tested whether BirA-mediated biotinylation tagging
would also work in vivo in transgenic mice. Because GATA-1
overexpression leads to embryonic lethality in mice (28), we tested
this approach by tagging the essential erythropoietic transcription
factor EKLF (29). Mouse EKLF cDNA was tagged with the
biotinylation tag and a double hemagglutinin epitope and micro-
injected in mouse eggs to establish transgenic mouse lines. Simi-
larly, transgenicmouse lines were also established bymicroinjecting
the BirA�erythroid expression cassette construct. Transgenic
mouse lines with detectable expression of tagged EKLF and BirA
in erythroid cells were selected and crossbred. In vivo biotinylation
of tagged EKLFwas assessed in nuclear extracts prepared from the
fetal livers of 13.5-day postcoitum embryos. Western blot analysis
with an anti-EKLF antibody detected endogenous EKLF as well as
tagged EKLF, which was visualized as a doublet (Fig. 4, lane 1).
Binding of the fetal liver nuclear extracts to streptavidin beads
shows that only the top band in the doublet is retained, suggesting
that it is biotinylated (Fig. 4, lanes 2 and 3). This observation is
confirmed by probing the same blot with streptavidin–HRP, which
detects only a single band (Fig. 4, lanes 7 and 9). The doublet
detected by the EKLF antibody is most likely due to the differential
utilization of translation initiation codons at the N-terminally fused
biotinylation tag (top band) and at the double hemagglutinin
epitope present immediately downstream, which also contains an
initiation codon (bottom band). As a result, only the top band
bearing the biotinylation tag serves as a substrate for BirA, thus
further demonstrating the in vivo specificity of this approach. The
binding of nuclear extracts to streptavidin beads also showed that
a significant proportion (�50%) of tagged EKLF is biotinylated in
the fetal livers of transgenic mice. We speculate that the difference
in biotinylation efficiencies between transfected cells and fetal livers
(apart from the use of different fusion proteins) may reflect an in
vivo limitation in the availability of biotin (biotin is abundant in the
FCS used to supplement cell culture media) or a difference in BirA
expression levels. These results demonstrate that the specific bioti-
nylation of tagged EKLF by bacterial BirA can also be achieved
with high efficiency in vivo in transgenic mice.
Discussion
In this paper, we have demonstrated that expression of the bacterial
BirA biotin ligase in mammalian cells and transgenic mice leads to
the quantitative biotinylation of specific transcription factors bear-
ing a small artificial peptide tag. We also showed that, at least for
GATA-1, fusion of the peptide tag and specific biotinylation do not
interfere with the protein’s properties. We demonstrated that
Fig. 3. (A) Binding biotinylated GATA-1 to streptavidin beads specifically
pulls downFOG-1, as detectedbyWesternblottingbyusing a FOG-1 antibody.
By contrast, FOG-1 cannot be pulled down by streptavidin in nuclear extracts
expressing biotinylated expressing BirA only (Right). FOG-1 is detected as a
doublet (26). (B) Streptavidin pull-down of �maj globin promoter sequences
from crosslinked chromatin from MEL cells expressing biotinylated GATA-1
(Left) or BirA only (Right). Triangles indicate increasing amounts of pulled-
down crosslinked chromatin used as template in PCR reactions in detecting
amplification of the �maj sequences. Specific enrichment for �maj sequences
is observed in pulled-down chromatin from cells expressing biotinylated
GATA-1 but not from cells expressing BirA only.
Fig. 4. Specific biotinylation of tagged EKLF in transgenic mouse embryos.
Nuclear extracts from the fetal liver of 13.5-days postcoitum embryos from
a tagged EKLF�BirA double transgenic line (lanes 1–3 and 7–9) and from a
tagged EKLF transgenic line (lanes 4–6) were bound to streptavidin
beads. Tagged and biotinylated EKLF in input nuclear extract, unbound
material (sup., supernatant), and bound material was detected by an EKLF
antibody (Left) or by streptavidin–HRP (Right). EKLF biotinylation andbinding
to the beads is detected only in extracts from double transgenic embryos.
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biotinylation can be effectively used for the single-step affinity
purification of the tagged protein by binding to streptavidin beads.
Small (�23-aa) biotinylation tags have been previously obtained
through multiple rounds of screening combinatorial peptide librar-
ies for specific biotinylation by the BirA biotin ligase (16) and have
been shown to be biotinylated at rates similar to those of naturally
occurring substrates (17). Such peptide tags have been subsequently
used for the specific biotinylation of fusion proteins in E. coli
(12–15). Our work shows the utility of such a small tag for the
efficient BirA-mediated biotinylation of specific fusion proteins in
mammalian cells. Larger (�63-aa) tags derived from biotin accep-
tor domains present in naturally biotinylated proteins have been
previously used in biotinylating fusion proteins in mammalian cells
(10, 11). However, there are obvious advantages in using smaller
artificial tags. First, small tags are much less likely to affect the
structure and thus the properties of the fusion protein in vivo. It
should be noted that tag size can be reduced even further to �14
aa without compromising biotinylation efficiencies (17). Second,
the use of small tags avoids the extra complication of tag removal
by proteolytic cleavage that is often necessary with larger tags (e.g.,
TAP tag, ref. 4). Third, artificial tags are unlikely to be recognized
and biotinylated by endogenous biotin ligases. Indeed, in our assays,
we observed no biotinylation (in nuclear extracts) of the fusion
proteins in the absence of BirA. It is also important to note that
expression of BirA in mammalian cells did not lead to an increase
in nonspecific background biotinylation in nuclear extracts. We
conclude that, using this approach, biotinylation of tagged proteins
in mammalian cells is a highly specific tightly regulated process that
occurs only in the presence of BirA.
The demonstration that a small peptide tag can be efficiently
biotinylated in mammalian cells provides a very useful tool with a
number of advantages for protein purification. First, we showed that
the biotinylated protein can be efficiently purified directly from a
crude extract in a single-step procedure, whereas most commonly
used affinity tags require a number of purification steps before the
affinity-binding step. Second, there is low specific background
binding primarily due to the small number of endogenous naturally
biotinylated proteins. Under the mild conditions we used in our
purification procedure, we observed five strongly staining back-
ground protein bands binding to streptavidin that corresponded to
naturally biotinylated proteins, such as carboxylases, as well binding
by abundant nuclear proteins such as splicing factors. Third, the
very strong binding of biotin to avidin�streptavidin offers another
advantage in that it allows increasingly higher stringencies to be
used during purification without fear of early elution of the tagged
protein. Not only may this higher stringency further reduce non-
specific background binding (e.g., by splicing factors), but it can also
serve as a measure of the strength of interactions of proteins
copurifying with the biotin-tagged protein. Indeed, a systematic
comparison of different tags for purifying a rat neurotensin recep-
tor in E. coli showed biotinylation to be the best approach in terms
of efficiency and purity (12). Furthermore, the inclusion of specific
protease cleavage sites downstream of the biotinylation tag may be
used to specifically cleave and elute the tagged protein complex
from streptavidin, while leaving the endogenous biotinylated back-
ground proteins still bound. Fourth, another advantage is the
availability of modified forms of avidin with lower binding affinities
for biotin (e.g., monomeric avidin with aKd of�5� 10�8M), which
allow elution of bound biotinylated proteins under native condi-
tions. This option offers the possibilities of purifying active tagged
protein complexes as well as the better resolution and identification
of purified proteins by 2D gel electrophoresis. Finally, it is very
significant that the BirA-mediated specific biotinylation can also be
efficiently achieved in transgenic animals, thus raising the prospect
of using limiting animal tissues for protein purification by using
high-affinity interaction with streptavidin. This is, in principle, a
major advantage over other tagging approaches, such as the highly
efficient TAP tag approach (4), which also does not require
prepurification steps. The TAP tag includes two Ig-binding do-
mains from the Stahylococcus aureus protein A, which may be a
problem when expressed in transgenic animals that naturally ex-
press antibodies.
In conclusion, the efficient biotinylation of specific proteins in
mammalian cells demonstrated here raises the prospect of applying
the advantages and flexibility of the well-developed biotin�avidin
technology in the single-step purification and characterization of
mammalian protein complexes.
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GATA-1 forms distinct activating and repressive 
complexes in erythroid cells 
Abstract
 GATA-1 is a key transcription factor essential for the differentiation of the erythroid, 
megakaryocytic and eosinophilic lineages. In erythropoiesis, GATA-1 functions involve lineage-
specific gene activation, as well as repression, suppression of cell proliferation and anti-apoptotic 
functions. GATA-1 was reported to interact with other transcription factors, such as FOG-1, 
TAL-1 (and its co-factors Ldb1, E2A and Lmo2) and Sp1, and also with CBP/p300 and the 
SWI/SNF chromatin-remodeling complex in vitro. Nevertheless, the basis of all of GATA-1’s 
multiple functions in erythropoiesis remains unclear. Using an in vivo biotinylation tagging 
approach we isolated and characterized GATA-1 complex(es) from red cells. Biotinylated GATA-
1 from nuclear extracts was bound directly to streptavidin beads and co-purifying proteins were 
identified by mass spectrometry. In addition to the known GATA-1-interacting transcription 
factors FOG-1, TAL-1 and Ldb1, we describe novel interactions with the essential hematopoietic 
transcription factor Gfi-1b and the chromatin remodeling complexes MeCP1 and ACF/WCRF. 
The most abundant interactions are with FOG-1 and MeCP1 where FOG-1 is essential for the 
interaction. We show these complexes to be distinct with interactions differentially mediated 
via the zinc-fingers of GATA-1. Our findings on GATA-1 complexes provide important insight by 
revealing novel GATA-1 partners.
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Introduction
Hematopoiesis is the process responsible for the generation of the different blood 
cells and has often served as a model for understanding the basis of cellular commitment 
and differentiation. Hematopoiesis proceeds from multipotential, self-renewing hematopoietic 
stem cells (HSCs) to an increasing number of progressively more lineage restricted cells, each 
lineage giving rise to one type of mature blood cell. The differentiation of distinct hematopoietic 
lineages is the result of specific transcription programs regulated by a number of essential 
transcription factors1,2.
An example of a key hematopoietic transcription factor is GATA-1, the prototypical 
member of the GATA family of zinc-finger transcription factors3,4. GATA-1 is essential for the 
differentiation of the erythroid, megakaryocytic and eosinophilic lineages5-7 and is also expressed 
in mast cells and in some multipotential hematopoietic precursor cells. GATA-1 null embryonic 
stem cells fail to contribute to the generation of mature red blood cells in chimeric mice5. GATA-1 
null mice die from severe anemia at day 11.5 dpc because erythroid cells fail to mature beyond 
the proerythroblast stage and die of apoptosis8. Importantly, the forced ectopic expression 
of GATA-1 in an early myeloid cell line promotes megakaryocyte differentiation9. Similarly, 
enforced expression of GATA-1 in myelomonocytic and lymphoid precursor cells reprograms 
them to erythroid, megakaryocytic and eosinophilic fates, with the concomitant repression and 
upregulation of respective lineage-specific marker genes10-12. These observations suggest 
that GATA-1 is capable of dictating expression of a specific genetic program in a cell where 
it is not normally expressed. Thus, GATA-1 acts as a key regulator in the specification of the 
aforementioned lineages, a role that must involve the activation as well as repression of lineage-
restricted transcriptional programs. 
 Previous studies have identified several protein partners of GATA-1. The most 
prominent amongst the GATA-1 interacting partners is the zinc-finger protein FOG-1, which 
was originally identified in a yeast two-hybrid screen using GATA-1 as bait13. A direct interaction 
between the two factors is required for erythroid differentiation since a mutant of GATA-1 unable 
to bind to FOG-1 fails to support terminal erythroid differentiation14. FOG-1 is co-expressed 
with GATA-1 in fetal liver, mast cells and megakaryocytes. The overall GATA-1 and FOG-1 
knockout phenotypes are very similar in that they both result in a block in erythropoiesis and 
early embryonic lethality due to anemia15. Ablation of GATA-1 leads to a block of erythroid 
differentiation at the proerythroblast stage and apoptosis, whereas ablation of FOG-1 leads to 
a marked but partial block at the same stage. In megakaryopoiesis, FOG-1-/- embryos exhibit 
a complete failure of development whereas megakaryocytes lacking GATA-1 are increased in 
number but have a block in their development at mid-maturation. 
In addition, in erythroid cells GATA-1 is part of a pentameric protein complex that 
includes the essential hematopoietic transcription factor TAL-1 and its associated co-factors 
Ldb1, LMO2 and E2A16. This complex was first shown to bind to GATA-E-box motifs in vitro and 
has since been implicated in the positive regulation of the expression of a number of erythroid 
genes, such as protein 4.2, c-kit and glycophorin A and GATA-1 itself17-19. In addition, GATA-1 
interacts with the erythroid specific transcription factor EKLF, which is essential for the expression 
of β-globin genes, with PU.1, which is essential for normal myelopoiesis and lymphopoiesis, and 
also with the ubiquitously expressed transcription factor Sp1 (reviewed by Cantor 2). 
A role for GATA-1 in regulation of chromatin structure was suggested by its 
interactions with chromatin remodeling/modification proteins, including the CBP/p300 histone 
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acetyltransferases and the SWI/SNF chromatin remodeling complex in vitro20,21. Acetylation of 
histones is associated with an open chromatin configuration and the interaction of GATA-1 with 
CBP was shown to stimulate transcriptional activation by GATA-1. In addition, the SWI/SNF 
complex was shown to interact with the erythroid specific transcription factor EKLF in activating 
the β-globin locus22. In the same biochemical studies it was shown that the GATA-1 Zn-fingers 
also have the capacity to interact with the SWI/SNF complex21, but so far no functional evidence 
for these interactions has been demonstrated in vivo.
Despite all these data, important questions remain as to how can GATA-1 accommodate 
all these interactions at the same time in erythroid cells and how these interactions relate to the 
multiple GATA-1 functions? In addressing these questions, we have undertaken a biotinylation 
tagging-proteomics approach to characterize GATA-1 complexes from erythroid cells23. First, 
we show that GATA-1 interacts with previously reported interacting proteins thus validating our 
approach. In addition, we identify novel partners of GATA-1, such as the essential hematopoietic 
transcription factor Gfi-1b and the chromatin remodeling and modification complexes MeCP1 
and ACF/WCRF. Moreover, we show a number of these complexes to represent distinct as well 
as overlapping GATA-1 interactions in erythroid cells. Using GATA-1 mutants, we show that 
the GATA-1 zinc fingers differentially mediate these interactions and, lastly, we show that the 
interaction of GATA-1 with the MeCP1 complex is mediated via FOG-1. Our findings provide 
an explanation for a number of previous observations regarding GATA-1 functions and protein 
interactions.
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Results
Identification of GATA-1 complexes from erythroid cells by biotinylation 
tagging and mass spectrometry
GATA-1 was tagged by fusing of a small (23aa) peptide sequence to its N-terminus. 
This tag is efficiently biotinylated by the bacterial BirA biotin ligase which is co-expressed in 
stably transfected mouse erythroleukemic (MEL) cells, allowing the single step purification of 
biotinylated GATA-1 using streptavidin beads under mild conditions23. Proteins co-purified with 
GATA-1 from MEL cells chemically induced to undergo terminal differentiation, were identified 
by mass spectrometry, classified according to Gene Ontology terms or by BLAST searches 
and compared to the background (Table 1). Additional experiments employed more stringent 
conditions and different nuclear extract preparations from induced MEL cells. We rejected 
proteins that appeared in the background binding experiments23, or proteins that belonged to a 
subnuclear compartment from which GATA-1 is excluded, e.g. the nucleolus24. Streptavidin pull-
downs of nuclear extracts under more stringent conditions (Fig. 1A-C) and immunoprecipitations 
of induced non-transfected MEL nuclear extracts provided further validation (Fig. 1D-G). The 
identities of proteins confirmed in this way as co-purifying with GATA-1 are shown in Table 2. 
We found FOG-1, TAL-1 and Ldb1 co-purifying with GATA-113,16 thus validating our 
approach. The Gfi-1b hematopoietic transcription factor was also identified under moderate 
Figure 1: Confirmation by 
streptavidin pull-downs (A-C) and 
immunoprecipitations (D-G) of 
proteins identified co-purifying 
with GATA-1.
(A) Streptavidin pull-downs of transcription 
factors. Biotinylated GATA-1 (top panel) 
is detected by streptavidin-HRP and is 
absent from the BirA only transfected 
cells. (B) Pull-downs of the MeCP1 
complex. (C) Pull-downs of ISWI-
containing complexes. SB: streptavidin-
bound. (D) Immunoprecipitations (IP) 
using antibodies against GATA-1, TAL-1, 
FOG-1 (lanes 2, 3 and 4, respectively) 
and nucleophosmin as negative control 
(lane 5). (E) IP of the MeCP1 complex 
by antibodies against GATA-1 and MTA2 
(lanes 2 and 3) and nucleophosmin (lane 
4). (F) GATA-1, can be specifically IP’d 
by an antibody against MTA2 (G) IP of 
the ACF/WCRF complex by GATA-1 
antibodies. Nuclear extract equivalent 
to 5% used in each pull-down or IP was 
loaded as control for input material. IP: 
immunoprecipitating antibody. Arrows 
show the detecting.
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stringency conditions and verified by immunoprecipitation (Fig. 1D, lane 2) demonstrating 
an interaction between the two factors. This is in line with the similarities observed in the 
Gfi-1b and GATA-1 knockout phenotypes which result in differentiation arrest of the erythroid 
and megakaryocytic lineages8,25. Chromatin remodeling and modification proteins also co-
eluted with GATA-1 (Table 1) including the entire MeCP1 complex (Fig. 1). MeCP1 consists of 
the methyl-DNA binding protein MBD226, p66/p6827 and the multi-subunit Mi-2/NuRD complex 
containing the nucleosome stimulated Mi-2β ATPase, the histone deacetylases HDAC1 and 
HDAC2 and other subunits of unknown function. The Mi2/NuRD and MeCP1 complexes are 
associated with epigenetic mechanisms of repression during development28, potentially linking 
the GATA-1 repressive functions to the MeCP1 complex.
The SNF2h and ACF1 members of mammalian ISWI chromatin remodeling complexes 
also co-purified with GATA-1 (Table 1, Fig. 1C, G). SNF2h, a homologue of the Drosophila 
PROTEIN IDENTITY NUMBER OF PEPTIDES ADDITIONAL PURIFICATIONS
MeCP1 complex
Mi-2 82 +
HDAC 1 10 +
HDAC 2 17 +
MTA1 47 +
MTA2 10 +
MTA3 4 -
Mbd2 14 +
Mbd3 9 +
p66 11 +
RbAp46 10 +
RbAp48 8 +
ACF/WCRF complex
SNF2h 21 +
ACF1 4 -
Transcription factors
FOG-1 (Hem.) 47 +
TAL-1 (Hem.) 2 +
Gfi-1b (Hem.) 1 -
Ldb1 (Ubiq.) 1 +
DNA repair
Rfc5 10 +
XRCC1 3 -
Ku70 9 +
PARP 10 +
DNA ligase III-β 1 -
DNA Topological change
DNA Topo I 34 +
DNA Topo II α 64 +
DNA Topo II β 32 -
Table 2: Proteins specifically co-purifying with biotin tagged GATA-1 as compared to 
the control purification23.
A number of these proteins have been validated by immunoprecipitations and other assays (see text). 
Hem: hematopoietic transcription factors. Ubiq: ubiquitous transcription factors.
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protein ISWI, is the “signature” ATPase of this class of complexes and participates in three 
distinct complexes in human cells: RSF, hACF/WCRF, hCHRAC29. We did not detect by mass 
spectrometry or immunoprecipitation (not shown) the additional p15 and p17 protein partners 
present in the hCHRAC complex hence GATA-1 appears to interact with SNF2h/ACF1 in the 
context of the ACF/WCRF complex30. ISWI/SNF2h-containing chromatin remodeling complexes 
have been associated with gene activation and repression (reviewed by29). The interaction 
between SNF2h and GATA-1 may help to explain the observation that knocking down SNF2h 
expression in primary hematopoietic progenitor cells blocked erythroid differentiation31.
Further validation for the GATA-1 interactions was provided by reverse 
immunoprecipitations using antibodies against TAL-1, FOG-1 (Fig. 1D) or MTA2 (Fig. 1E). 
TAL-1 antibodies specifically immunoprecipitated GATA-1 and Ldb1 (Fig. 1D), as previously 
observed32,33. LMO2 or E2A were not detected co-purifying with GATA-1 from induced MEL cells, 
but it cannot be excluded that their absence is due to the very low abundance of the GATA-1/ 
TAL-1/Ldb1/E2A/LMO2 complex (Table 1), in agreement with previous reports of a very small 
fraction of LMO2 being immunoprecipitated by GATA-1 antibodies32. Interestingly, FOG-1 
antibodies immunoprecipitated GATA-1 but not TAL-1, Ldb1, or Gfi-1b (Fig. 1D, lane 4). The 
converse was also true using TAL-1 antibodies (Fig. 1D, lane 3). Thus, GATA-1 interactions with 
TAL-1, FOG-1 and Gfi-1b are non-overlapping and must thus occur in distinct complexes. GATA-1 
was also immunoprecipitated by MTA2 antibodies (Fig. 1F). By contrast, the Sin3A co-repressor, 
which interacts with HDACs but not in the MeCP1 complex, was not immunoprecipitated by 
GATA-1 or MTA2 antibodies (Fig. 1E) further supporting the specificity of the GATA-1 interactions 
with MeCP1.  
Other abundant chromatin-associated proteins also co-purified with GATA-1 (Table 1), 
including topoisomerases and Ku autoantigen or ADP ribosyltransferase (PARP). We tested the 
association of these proteins with DNA and GATA-1 by treating nuclear extracts with DNase I. 
In contrast to MTA2, there were no topoisomerase I or PARP co-purifying with GATA-1 following 
DNase I treatment (Fig. 2). Though it remains formally possible that interactions of GATA-1 with 
topoisomerase I or PARP are relevant and require DNA, on the basis of our DNase I results and 
on previous evidence by other groups describing topoisomerases as a common contaminant34, 
we did not pursue these further. 
GATA-1 and co-purifying proteins interact as large complexes 
We also tested whether GATA-1 and interacting proteins share overlapping size-
fractionation profiles, as would be predicted for proteins participating in the same multi-protein 
complexes. Nuclear extracts from induced MEL cells expressing biotinylated GATA-1 were size-
Figure 2: DNase I treatment of nuclear extracts 
shows the indirect co-purification of abundant 
chromatin associated proteins with GATA-1. 
Nuclear extracts from MEL cells treated or not treated with 
DNAse I were immunoprecipitated with GATA-1 antibodies. 
Co-immunoprecipitation of abundant chromatin associated 
proteins such as topoisomerase I orPARP, identified by mass 
spectroscopy as co-purifying with GATA-1, was lost upon 
DNAse I treatment. By contrast, co-immunoprecipitation 
of MTA2, a member of the MeCP1 complex co-purified with 
GATA-1, was unaffected by DNase I treatment thus showing a 
direct interaction with GATA-1.
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fractionated by Superose-6 gel filtration and the fractionation profiles of GATA-1 and co-purifying 
proteins were determined (Fig. 3). GATA-1 displays a broad fractionation profile with several 
peaks at the high (fractions 16-25) and low (e.g. fraction 34 and below) molecular weight ends 
(Fig. 3A). The profile of tagged GATA-1 closely follows that of endogenous GATA-1 (Fig. 3A) is 
stable in salt concentrations of up to 1M and is not dependent on the presence of DNA (data 
not shown). The fractionation profiles of members of the MeCP1 complex showed overlapping 
peaks around fractions 20-22 (e.g. MTA2, RbAp46/48, Mbd2/3; Fig. 3B). By contrast, Sin3A 
fractionated with a peak around fractions 18-20 (Fig. 3B). The fractionation peaks of SNF2h, 
Figure 3: Size-fractionation profiles by Superose 6 column of GATA-1 (panel A), members 
of the MeCP1 and ACF/WCRF complexes (panel B) and transcription factors (panel C).
Molecular mass markers are indicated on the top. V0: void volume. N.E.: input nuclear extract. 
GATA-1 displays a broad fractionation profile with several peaks. The profile of tagged GATA-1 closely 
follows that of endogenous GATA-1, is stable in salt concentrations up to 1M and is not dependent on the 
presence of DNA (data not shown). Members of the MeCP1 complex showed overlapping peaks around 
fractions 20-22 (e.g. MTA2, RbAp46/48, Mbd2/3) in contrast to Sin3A which peaked around fractions 18-
20. SNF2h and ACF1 peaked around fractions 26-28 and are distinctly different from those of the MeCP1 
complex. p17 elutes in fractions 34-36, further suggesting that GATA-1 interactions with SNF2h and ACF1 
occur in the context of the ACF/WCRF complex. These observations also suggest that GATA-1 interactions 
with MeCP1 and ACF/WCRF occur in distinct complexes. Fractionation profiles of transcription factors 
FOG-1, Ldb1, TAL-1 and Gfi-1b are largely coincident within the higher molecular weight fractions 16-28, 
though peaks vary between them. For most of these factors little or no protein is detected in the free protein 
fractions (i.e. fractions 32-38), in contrast to Sp1, which elutes as free protein.
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ACF1 overlap between fractions 26-28 and are distinct from those of the MeCP1 complex 
(Fig. 3B). The peak of p17 in fractions 34-36 provides further support for GATA-1 interactions 
with SNF2h and ACF1 occurring in the context of the ACF/WCRF complex. Furthermore, indirect 
purification in our experiments of SNF2h by association with the MeCP1 complex, as has been 
previously described35, is unlikely. These observations also suggest that GATA-1 interactions 
with MeCP1 and ACF/WCRF occur in distinct complexes.
The fractionation profiles of transcription factors FOG-1, Ldb1, TAL-1 and Gfi-1b are 
largely coincident within the higher molecular weight fractions 16-28 (Fig. 3C), though peaks 
vary between them. For most of these factors little or no protein is detected fractionating with 
a molecular weight corresponding to that of the free protein (i.e. around fractions 32-38). By 
contrast, the fractionation profile of Sp1 corresponds to that of the free protein (Fig. 3C), in 
agreement with the lack of a detectable complex between GATA-1 and Sp1 in MEL cells. In 
conclusion, the broad fractionation profile of GATA-1 most likely reflects the participation of 
GATA-1 in several distinct high molecular weight complexes with transcription factors and/or 
chromatin remodeling/modification complexes. 
GATA-1 forms several distinct complexes 
To directly confirm the distinct GATA-1 interactions and to assess how the GATA-1 
partners may be partitioned in the GATA-1 complexes, we carried out sequential immunodepletion 
experiments. First, we used an antibody against one of the GATA-1 partners, i.e. FOG-1, 
TAL-1 or MTA2 in order to immunodeplete from a nuclear extract the fraction of GATA-1 that is in 
complex with this factor (Fig. 4A). The remaining GATA-1 in the supernatant was subsequently 
immunoprecipitated with a GATA-1 antibody and both immunoprecipitates were tested for the 
presence or absence of GATA-1 and interacting proteins (Fig. 4A). 
We first established that the antibodies against GATA-1, TAL-1, FOG-1 and MTA2 
were efficient in immunodepleting most of these proteins from nuclear extracts (Fig. 4B). 
As expected, FOG-1 antibodies immunoprecipitated a fraction of GATA-1 (Fig. 4C, lane 
2). Surprisingly, MTA2 was also specifically immunoprecipitated by FOG-1 antibodies 
(Fig. 4C, lane 2), suggesting an interaction between FOG-1 and the MeCP1 complex. This 
was confirmed by the reverse immunoprecipitation of FOG-1 by an MTA2 antibody (Fig. 4E). 
There was no immunoprecipitation of TAL-1, Gfi-1b or ACF1 by FOG-1 antibodies (Fig. 4C, 
lane 2). Importantly, MTA2 could no longer be detected in the subsequent immunoprecipitation 
of the supernatant with GATA-1 antibodies (Fig. 4C, lane 3). Thus the fraction of GATA-1 that 
is in complex with MTA2 (and MeCP1) was depleted in the first step by the FOG-1 antibodies, 
leading to the conclusion that GATA-1 and FOG-1 interact together in the same complex with 
MeCP1. Following the FOG-1 immunodepletion, GATA-1 antibodies could still immunoprecipitate 
TAL-1, Gfi-1b and ACF1 (Fig. 4C, lane 3). This confirms that GATA-1 participates in a complex 
with FOG-1 and MeCP1 that is distinct from those with TAL-1, Gfi-1b or ACF/WCRF. Using 
TAL-1 antibodies in the first immunodepletion step, a small fraction of GATA-1, but no MTA2 or 
ACF1 was immunoprecipitated (Fig. 4D, lane 2). 
We also carried out an MTA2 immunodepletion to determine whether the entire fraction 
of GATA-1 interacting with FOG-1 does so in the context of the MeCP1 complex. Following 
the immunodepletion of MTA2 (Fig. 4B), an appreciable amount of FOG-1 was subsequently 
immunoprecipitated by GATA-1 antibodies (Fig. 4E, lane 3). Thus, GATA-1 also interacts with 
FOG-1 independently of the MeCP1 complex. Interestingly, the MTA2 antibody specifically 
immunoprecipitated the slower migrating of the two bands detected by the FOG-1 antibody, 
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suggesting differential interaction with one of the two FOG-1 isoforms, while GATA-1 can interact 
with both FOG-1 isoforms (Fig. 4E, lane 3). Taken together, these experiments show that 
GATA-1 forms at least five complexes: first with FOG-1 and MeCP1, second with FOG-1 
alone, third with TAL-1 (and Ldb1 since it can be almost completely immunodepleted by TAL-1 
antibodies [not shown]), fourth with Gfi-1b and fifth with ACF/WCRF. 
The GATA-1 zinc fingers mediate differential protein interactions 
GATA-1 contains two evolutionarily conserved, closely spaced zinc finger domains. The 
C-terminal zinc finger (C-ZnF) is essential for DNA binding whereas the N-terminal zinc finger 
(N-ZnF) is primarily involved in protein-protein interactions, for example with FOG-1, which 
contribute to the specificity and stability of DNA binding by the C-ZnF (review36). Significantly, the 
C-ZnF is essential for all in vivo GATA-1 functions, whereas the N-ZnF is required for definitive, 
but not primitive erythropoiesis37. We addressed how the GATA-1 zinc fingers mediated its 
multiple protein interactions by expressing in MEL cells biotin-tagged mutants lacking the 
N-ZnF or the C-ZnF followed by streptavidin pull-downs (Fig. 5A-C). As described15, GATA-1 
interaction with FOG-1 requires the N-ZnF. Interactions of the MeCP1 members MTA2, MBD2 
Figure 4: Distinct GATA-1 complexes by sequential immunoprecipitations (IP). (A) 
Experimental procedure.
(B) Efficiency of immunoprecipitating antibodies (also used to detect the immunoprecipitated protein). 
Sup: supernatant after IP. (C) FOG-1 immunodepletion, FOG-1 IP (lane 2) followed by IP of supernatant 
with GATA-1 or control antibodies (lanes 3 and 4). (D) TAL-1 immunodepletion, same as (C) using TAL-1 
antibodies in first IP. (E) MTA2 immunodepletion, same as (C) and (D) using MTA2 antibodies in first IP. The 
MTA2 antibody used in panels B and E is different to that used in panels C and D (see Suppl. Methods). IP: 
immunoprecipitating antibody. Arrows show the detecting antibodies.
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and HDAC 1 also occur through the N-ZnF of GATA-1 (Fig. 5A). Interestingly, interactions of 
GATA-1 with TAL-1 require both zinc fingers (Fig. 5B), whereas interactions with SNF2h or 
Gfi-1b require only the C-ZnF (Fig. 5C). We tested by immunoprecipitation using Gfi-1b antibodies 
whether Gfi-1b and SNF2h were in complex but found no evidence of such an interaction (not 
shown). Thus the multiple, distinct interactions of GATA-1 are differentially mediated through its 
zinc finger domains.
GATA-1 and FOG-1 associate with histone deacetylase activity
We further focused on the GATA-1 association with MeCP1 for the reasons 
that: (i) this is a novel finding, (ii) it represents the most abundant of the GATA-1 
complexes linked to chromatin structure and (iii) it involves FOG-1, an essential hematopoietic 
transcription factor. We first tested whether GATA-1 and FOG-1 are associated with histone 
deacetylase (HDAC) activity, as would be predicted by their association with the MeCP1 
complex. We first assayed for HDAC activity a number of immunoprecipitates using antibodies 
against GATA-1 as well as antibodies against Rpd3 (class I HDAC enzyme), FOG-1, TAL-1 
and members of the MeCP1 complex (Fig. 6A). As expected, the highest HDAC activity was 
immunoprecipitated by the anti-Rpd3 antibody. HDAC activity was also clearly detectable in 
the GATA-1 immunoprecipitation. FOG-1 antibodies immunoprecipitated significant HDAC 
activity, further establishing its association with the MeCP1 complex. By contrast, little HDAC 
activity was immunoprecipitated by TAL-1 antibodies. All immunoprecipitates with antibodies 
against members of the MeCP1 complex contained significant HDAC activity (Fig. 6A). The 
HDAC activity immunoprecipitated by HDAC2, FOG-1 and GATA-1 antibodies was sensitive 
to the Class I HDAC inhibitors trichostatin A (TSA) and OSI-2040 (Fig. 6B)38,39. In addition, we 
immunodepleted the MeCP1 complex from nuclear extracts using MTA2 antibodies and found 
that most of the HDAC activity associated with the FOG-1 and GATA-1 immunoprecipitates was 
also depleted (Fig. 6C). Under the same conditions, there is considerable total HDAC activity 
remaining in the supernatant following MTA2 immunodepletion (not shown).
FOG-1 mediates interactions of GATA-1 with the MeCP1 complex in repressing 
transcription
 We next tested whether FOG-1 mediates interactions between GATA-1 and the 
MeCP1 complex. GATA-1 was transiently expressed in HeLa cells (which express endogenous 
Figure 5: (A-C): Differential interactions mediated by the 
GATA-1 zinc fingers.
GATA-1 zinc finger deletions were expressed as biotin tagged proteins 
in MEL cells and interactions were assessed by streptavidin pull-
downs and Western blots. (A) FOG-1 and the MeCP1 complex require 
the N-ZnF for interactions. (B) TAL-1 requires both zinc fingers. (C) 
Gfi-1b and SNF2h require the C-ZnF for interactions with GATA-1. The 
TAL-1 antibody used is different to that used in Fig. 1. 
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MeCP1, but not GATA-1 or FOG-1) with or without FOG-1, followed by immunoprecipitation 
using FOG-1 or MTA2 antibodies (Fig. 7A-B). We find that the interaction of GATA-1 with MTA2 
occurs only in the presence of FOG-1 (Fig. 7B), whereas FOG-1 interacts with MTA2 regardless 
of the presence or absence of GATA-1 (Fig. 7B, upper panel). Expression of the GATA-1 zinc-
finger deletion mutants (Fig. 7B, lower panel) confirmed these observations. We conclude that 
interaction of GATA-1 with the MeCP1 complex requires interaction with FOG-1, which thus 
serves as the bridging factor.
We next tested whether the well known GATA-1 and FOG-1 mediated repression is 
Figure 6: Histone deacetylase (HDAC) assays. 
(A) HDAC activity associated with proteins immunoprecipitated by the indicated antibodies. Protein G beads 
and rat and goat immunoglobulins (IgG) were used as background controls. Three different nuclear extracts 
were used in the GATA-1 immunoprecipitations (extract 1: non-transfected MEL cells; extracts 2 and 3: 
biotinylated GATA-1). (B) HDAC activity immunoprecipitated by HDAC2, FOG-1 and GATA-1antibodies 
is sensitive to the Class I HDAC inhibitors TSA and OSI-2040. (C) Antibodies against the Mi2/NuRD-
associated protein MTA2 deplete a considerable part of the HDAC activity associated with FOG-1 and 
GATA-1 immunoprecipitates. Immunoglobulins (IgG) were used as background control.
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due to the recruitment of the MeCP1 complex to a GATA-dependent promoter. To this end, we 
used a reporter plasmid containing the rabbit β-globin minimal promoter (pOVEC-1,40, carrying 
four copies of an optimal GATA-1 binding sequence, or four copies of a mutated sequence that 
abolish GATA-1 binding41). The GATA-binding promoter was activated more than six-fold by 
co-transfection of GATA-1 alone (Fig. 7C). As expected, co-transfection of FOG-1 and GATA-1 
repressed activation of the GATA-dependent promoter (Fig. 7C). Chromatin immunoprecipitations 
(ChIP) showed that repression by GATA-1 and FOG-1 was due to the specific recruitment 
of the MeCP1 complex. Binding of Mi-2β to the repressed gene was specifically enriched in 
GATA-1 and FOG-1 transfected cells (Fig. 7D), but not in cells transfected with GATA-1 only. The 
promoter bearing the mutated GATA binding sites does not bind MeCP1, even in the presence 
of FOG-1 (Fig. 7D). Thus, FOG-1/MeCP1 repression is mediated through GATA-1 binding at its 
cognate binding sites.
Figure 7: (A-B): FOG-1 bridges GATA-1 and MeCP1.
Nuclear extracts from HeLa cells transfected with the FOG-1 and GATA-1 combinations indicated, were 
immunoprecipitated with FOG-1 (panel A) or MTA2 antibodies (panel B) and detected with FOG-1 and 
GATA-1 antibodies. ∆Zn-N and ∆Zn-C: GATA-1 N- and C-terminal zinc-finger deletion mutants. Arrows: 
cross-reacting IgG. Asterisk (panel B): GATA-1 signal. 
(C) Real-Time PCR transcription assays in transfected HeLa cells. GATA-1 activates 
transcription of pG-OVEC, whereas co-transfection of FOG-1 represses to basal levels.
(D) Specific recruitment of Mi-2β by co-transfected GATA-1 and FOG-1 by ChIP assays in 
HeLa cells. Mi-2β recruitment to the repressed gene requires GATA-1 binding to the promoter.
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Discussion
We describe here the characterization of GATA-1 complexes from erythroid cells 
by in vivo biotinylation tagging and purification by streptavidin beads. This work has led to a 
number of important findings. First, we identified novel GATA-1 partners, including the essential 
hematopoietic factor Gfi-1b and the chromatin remodeling and modification complexes MeCP1 
and ACF/WCRF, in addition to the known GATA-1 interacting factors FOG-1, TAL-1 and Ldb1. 
Second, we showed that GATA-1 forms several distinct complexes with FOG-1, with FOG-1 and 
MeCP1, with TAL-1/Ldb1, with Gfi-1b and with the ACF/WCRF complex. Third, we found that the 
most abundant of the GATA-1 complexes are those with FOG-1 and with FOG-1 and MeCP1, 
with FOG-1 serving as the bridging factor between GATA-1 and the MeCP1 complex. Fourth, 
we showed that the distinct interactions of GATA-1 with its protein partners are differentially 
mediated through the two GATA-1 zinc finger domains. Finally, our work demonstrates the utility 
of biotinylation tagging as an efficient approach for the rapid isolation and identification by mass 
spectrometry of multiple protein complexes.
Biotinylation tagging and protein complex purification
From our previous work23 and the work described here, we show that background using 
biotinylation tagging consists of naturally biotinylated proteins, of abundant nuclear proteins 
such as splicing factors binding nonspecifically to the beads23 and, potentially, of abundant 
chromatin-associated proteins, such as topoisomerase I, which are indirectly pulled-down with 
the tagged transcription factor (Table 1). We have validated a number of the remaining proteins 
as being true GATA-1 partners, some of which represent low abundance or weaker GATA-1 
interactions, e.g. with TAL-1/Ldb1, Gfi-1b and ACF/WCRF. Importantly, purification required a 
single capture step. 
We cannot be certain that we identified all GATA-1 complexes in differentiated MEL 
cells. Indeed, some of the size-fractionation profiles (Fig. 3) suggest that there may be additional 
protein partners that were not identified perhaps due to their very low abundance or instability. 
This may be the case for the multimeric GATA-1/TAL-1/Ldb1/E2A/LMO2 complex. Several lines 
of evidence have suggested the presence of this complex in erythroid cells binding to distinct 
E-box and GATA motifs spatially arranged 9 to 12 nucleotides apart (review by42). Many erythroid 
genes identified to-date contain such motifs, including GATA-1 itself, EKLF, glycophorin A and 
4.2 protein42. Evidence for the multimeric GATA-1/TAL-1 complex binding to erythroid genes 
in vivo, such as α globin and glycophorin A, has been provided recently by ChIP assays19,43. 
Nevertheless, we did not find any co-purification of E2A or LMO2 with GATA-1 from induced MEL 
cells. The complementary isolation by biotinylation tagging of protein partners, such as TAL-1, 
will be informative in that respect and may also reveal additional protein partners. Indeed, work 
presented in chapter 4 shows the co-purification of GATA-1 with complexes purified by biotin 
tagged Ldb1.
Novel GATA-1 protein partners
We describe here, for the first time, an interaction of GATA-1 with the essential 
hematopoietic transcription factor Gfi-1b. This factor contains six C-terminal C2H2 zinc fingers, 
which bind a defined DNA consensus sequence, and an N-terminal SNAG domain associated 
with repression44,45. The Gfi-1b knockout is remarkably similar to that of GATA-1, i.e. it shows 
embryonic lethality E15 due to the developmental arrest of erythroid and megakaryocytic 
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differentiation in the fetal liver25. It is important to note that although there are also similarities 
between the FOG-1 and Gfi-1b knockout phenotypes, we did not find FOG-1 and Gfi-1b to 
directly interact in induced MEL cells (Fig. 1 and 4). Possibly, the two factors regulate common 
gene targets through distinct complexes and binding sites. Alternatively, the functions of GATA-1 
with FOG-1 or Gfi-1b could be separate, e.g. differentiation (FOG-1) versus proliferation arrest 
(Gfi-1b), with each function being essential for erythropoiesis. We also provide preliminary 
evidence for distinct gene targets for FOG-1 and Gfi-1b in Chapter 4.
We also describe, for the first time, interactions of GATA-1 with the MeCP1 and 
ACF/WCRF complexes, linking GATA-1 to repressive functions (with MeCP1) and chromatin 
structure. Previous evidence linking GATA-1 to chromatin structure involved interactions 
with the histone acetyltransferases (HATs) CBP and p30020 and in vitro experiments where 
GATA-1 co-operated with the SWI/SNF remodeling complex in transcriptional activation21. 
However, we did not observe these interactions in our GATA-1 purification from induced MEL 
cells or in immunoprecipitations (data not shown). 
Our observations on the interactions of GATA-1 (and FOG-1) with the MeCP1 complex 
add to previous reports linking MeCP1 (and the closely related NuRD complex) to transcription 
factors in hematopoiesis46-48. Significantly, the transcription factor Ikaros was shown to interact 
with the NuRD complex in erythroid cells (O’Neill et al. 2000). In addition, the third member of the 
GATA family, GATA-3 was shown to functionally interact with the NuRD complex in differentiating 
T cells, where GATA-3 was shown to displace Mbd2 from the repressed IL-4 gene thus allowing 
its activation. These observations suggest that GATA-3 is antagonistic to MeCP1-mediated gene 
repression, in contrast to GATA-1 which tethers MeCP1 for gene repression46. Furthermore, 
the conditional knockout of Mi-2β in thymocytes revealed a requirement in different stages of 
T cell maturation49. Lastly, the characterization of the MTA3 member of NuRD in B lymphocytes 
showed an interaction with BCL-6, a key repressor of the mature plasma cell transcription 
program50. In these experiments, it was suggested that MTA3 and the NuRD complex play 
a role in the maintenance of a population of less differentiated, “poised” B lymphocytes50. By 
contrast, our data in erythroid cells suggest that the MeCP1 complex works with tissue-specific 
transcription factors to effect terminal differentiation by shutting down transcription programs 
associated with early multipotential (“poised”) states (see next chapter). 
 A specific interaction between GATA-1 and ACF/WCRF was also found. It is of note 
that the knockdown of SNF2h in primary human proerythroblasts blocks erythroid differentiation, 
a phenotype similar to that of the GATA-1 knockout31. Thus, the GATA-1/ACF/WCRF complex 
could provide an essential aspect in GATA-1 functions in erythroid differentiation. However, 
it remains unclear as to whether the GATA-1/ACF/WCRF interactions lead to repression or 
activation. Interestingly, in Drosophila, mutations in the NURF complex, an ISWI family 
complex, were shown to lead to blood defects. Mutants of the Nurf 301 subunit, a homolog 
of ACF, are characterized by a high number of circulating blood cells, suggesting a potential 
role in malignancy51. Whereas ISWI complexes were originally associated with activation29 
recent evidence in Drosophila showed by immunofluorescence that localization of ISWI does 
not overlap with transcriptionally active sites, as visualized by staining for RNA polymerase II52. 
By contrast, the SWI/SNF complex is almost exclusively associated with active genes53. These 
data suggest that ISWI is linked to both gene activation and gene repression. 
GATA-1 had previously been reported to bind to additional transcription factors (Sp1) 
and co-factors (SWI/SNF, CBP/P300) that we did not find by mass spectrometry to co-purify 
with biotin-tagged GATA-1 or by immunoprecipitations20,54-56. There are a number of reasons that 
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could account for these discrepancies. Firstly, the nature of GATA-1 complexes may vary during 
developmental stages of erythroid cells. Therefore, we can imagine that the interaction between 
CBP/P300 and GATA-1 in non-differentiated MEL cells is no longer detectable in the final stages 
of terminal differentiation. However, preliminary data from the characterization of GATA-1 
complexes from non-induced MEL cells showed that CBP/P300 are again absent. Nevertheless, 
we cannot exclude that the binding of CBP/P300 to GATA-1 is highly dynamic or labile or it only 
takes place on DNA, as evidenced by ChIP assays (REF). Secondly, the discrepancies may be 
due to the nature of the assay used previously to identify these interactions. The transcription 
factor Sp1 was shown to bind to GATA-1 either indirectly by using EMSA assays or by GST 
pull-downs54 . Though we found no evidence of a pre-formed, soluble GATA-1/Sp1 complex, we 
can think of a model in which Sp1 is interacting with GATA-1 via DNA to activate transcription. 
GATA-1 was also shown to interact with the chromatin remodeling complex SWI/SNF by 
GST-GATA-1 pull-downs56. Interestingly, we have not identified any SWI/SNF complex 
components in the GATA-1 purification, but instead all components of the MeCP1 and 
ACF/WCRF complexes to link GATA-1 to chromatin structure regulation. Again the absence of 
SWI/SNF in the GATA-1 purification may be due to limitations in the original assay used in the 
original report, or due to a highly dynamic nature of the interactions.
GATA-1 and FOG-1 interactions
Considerable evidence has linked GATA-1 functions to FOG-1 (reviewed by2,36). 
A single amino acid change in the N-terminal zinc finger of GATA-1 which abolishes interaction with 
FOG-114, resulted in lethality in mice due to severe anemia57 and is associated with dyserythropoietic 
anemia in patients58. Our work suggests that the overlapping functions of GATA-1 and 
FOG-1 in erythropoiesis occur in the context of two distinct complexes, a GATA-1/FOG-1/MeCP1 
complex and a GATA-1/FOG-1 complex. Clearly, the association of GATA-1 and FOG-1 with the 
MeCP1 complex provides the molecular basis for the well-documented repressive properties of 
GATA-1 and FOG-1 interactions14,59-61. This is supported by our experiments using transcription 
and ChIP assays in transfected HeLa cells. It is of note that only the slower migrating isoform of 
FOG-1 (Fig. 4) interacts with the GATA-1/MeCP1 complex, providing a potential mechanism for 
the selective formation of the GATA-1/FOG-1/MeCP1 complex. 
Hong and colleagues have purified a similar FOG-1 complex using an alternative 
approach62. These authors did not detect the presence of MBD2 during purification of the 
FOG-1 complex, which led them to suggest that FOG-1 interacts with the NuRD complex instead 
of the MeCP1 complex. Interestingly, GATA-1 was also not identified as co-purifying with the 
FOG-1/NuRD complex. Since Hong and colleagues used only the N-terminal 45 amino acids 
of FOG-1 in the purification, it is possible that Mbd2 might bind to another domain of FOG-1 
outside the 45aa used in the purification. This would certainly be the case for GATA-1 since it 
has been shown to interact with FOG-1 through the latter’s zinc fingers and not the N-terminal 
45aa domain used in the purification. Another explanation could be that MBD2 would interact 
with the FOG-1/NuRD complex only in the presence of GATA-1.
We suggest that the separate GATA-1/FOG-1 complex without MeCP1 is responsible 
for the transcriptional activation functions that have been previously described for GATA-1 with 
FOG-1. For example, disruption of GATA-1 and FOG-1 interactions down-regulates erythroid 
genes such as α and β globin, Band 3, DC11 and HD2 genes14,61. ChIP assays have also shown 
GATA-1 and FOG-1 to be bound in vivo to active genes such as the Α globin locus and the 
GATA-1 gene itself43,60. Significantly, in the α globin locus the GATA-1/FOG-1 complex occupies 
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sites distinct from those occupied by the GATA-1/TAL-1/Ldb1 complex43, in agreement with our 
findings of distinct GATA-1 complexes.
Our finding that FOG-1 bridges GATA-1 to the repressive MeCP1 complex partly 
explains the common features of the GATA-1 and FOG-1 knockouts and the phenotypes caused 
by the single amino acid change in the N-terminal zinc finger of GATA-1 in mice and patients. 
In the GATA-1 knockout FOG-1/MeCP1 cannot be tethered to target genes, whereas in the 
FOG-1 knockout, the interaction between GATA-1 and the MeCP1 complex cannot take place. 
In patients, the lack of interaction between GATA-1 and FOG-1 would also fail to tether the 
MeCP1 complex to some of their target genes.
In conclusion, we have identified at least five distinct complexes involving essential 
transcription factors and chromatin remodeling and/or modifying complexes (Figure 8). These 
observations on the GATA-1 interactions raise important questions as to what the functions 
of these complexes are in vivo and which genes are the in vivo targets of these complexes in 
erythroid cells.
Figure 8: Model for the distinct GATA-1 complexes in erythroid cells.
- 73 -
GATA-1 complexes in erythroid cells 
Materials and methods 
Constructs, nuclear extract preparation, streptavidin binding, mass spectrometry and 
immunoblot analysis. Tagged constructs and procedures involving MEL cells, biotinylated 
proteins and mass spectrometry were previously described23. The GATA-1 zinc finger deletions 
have been described 41. G1E cells and induction were described13,63.
Superose 6 gel filtration. Size fractionation of protein complexes was done on an AKTA FPLC 
apparatus with a Superose 6 10/30 column (Amersham Biosciences, Piscataway NJ). Fractions 
were precipitated with 100% trichloroacetic acid and analyzed by Western immunoblotting, 
as described23. Molecular size standards were thyroglobulin (670kDA) and albumin (66kDa) 
(Amersham Biosciences, Piscataway NJ).
Immunoprecipitations. Nuclear extracts were ple-cleared at 4°C using Protein G sepharose 
beads and affinity-purified IgG (rat [Santa Cruz, CA, sc-2026], rabbit [Santa Cruz, sc-2027], 
goat [Santa Cruz, sc-2028]) in HENG150 buffer. GATA-1 and TAL-1 antibodies were crosslinked 
to beads using dimethyl pimelimidate. Immunoprecipitations were performed in HENG150 / 
0.3% NP-40 buffer overnight at 4°C using protein-G Sepharose beads. Washes were done at 
room temperature in HENG250 / 0.3% NP-40 buffer. Bound material was eluted by boiling in 1x 
Laemmli buffer. 
HDAC assays. Immunoprecipitations for HDAC assays were carried out using 0.3-0.5mg of 
nuclear extracts in HENG150 / 0.1% NP-40, as described above. Immunoprecipitates were 
washed once for 10 minutes in HENG150 / 0.3% NP-40 and three times for 10 minutes each 
in HENG300 / 0.3%NP-40. Beads were resuspended in HENG50 and HDAC assays were 
done using approximately 32,000cpm of 3H-labelled core histones per reaction, as previously 
described64.
HeLa transient transfection and transcription assays. GATA-1 and FOG-1 cDNAs cloned 
in pCDNA 3.1 (Invitrogen, Carlsbad CA) were transiently transfected using 2µg DNA and 
Lipofectamine 2000 (Invitrogen, Carlsbad CA). Cells were harvested after 24 hours and nuclear 
extracts were used for immunoprecipitations as above. pEGFP-N1 (Invitrogen, Carlsbad CA) 
was included as transfection efficiency control. Transcription was assayed by Real-Time PCR 
with primers for exon 2 of the pOVEC reporter plasmid. ChIP assays were done as below using 
GATA-1 and Mi-2β antibodies. The endogenous human GAPDH gene was used as control.
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Distinct GATA-1 complexes bind to different 
target gene subsets in erythroid cells
Abstract
The hematopoietic transcription factor GATA-1 belongs to a family of factors that binds 
DNA through a GATA consensus-binding site. GATA-1 is essential for the generation of the 
erythroid, megakaryocytic, eosinophilic and mast lineages. Its functions involve lineage-specific 
gene activation and repression of early hematopoietic or alternative transcriptional programs. 
Roles in suppressing cell proliferation and in protecting differentiating erythroid cells from 
apoptosis have also been suggested. However, little is known about the molecular basis of 
GATA-1 function. In erythroid cells, we have shown that GATA-1 forms several distinct complexes 
with transcription factors and chromatin remodeling and/or modifying complexes. Here, we show 
that distinct GATA-1 complexes bind to specific subsets of target genes. Firstly, the repressive 
GATA-1/FOG-1/MeCP1 complex binds to the early hematopoietic GATA-2 gene locus. The 
interaction of GATA-1 with the FOG-1/MeCP1 complex is required for GATA-2 silencing during 
erythroid differentiation. The same GATA-1 repressive complex binds to the promoter of the 
eosinophilic Major Basic Protein (MBP) gene, which is upregulated by GATA-1 in eosinophils 
but repressed in erythroid cells. Similar observations were made for another eosinophilic 
gene (IL-5RΑ) and for the myeloid PU.1 transcription factor. Secondly, we show evidence of 
GATA-1 interacting with Gfi-1b in binding to the cell proliferation related c-myb and c-myc genes, 
which are repressed during erythroid differentiation. In contrast, the GATA-1/TAL-1 complex 
involved in erythroid gene activation, is stably bound to regulatory elements of the active EKLF 
gene. Our results suggest that the distinct GATA-1 complexes regulate subsets of genes 
involved in different aspects of GATA-1 function.
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Introduction
Hematopoiesis is characterized by the generation of all blood cells from a unique 
hematopoietic stem cell (HSC) that has the capacity to self-renew or to differentiate into distinct 
lineages. Progressive differentiation gives rise to an increasing number of divergent and tightly 
defined lineages expressing a more restricted genetic program at each branch point. This 
stepwise process is regulated by signaling molecules and transcription factors that modulate 
the response of the downstream target genes1,2. 
Recent evidence has indicated that considerable plasticity exists in the transcriptional 
programs governing hematopoietic lineage specification. It has been shown that HSCs and 
multipotential progenitor cells are transcriptionally “promiscuous” in that they express, at low 
levels, genes associated with committed hematopoietic lineages3-6. These findings led to a model 
whereby multipotential progenitors are transcriptionally “primed” for differentiation along several 
different lineages. Commitment to a specific lineage occurs through the (stochastic) selection 
of a particular transcription program and the concomitant suppression of programs specifying 
alternative lineages7-9. Enforced ectopic expression of a key lineage-specific transcription factor 
in a lineage where it is not normally expressed, or expressed at low levels, can result in the 
reprogramming of this lineage towards other fates normally regulated by this factor (reviewed by 
Graf T.10). This reprogramming is accompanied by the repression of the original lineage-specific 
transcriptional program. Thus, hematopoietic lineage specification involves two key aspects, 
firstly, the appearance or increase in levels of key transcription factors which up-regulate 
lineage-specific transcription and, secondly, the suppression of alternative, “poised” lineage 
transcription programs, often by the same transcription factors that up-regulate lineage specific 
programs7-9.
An example of such a key hematopoietic transcription factor is GATA-1. It is essential 
for the differentiation of the erythroid, megakaryocytic (Meg/E) and eosinophilic lineages11-13. 
GATA-1 is also expressed in mast cells and in some multipotential hematopoietic precursor 
cells. GATA-1 null mice are characterized by an absence of these lineages. Specifically in the 
erythroid lineage, the absence of mature red blood cells is due to a block of the progenitors 
at the proerythroblast stage, which leads to embryonic lethal anemia. The instructive role of 
GATA-1 to generate Meg/E and eosinophils was demonstrated in an avian in vitro system 
using a Myb-Ets-transformed multipotential chicken cell line14. In the murine model, the 
ectopic expression of GATA-1 in an early myeloid cell line, which can differentiate towards 
megakaryocytic or granulocytes lineages, led to the generation of megakaryocytic only cells15. 
In addition, the expression of megakaryocytic and erythroid-associated genes in the same 
system was shown to be up regulated16,17. Significantly, enforced expression of GATA-1 in 
common lymphoid progenitors and common myeloid progenitors reprograms them to erythroid, 
megakaryocytic and eosinophilic fates, with the concomitant repression and up regulation of 
respective lineage-specific marker genes14,18,19. Thus, GATA-1 acts as a key regulator in the 
specification of the aforementioned lineages, a role that apparently involves the activation as 
well as repression of lineage-restricted transcriptional programs. This hypothesis was confirmed 
by microarray analysis of GATA-1 dependent erythroid differentiation showing the up and down 
regulation of several classes of genes20.
GATA-1 carries out activating and repressive functions in erythroid cells. GATA-1 was 
shown to activate several target genes, such as β-globin genes or EKLF21,22. In association 
with the pentameric complex which includes TAL-1/Ldb1/E2A/Lmo2, GATA-1 has been reported 
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to activate glycophorin A and the α-globin genes21,23. GATA-1 was shown to repress early 
hematopoietic programs genes, such as GATA-224, and was also linked to the down-regulation 
of cell proliferation related genes, such as c-myc and c-myb25. Analysis of GATA-1 dependent 
changes in gene expression obtained by microarray data clearly shows gene activation and 
repression providing further evidence for the dual functions of GATA-120. 
 Despite this evidence, it is still unclear how GATA-1 functions as an activator and 
a repressor in the same cell. Using the in vivo biotinylation tagging method (Chapter 2), 
we purified five distinct GATA-1 complexes containing other hematopoietic transcription 
factors and chromatin remodeling complexes. We show that distinct GATA-1 complexes are 
bound in vivo to genes that belong to different classes. We also provide direct evidence for 
GATA-2 gene repression by GATA-1 through the recruitment of the FOG-1/MeCP1 complex. 
On the basis of the evidence presented here and in Chapter 3, we propose a model in which 
GATA-1 has specific early versus late differentiation functions in the context of distinct complexes 
and subsets of target genes. This model is also supported by the observations of Welch et 
colleagues20.
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Results
GATA-1/ FOG-1/ MeCP1 and GATA-1/Gfi-1b are bound to repressed genes in 
vivo
The results presented in Chapter 2 suggest that GATA-1/FOG-1 interactions can tether 
MeCP1 to repressed GATA-1 target sequences in vivo. We therefore employed ChIP assays 
using the GATA-2 locus, the best characterized example of a target gene being repressed 
by GATA-1 in a FOG-1 dependent manner22,24,26. We had previously found that the -2.8kb 
region upstream of the GATA-2 locus was enriched for GATA-1 and FOG-1 binding (Fig. 1A). 
Significantly, the same sequence was also enriched for MBD2 binding (Fig. 1A). Similar results 
were obtained with an antibody against Mi-2β, another component of the MeCP1 complex 
(Fig. 1B). No binding of TAL-1 or Gfi-1b was observed in any of the GATA-2 sequences. Interestingly, 
FOG-1 and MBD2 were shown also to bind to the -3.4kb region, but not to the -4.2kb and 
-2.2kb flanking sequences (Fig. 1A and 1B). This suggests that the FOG-1/MeCP1 binding at 
-3.4kb may reflect a localized spreading of these proteins over a few nucleosomes to sequences 
upstream of the -2.8kb element, or that they were accidentally crosslinked to neighbouring DNA. 
The latter possibility would suggest that the FOG-1/MeCP1 complex is closer to the upstream 
sequences around the GATA binding sites (see also below).
As MeCP1 contains methyl-binding protein, we investigated the methylation status of 
the GATA-2 locus around the MeCP1 binding region. A 3.9kb EcoRI DNA fragment was digested 
Figure 1: Binding of GATA-1 repressive complexes to target genes by ChIP assays in 
induced MEL cells.
Binding patterns of GATA-1, FOG-1, MBD2, TAL-1 and Gfi-1b (A) and of MBD2 and Mi2 (B) to the -2.8kb 
element of the GATA-2 locus. GATA-1 enriches the –2.8 kb region of the GATA-2 locus, with FOG-1 and 
MeCP1 components. MeCP1 presents a narrow spreading around the -2.8 kb region. None of the other 
antibodies were shown to enrich sequences tested. Relative enrichment has been normalized to input and 
corrected for background binding of species- and isotype-matched immunoglobulins. Antibodies: GATA-1, 
N6 (Santa Cruz); FOG-1 as in Tsang et al. (1997); MBD2 S923 63; TAL-1 as in Porcher et al. (1996); Gfi-1b, 
D19 (Santa Cruz), Mi2 (Paul Wade). 
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either with XmnI as a control for complete DNA digestion or by EagI that is methylation sensitive 
(Fig 2). EagI maps to the GATA binding site in the -2,8kb element of the GATA-2 locus. A 1.2kb 
Apa I probe (solid line) detects 1kb and 2.1kb fragments after Eag I digestion and 1.7kb and 
2.2kb fragments after Xmn I digestion. Eag I digests completely DNA of both induced and non-
induced MEL cells, suggesting that its consensus sequence is not affected by DNA methylation 
despite the fact that MBD2 is a methyl DNA-binding protein (Fig. 3)27. However this does not 
exclude the possibility of highly localized methylation to specific CpG residues elsewhere in 
the GATA-2 locus. Thus, considering that GATA-1 binding is essential for GATA-2 repression24, 
our findings strongly suggest that GATA-1, FOG-1 and MeCP1 form the repressive complex 
responsible for GATA-2 silencing. 
We extended our ChIP assays to investigate the binding of GATA-1 repressive 
complexes to other genes that are GATA-1 targets. In eosinophils, ectopic expression of 
FOG-1 results in the downregulation of eosinophilic GATA-1 target genes and the reprogramming 
of these cells towards an earlier, less differentiated cell type which may represent a common 
progenitor for the erythroid/megakaryocytic and eosinophilic lineages28. We thus reasoned 
that eosinophilic GATA-1 target genes, like the major basic protein (MBP)29 which is inactive 
in erythroid cells20, may be suppressed by the GATA-1/FOG-1/MeCP1 complex. We tested this 
Figure 2: DNA methylation assay by restriction enzyme digestion at the -2.8kb element 
of the GATA-2 locus.
Genomic DNA (5-10µg) from non-induced (left panel) and induced (right panel) MEL cells was first digested 
with Eco RI, which releases a 3.9kb fragment, followed by digestion with Eag I (methylation sensitive, 
indicated by asterisk), or Xmn I as control for complete digestion of the genomic DNA samples. Eag I maps 
close to the GATA-1 binding sites in the -2.8kb element of the GATA-2 locus and within the PCR fragment 
(grey box, not to scale) amplified in the ChIP assays shown in Figures 5 and 6. Digested DNA was blotted 
and probed with a 1.2kb Apa I fragment (solid line) which detects 1kb and 2.1kb fragments on the Eag I 
digests and 1.7kb and 2.2kb fragments on the Xmn I digests. For both digests, the larger fragments are 
weaker due to their limited overlap with the probe. It can be seen that Eag I digests completely in DNA of 
both induced and non-induced MEL cells, thus suggesting that its recognition site is not affected by DNA 
methylation.
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hypothesis by ChIP in induced MEL cells using as control chromatin from mouse eosinophils 
where MBP is expressed30. As expected, the promoter of the MBP gene was bound by 
GATA-1 in eosinophils (Fig. 3A). Importantly, GATA-1 was also bound to the inactive MBP 
promoter in induced MEL cells (Fig. 3B). FOG-1 and Mbd2 were also bound to the MBP promoter 
in MEL cells but not in eosinophils (Fig. 3B), consistent with the prediction above. Similar results 
were also obtained with an antibody against Mi-2β (Fig. 3C). Again, no TAL-1 of Gfi-1b binding 
was detected in the MBP promoter (Fig. 3B). Strikingly, in MEL cells, we found binding of the 
FOG-1 and MeCP1 complex, but not of GATA-1, to the +0.6kb sequence located close to the 
MBP promoter but not to other sequences located further upstream (-1.8kb) or downstream 
(+1.2kb) of the promoter (Fig. 3B and C). This observation is similar to that seen at the GATA-2 
-2.8kb element.
We also investigated whether the interleukin-5 receptor α (IL-5Rα) gene is a repressed 
GATA-1 target gene in erythroid cells. IL-5Rα is a key regulator in the specification of the 
eosinophilic lineage and is involved in allergic responses31. The analysis of the upstream region 
of the IL-5Rα gene revealed the presence of several transcription factors binding sites, including 
GATA-132. We thus reasoned that the eosinophilic IL-5Rα gene might also be down regulated by 
the GATA-1/FOG-1/MeCP1 complex in erythroid cells. Indeed, we detected binding of GATA-1 
at the promoter of the IL-5Rα gene in erythroid cells (Fig. 4A). Significantly, FOG-1, Mi-2 and 
MBD2 were also detected binding to the IL5Rα promoter (Fig. 4B). These observations are 
consistent with the notion that the GATA-1/FOG-1/MecP1 complex is involved in the repression 
of alternative hematopoietic programs, such as the eosinophil program in erythroid cells. Thus, 
Figure 3: Binding of GATA-1 repressive complexes to target genes by ChIP assays in 
induced MEL cells.
Binding patterns of GATA-1, FOG-1, MBD2, TAL-1 and Gfi-1b to the MBP promoter in eosinophils (A) and in 
MEL cells (B). Binding of MBD2 and Mi2 to the MBP (C) promoter. GATA-1 was shown to bind to the MBP 
promoter in eosinophils as well as in erythroid cells. In erythroid cells, GATA-1 binds with MeCP1, whereas 
TAL-1 and Gfi-1b did not show any enrichment. Relative enrichment has been normalized to input and 
corrected for background binding of species- and isotype-matched immunoglobulins. Antibodies are similar 
to the ones used for Fig 1.
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GATA-1 may regulate diffrerent programs in the context of different complexes.
The Ets family hematopoietic transcription factor PU.1 is expressed in both myeloid 
and lymphoid progenitors33 and the analysis of PU.1 knockout mice has shown that it is 
essential for the differentiation of both lineages34. Several lines of evidence have shown 
GATA-1 and PU.1 to be functionally antagonistic. GATA-1 was shown to bind to PU.1 in myeloid 
cells35. This interaction prevents recruitment of c-jun by PU.1 and therefore inhibits the ability 
of PU.1 to activate myeloid target genes. Similarly, in erythroid cells, PU.1 was shown to inhibit 
GATA-1-mediated transcriptional activation by interacting with GATA-136. Ectopic expression 
of PU.1 in erythroid cells blocks terminal erythroid differentiation37. Thus we reasoned that the 
transcription factor PU.1, which would need to be repressed during erythroid differentiation, 
could also be a candidate for GATA-1 mediated repression. Indeed, we find that GATA-1 shows 
a clear enrichment for binding to the PU.1 promoter (Fig 4C). We also find enrichment for 
FOG-1, MBD2 and Mi-2 binding (Fig. 4D). We observe binding of the MeCP1 and FOG-1 also at 
the negative control sequence, suggesting a narrow spreading of the complex as observed for 
MBP and GATA-2. Although additional sequences in the PU.1 locus need to be investigated by 
ChIP assays, these preliminary data provide another example of a gene of an alternative lineage 
(the myeloid) that is repressed by the GATA-1/FOG-1/MeCP1 complex in erythroid cells.
We next tested the c-myc and c-myb genes which are down-regulated with MEL cell 
differentiation38,39. Repression of the c-myc and c-myb genes has been linked to the proliferation 
arrest that accompanies terminal erythroid differentiation. The c-myc gene has also been shown 
to be a GATA-1 target gene in G1E cells20,25. We found GATA-1 binding to both promoters in 
induced MEL cells but we could not detect binding of FOG-1 or MBD2 to the same sequences 
(Fig. 5A and B). By contrast, Gfi-1b (absent from all other genes tested) was found binding to 
Figure 4: Binding of GATA-1 complexes to target genes by ChIP assays in erythroid 
cells.
The repressive GATA-1/FOG-1/MeCP1 complex binds to the promoters of the eosinophilic IL-5Rα (A and 
B) and of the myeloid PU.1 (C and D). Panels A and C represent relative enrichment for GATA-1 and IgG 
isotypes to input. Relative enrichment has been normalized to input and corrected for background binding 
of species- and isotype-matched immunoglobulins for panels B and D. Antibodies are similar to the ones 
used for Fig 1.
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both promoters (Fig. 5A and B), thus suggesting a role for the GATA-1/Gfi-1b complex in the 
repression of genes associated with cell proliferation. This may explain the observations of 
rapidly proliferating Gfi-1b-/- immature erythroid precursors in colony assays40 and of Gfi-1b 
overexpression inducing proliferation arrest and differentiation in erythroid progenitors41.
We also tested other genes to investigate functions of GATA-1 in apoptosis and cell 
survival. Bcl-XL is a member of the Bcl2 family and has been associated with anti-apoptotic 
functions, also in erythropoiesis42. Bcl-XL has been shown to be up-regulated during erythroid 
differentiation, this being dependent on Epo signaling43. Expression analysis of Bcl-XL in G1E 
cells showed that GATA-1 is also required for Bcl-XL up-regulation
42. In addition, differentiation 
of Bcl-XL
-/- ES cells in vitro is characterized by a block of maturation of definitive erythroid 
precursors that die from apoptosis, an observation similar to that of the GATA-1 null ES cells42. 
Taken together, these observations suggest a regulatory role for GATA-1 in Bcl-XL expression. 
Furthermore, the p16INK4a tumor suppressor that acts as an inhibitor of cyclin kinases such 
as CDK4 and CDK644 which phosphorylate retinoblastoma, was shown to be up-regulated 
in GATA-1 infected erythroid cells45. We tested GATA-1 binding at both Bcl-XL and p16
INK4a
 
promoters but failed to detect any GATA-1 binding (data not shown), suggesting a possible 
indirect regulating effect of GATA-1 on those genes. For example, up-regulation of Bcl-XL during 
erythroid differentiation is a late event compared to expression of GATA-142. 
 
GATA-1 and TAL-1/Ldb1 are bound to an activated erythroid gene in vivo
Finally, we also tested the EKLF gene as an example of a gene that is activated during 
erythropoiesis. The EKLF enhancer sequence contains a GATA-E-box motif46 which is bound 
in vivo by GATA-1 independently of FOG-122. Strong GATA-1 binding and a clear enrichment 
for TAL-1 binding was indeed detected at the EKLF enhancer (Fig. 5C), thus providing a clear 
demonstration for the alternative (activating) GATA-1 complex with TAL-1 binding to a target 
gene in vivo. This may be related to the low level of HDAC activity associated with the TAL-1 
immunoprecipitate (Chapter 2, Fig. 6A). No significant binding of FOG-1, MBD2 or Gfi-1b could 
be detected in the EKLF enhancer sequences (Fig. 5C). 
Our analysis of the GATA-1/ACF/WCRF complex by ChIP, or any other, assays has 
been hindered by the quality of ACF/WCRF reagents available to us, hence it is presently not 
known whether the GATA-1 and ACF/WCRF complex binds to active or repressed genes.
GATA-1/FOG-1/MeCP1 binding in the GATA-2 gene locus 
The binding of FOG-1 and MeCP1 to sequences adjacent to a GATA-1 binding site 
in the GATA-2 gene locus suggested that these proteins might spread along the DNA after 
GATA-1 mediated binding. We tested this possibility using ChIP analysis across the GATA-2 locus 
(Fig 1D and E, and Fig 6). The results showed that there is no binding of MeCP1 across the 
GATA-2 locus, suggesting that the spreading of the complex in differentiated MEL cells is 
restricted to sequences adjacent to the GATA binding sites of the -2.8kb region. This might also 
reflect the highly localized 3D structure of the locus where the two sequences that are showing 
enrichment are closer in a spatial organization than on a linear configuration. Within the GATA-2 
gene locus, MeCP1 binding was detected only at a region neighbouring the -2.8 kb element. In 
contrast, GATA-1 was shown to bind, in addition to the -2.8kb region26, to a sequence containing 
a GATA binding site located -3.9 kb upstream of the promoter. Both -2.8kb and -3.9kb elements 
coincide with the DNase I Hypersensitive sites in the active GATA-2 locus47 (Fig. 6).
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Figure 5: Binding of GATA-1 repressive and activating complexes to target genes by ChIP 
in induced MEL cells.
Binding patterns of GATA-1, FOG-1, MBD2, TAL-1 and Gfi-1b the myb (A) and myc (B) promoters and 
at the EKLF upstream enhancer (C). GATA-1 binds to the repressed c-myc and c-myb promoter genes 
with Gfi-1b, whereas GATA-1 and TAL-1 bind to the GATA-E-box motif of the EKLF enhancer. Relative 
enrichment has been normalized to input and corrected for background binding of species- and isotype-
matched immunoglobulins. GATA containing sequences are indicated in bold.
Figure 6: ChIP analysis of GATA-1 and MeCP1 (Mi2 and MBD2/3) across the GATA-2 
locus.
GATA-1 is binding specifically at two regions defined as DNase Hypersensitive sites in the active locus, 
at -2.8 kb and -3.9 kb. The -2.8 kb region shows an enrichment for binding of FOG-1 and of the MeCP1 
complex with a narrow spreading. In contrast, the -3.9 kb is not enriched by MeCP1 complex, suggesting 
that GATA-1 is bound to the GATA-2 locus as two independent protein complexes. Relative enrichment 
has been normalized to input and corrected for background binding of species- and isotype-matched 
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GATA-1 represses GATA-2 expression through the recruitment of FOG-1 and 
MeCP1
 In order to confirm that GATA-2 repression during erythroid differentiation is specifically 
due to GATA-1 recruiting FOG-1 and the MeCP1 complex, we took advantage of the GATA-1 null 
G1E proerythroblastic cell line. These cells are derived from in vitro differentiated GATA-1 null 
ES cells and can undergo terminal differentiation only upon restoration of GATA-1 expression48. 
We used two G1E cell lines. The first one expresses wild type GATA-1 fused to an estrogen 
receptor (ER) ligand binding domain (GATA-1-ER) which can mediate terminal erythroid 
differentiation upon induction by estradiol49. The second cell line expresses ER fused to a mutant 
GATA-1 form bearing a single V205M amino acid substitution in the GATA-1 N-terminal zinc 
finger. Whilst not affecting GATA-1 DNA binding, this mutant abrogates interaction with FOG-1 
and fails to rescue differentiation of G1E cells50,51. We first determined that repression of the 
GATA-2 gene in G1E cells was absolutely dependent on GATA-1 being capable of interacting 
with FOG-1 (Fig. 7A). We next tested by ChIP whether interaction of GATA-1 with FOG-1 binding 
at -2.8kb was responsible for the recruitment of MeCP1 to this sequence and to the neighboring 
-3.4kb sequence (Fig. 1A). As control, we also tested the more distal -4.2kb sequence, which 
did not show binding for any of these factors (Fig. 1A). In agreement with the MEL data, 
GATA-1, FOG-1 and Mi-2β were bound to the -2.8kb and to the -3.4kb sequence (for FOG-1 and 
Mi-2β) in differentiated GATA-1-ER cells (24 hours after induction with estradiol), albeit at lower 
levels compared to MEL cells (Fig. 7B, left panels). By contrast, in the GATA-1(V205M)-ER 
expressing cells GATA-1 was bound to the -2.8kb sequence, but no binding of FOG-1 and 
Mi-2β to the -2.8kb or -3.4kb sequences was detected (Fig. 7B right panels). We conclude that 
FOG-1 and the MeCP1 complex are specifically recruited by GATA-1 to the GATA-2 locus and 
are responsible for GATA-2 repression in terminal erythroid differentiation.
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Figure 7: Silencing of GATA-2 requires recruitment of FOG-1 and MeCP1 by GATA-1.
(A) The V205M GATA-1 mutation fails to repress GATA-2. GATA-2 mRNA was measured by Real-Time 
PCR in G1E GATA-1-ER and G1E GATA-1(V205M)-ER cells before (0 hours) and after 24 hours of estradiol 
induction. Expression at 0 hour was normalized against GAPDH expression and set as 1. (B) ChIP to 
show binding of GATA-1, Mi-2β and FOG-1 in G1E GATA-1-ER (left panels) and in G1E GATA-1(V205M)-
ER (right panels) at time 0 and 24 hours of estradiol induction. Relative enrichment has been normalized 
to input and corrected for background binding of species- and isotype-matched immunoglobulins. Data 
represent an of two independent IPs and three PCRs with duplicate samples. Antibodies used were as in 
the legend of Figure 5, except Mi-2β antibody66.
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Discussion
We provide here evidence for the in vivo binding of the five distinct GATA-1 complexes 
in erythroid cells. We show that the repression of the early hematopoietic gene GATA-2, which 
is mediated by GATA-1 and FOG-1, is due to the recruitment of the MeCP1 complex. In addition, 
we provide evidence for the in vivo binding of this complex to the repressed eosinophilic MBP 
and IL-5Rα genes and the myeloid PU.1 gene. Significantly, we also show the binding of 
GATA-1 in complex with TAL-1 to the active erythroid specific EKLF gene. Finally, we also show 
binding of the GATA-1/Gfi-1b complex to genes associated with cell proliferation functions, which 
become repressed with late stages of erythroid differentiation. These data strongly suggest that 
GATA-1 carries out different functions by targeting different genes through different complexes 
in erythroid cells.
GATA-1 complexes and target genes
 We have identified the mechanism by which GATA-2 gene locus is repressed by 
GATA-1 during erythroid differentiation. GATA-2 gene expression was shown to be repressed 
by GATA-1 in a FOG-1 dependent manner, and GATA-1 was identified to bind at the -2.8kb 
region of the GATA-2 locus24,26. Here, we show in erythroid cells that GATA-1 recruits MeCP1 
to the -2.8kb region through its interaction with FOG-1. Identification of MeCP1 as a co-factor 
of the GATA-2 gene repression is in agreement with the wave of deacetylation observed after 
GATA-1 binding, since MeCP1 carries histones deacetylase activities26. In addition, we have 
shown in chapter 2 that GATA-1 was associated with histone deacetylase activity. We show that 
GATA-1/FOG-1/MeCP1 is used in erythroid cells to repress early hematopoietic programs for 
the proper erythroid differentiation.
Determining cell fate is a complex process in which transcription factors play an 
essential role on the concomitant gene activation and repression. We found three non-erythroid 
lineage genes to be bound specifically by the repressive GATA-1/FOG-1/MeCP1 complex in 
erythroid cells. The MBP and IL-5Rα genes are expressed in eosinophils. MBP is activated 
by GATA-152, and the promoter of IL-5Rα contains GATA binding sites53. The fact that the 
GATA-1/MeCP1 complex is bound to these repressed genes in erythroid cells suggests that 
this complex acts early in erythroid cell differentiation to suppress alternative hematopoietic 
programs. The GATA-1 binding to the PU.1 promoter is also of interest since GATA-1 and 
PU.1 seem to have antagonistic functions in differentiation. For example, overexpression of 
PU.1 in MEL cells leads to a block of differentiation at the proerythroblast stage, similar to the 
GATA-1 knockout phenotype54. In addition, these two factors were shown to physically interact, 
perhpas affecting the DNA binding properties of the individual factors36. This direct interaction 
was thought to be sufficient to explain the down regulation of GATA-1 expression in myeloid 
cells, and conversely the down regulation of PU.1 in erythroid cells55,56. Here we show that in 
addition to the previously described GATA-1/PU.1 protein interactions, GATA-1 also regulates 
PU.1 gene expression directly as it binds to its promoter. However, we also detected MeCP1 
binding to a region adjacent to this GATA site. Additional DNA sequences of the PU.1 gene locus 
must be examined to demonstrate specificity of the MeCP1 binding. These results suggest that 
the balance between myeloid and erythroid lineage is very tightly regulated by the fine-tuning 
of key transcription factor expression, such as GATA-1 and PU-1. We can speculate that the 
GATA-1/FOG-1/MeCP1 complex functions to suppress genes that need to be switched off early 
in hematopoiesis for erythroid differentiation, for example eosinophilic and myeloid lineages 
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associated genes.
DNA methylation is associated with gene repression. MeCP1 contains proteins that 
bind methylated DNA. Interestingly, FOG-1/MeCP1 binding at the GATA-2 and MBP loci show 
a narrow spreading into sequences adjacent to the GATA-1 binding sites, indicating that the 
chromatin complex can possibly spread along the chromatin. Alternatively, this enrichment might 
also reflect a cross-linking artefact due to the size of the complex that could be cross-linked to 
very close sequences. Other MeCP1 components such as Mi2-β and HDAC1 exhibit similar 
profiles at the same site (this thesis and 57). Finding MeCP1 bound to GATA-2, MBP, IL-5Rα and 
PU.1 genes suggest therefore that these loci maybe methylated. However, we did not detect 
any methylation in the GATA-2 -2.8kb element in non-differentiated or differentiated MEL cells by 
southern blot. An analysis of CpGs in the GATA-2 locus has revealed the presence of a typical 
CpG island (CpG islands are usually located around the promoters of housekeeping genes) in 
the region between -2.2kb and -4.2kb of the GATA-2 locus (Fig. 6). It is very intriguing to detect 
MeCP1 binding in the -2.8kb region, since this is the first time to our knowledge that MeCP1 (and 
MBD2) is bound to non-methylated DNA in vivo. In contrast to our results, Hong and colleagues 
have not detected the presence of the MBD2 protein during purification of the FOG-1 complex, 
which led them to suggest that FOG-1 interacts with the NuRD complex instead of the MeCP1 
complex. However, we have unequivocally identified MBD2 by mass spectrometry and also 
using a MBD2 specific antibody which detected interaction with GATA-1 by immunoprecipitations 
(data not shown) and binding to target genes. Despite these differences we would propose that 
GATA-1 uses the NuRD/MeCP1 complex to repress genetic programs that are “primed” in early 
stages of hematopoiesis. As this complex carries histone deacetylase activity, we can imagine 
modification of the chromatin structure that leads to repression throughout cell differentiation. 
Loss of function of Gfi-1b in hematopoiesis has highlighted an essential role in 
megakaryocytic and erythroid linages40. The similar phenotypes of the Gfi-1b and GATA-1 
knockouts suggest that they may act in a common pathway. Several lines of evidence have 
suggested that GATA-1 and Gfi-1b might be involved in cell cycle regulation. GATA-1 interacts with 
the retinoblastoma protein and GATA-1 overexpressing cells fail to arrest at G158. Interestingly, 
Gfi-1b was shown to inhibit myeloid cell differentiation by repressing the cyclin kinase inhibitor 
p21WAF1, 59. The c-myc and c-myb genes have been reported to be down-regulated in GATA-1-
mediated differentiation of erythroid cells20. The binding of GATA-1 and Gfi-1b to the repressed 
c-myc and c-myb genes provide important clues as to how these genes may regulate cell 
cycle and cell proliferation in erythroid differentiation. Gfi-1b contains a SNAG domain that has 
been linked to gene repression59, for example by recruiting HDAC containing complexes60. It is 
possible that GATA-1 represses target genes via Gfi-1b recruiting co-repressors. Interestingly, 
we did not find Gfi-1b to bind to the GATA-2 locus, suggesting a tight regulation in the specific 
recruitment of complexes to different subsets of gene targets. However, previous studies have 
suggested a repression of c-myc by GATA-1 and FOG-161. We therefore cannot exclude an 
indirect effect of GATA-1/FOG-1 on c-myc expression. A second discrepancy comes from ChIP 
analysis showing FOG-1 binding to the c-myc promoter in erythroid cells and recruitment of the 
NuRD complex57. This is in contrast to our data where we have failed to detect binding of FOG-1 
despite using two different FOG-1 antibodies, or of MeCP1 members to the c-myc promoter.
GATA-1 complexes and erythropoiesis
An important aspect in hematopoietic differentiation, is the suppression of alternative 
“primed” lineage transcription programs and genes that maintain multipotentiality, while 
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upregulating genes associated with the differentiated cell type7,9. In addition, erythroid terminal 
differentiation is accompanied by cell cycle arrest. GATA-1 has been implicated in the regulation 
of most of these aspects62. In fact, a recent microarray analysis of GATA-1-dependent erythroid 
terminal maturation revealed an early wave of repression of genes like GATA-2, c-myc and 
c-myb, followed by the upregulation of erythroid specific genes20. Here we identified two 
GATA-1 repressive complexes acting on distinct sets of genes. We suggest that the 
GATA-1/Gfi-1b complex acts early and suppresses genes involved in cell proliferation, 
e.g. c-myc and c-myb. The GATA-1/FOG-1/MeCP1 complex also acts early to suppress genes 
required to maintain the “primed” multipotential state, e.g GATA-2 and alternative hematopoietic 
lineage genes, MBP, PU.1 and IL-5Rα (Fig. 1 and 2). In contrast, the GATA-1/FOG-1 and the 
GATA-1/TAL-1/Ldb1 complexes would play a major role in the later upregulation of erythroid 
genes (Fig. 4).
 In conclusion, we suggest that GATA-1 provides specific early versus late differentiation 
functions in the context of distinct complexes (Fig. 8). The model of different GATA-1 complexes 
executing specific tasks in different stages of erythroid differentiation suggests a dynamic 
aspect in the GATA-1 complex interactions during differentiation and also raises the prospect of 
dissecting the contribution of distinct GATA-1 interactions in erythropoiesis (i.e. essential versus 
dispensable) by selectively manipulating a specific GATA-1 complex at a time.
Figure 8: Model for the distinct GATA-1 complexes and their role in erythropoiesis. 
Broken arrow indicates unknown function and timing. See text for explanation.
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Material and methods
ChIP assays. Preparation of crosslinked chromatin (2x107 induced MEL cells treated with 
0.4% formaldehyde for 10 minutes at room temperature), sonication to 300-800 base pair 
fragments and immunoprecipitations were as described in the Upstate protocol (www.upstate.
com). Anti-GATA-1 protein-DNA immunocomplexes were immunoprecipitated in an additional 
step with an AffiniPure rabbit anti-rat antibody (Jackson ImmunoResearch Laboratories, West 
Grove, PA). Eosinophilic chromatin was prepared as previously described30. At least two 
independent chromatin immunoprecipitations were carried out per experiment. Antibodies used 
: GATA-1, N6 (Santa Cruz); MBD2, S923 sheep polyclonal63 and rabbit polyclonal anti MBD2/3 
antibody (Upstate 07-199); FOG-1 rabbit polyclonal49; TAL-1 rabbit polyclonal64; Gfi-1b D19 goat 
polyclonal (Santa Cruz sc-8559).
Real time PCR. Quantitative RealTime PCR (Opticon I, MJ Research) was done using 
SYBR Green I. PCR primers were designed by Primer Express 2.0 (PE Applied Biosystems). 
The qPCR Core Kit (Eurogentec, Belgium) was used with 400 nM of each primer under the 
following cycling conditions: 950C for 10 minutes, 40 cycles of 30 seconds at 950C, 60 seconds 
at 600C, 15 seconds at 750C. Enrichment for a specific DNA sequence was calculated using the 
comparative CT method 
65. PCR primer sequences are provided in Supplementary Materials 
and Methods.
ChIP PCR primer sequences:
EKLF upstream enhancer forward PCR primer: 5’-CTGGCCCCCCTACCTGAT-3’
EKLF upstream enhancer reverse PCR primer: 5’-GGCTCCCTTTCAGGCATTATC-3’
EKLF -1.35kb forward PCR primer: 5’-TGCTCCCCACTATGATAATGGA-3’
EKLF -1.35kb reverse PCR primer: 5’-GCCACAACCAAAGAAGACATTTT-3’
MBP -1.2kb forward PCR primer: 5’-GGGTCTAATTCCGAGGGTGAGT-3’ 
MBP -1.2kb reverse PCR primer: 5’-GGCCTGGAAATCACTGAGCTA-3’
MBP promoter forward PCR primer: 5’-CCGCCAAGGTGTCTATAAATGC-3’
MBP promoter reverse PCR primer: 5’-TGGGTCTTGTCAAGTTTGCAAA-3’
MBP +0.6kb forward PCR primer: 5’-GAAGTAGAGGCAGGATAATCAGGAA-3’
MBP +0.6kb reverse PCR primer: 5’-AGGATGAACCAGGGCTAATGC-3’
MBP +1.8kb forward PCR primer: 5’-TGTGACAGACGTGGACCTTCA-3’ 
MBP +1.8kb reverse PCR primer: 5’-TGCATCCAGAGTCACCCATAAG-3’
GATA2 -4.2kb region forward PCR primer: 5’-GAATTTCCTGCCGGTCCAT-3’
GATA2 -4.2kb region reverse PCR primer: 5’-GACGCGTTGGCTTTGTGTG-3’
GATA-2 -3.4kb forward PCR primer: 5’-TCCATCCAGCAGCTTTAGGAA-3’
GATA-2 -3.4kb region reverse PCR primer: 5’-GGGTTCGAAGCCACTCCAA-3’
GATA-2 -2.8kb region forward PCR primer: 5’-CCGGGCAGATAACGATTGG-3’
GATA-2 -2.8kb region reverse PCR primer: 5’-TTCATCTCGGCCGGCTAAT-3’
GATA-2 -2.2kb region forward PCR primer: 5’-AGGACCCCCTGCTTCTTGTTTC-3’
GATA-2 -2.2kb region reverse PCR primer: 5’-GGCAGTATGAGGCCCAGAATCTT-3’
Myb promoter forward PCR primer: 5’-GGGCGCCAGATTTGG-3’
Myb promoter reverse PCR primer: 5’-GGAGGAAACAGGTTGATATTAAAGT-3’
Myb -0.8kb forward PCR primer: 5’-GTAGGTTTGTCCAGCAAGTGTTTG-3’
Myb -0.8kb reverse PCR primer: 5’-AGGTGCCTACCACGCACTTCT-3’
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C-myc promoter forward PCR primer: 5’-CCAGACATCGTTTTTCCTGCATA-3’
C-myc promoter reverse PCR primer: 5-‘CCGCTCAGTGTGTGGAGTGATA-3’
C-myc -0.7kb forward PCR primer: 5’-ACACACACATACGAAGGCA-3’
C-myc -0.7kb reverse PCR primer: 5’-ACCGTTAACCCCTTCCTCCC-3’
PU.1 promoter forward PCR primer: 5’-CCAGGGCTGCCCTTTGA-3’
PU.1 promoter reverse PCR primer:5’-TTGCATAAATCTCTTGCGCTACA-3’
PU.1 -0.8kb forward PCR primer: 5’-GCATCTGGTGGGTGGACAAG-3’
PU.1 -0.8kb reverse PCR primer:5’- GCGCGCCATCTTCTGGTA-3’
Il-5R promoter forward PCR primer: 5’-GCAGGTGTCTTCTTAACCATGACA-3’
Il-5R promoter reverse PCR primer: 5’-GGGTGCACTGGTGTTTGACTT-3’
Il-5R -1 kb forward PCR primer: 5’-CTGAACCAAACCTGAACCCAT-3’
Il-5R -1kb reverse PCR primer: 5’-CACCTGCATGTCTGATTTGTC-3’
PCR primers for RNA analysis in G1E cells
GATA-2 mRNA primers:
Exon III forward PCR primer: 5’-ACTATGGCAGCAGTCTCTTCCATC-3’
Exon V reverse PCR primer: 5’-AAGGTGGTGGTTGTCGTCTGAC-3’
Antibodies
The following antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA): 
N6 GATA-1 rat monoclonal (sc-265); Gfi-1b D19 (sc-8559)
Rabbit polyclonal antibodies against TAL-1 were a generous gift by Richard Baer (Columbia 
University, NY) and by Catherine Porcher (WIMM, Oxford). Rabbit polyclonal antibodies against 
Ldb1 were kindly donated by Gordon N. Gill (Stanford University, CA). Rabbit polyclonal 
antibodies against FOG-1 were a generous gift by Stuart H. Orkin (Harvard Medical School, 
MA). Rabbit polyclonal antibodies against MTA2, Mi2 and MBD2/3 were kindly donated by Paul 
A. Wade (NIH/NIEHS, NC). Sheep anti-serum S923 against MBD2 was generously provided by 
Adrian Bird (University of Edinburgh, UK).
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Novel binding partners of Ldb1 are required for 
hematopoietic development
Abstract
Ldb1, a ubiquitously expressed LIM domain binding protein, is essential in a number of 
tissues during development. It interacts with Gata1, Tal1, E2A and Lmo2 to form a transcription 
factor complex regulating late erythroid genes. We identify a number of novel Ldb1 interacting 
proteins in erythroleukemic cells, in particular the repressor protein Eto-2 (and its family member 
Mtgr1), the cyclin dependent kinase Cdk9 and the bridging factor Lmo4. Morpholino mediated 
knockdowns in zebrafish show these factors to be essential for definitive hematopoiesis. In 
accordance with the zebrafish results these factors are co-expressed in pre-hematopoietic cells 
of the early mouse embryo although we originally identified the complex in late erythroid cells. 
Based on the change in subcellullar localisation of Eto-2 we postulate that it plays a central role 
in the transition from the migration and expansion phase of the pre-hematopoietic cells to the 
establishment of definitive hematopoietic stem cells.
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Introduction
Erythrocytes are derived from an infrequently dividing cell type, the hematopoietic 
stem cell (HSC)1. The first wave of hematopoiesis generates primitive erythrocytes From 
approximately E8.5 to E10.5 in the mouse definitive HSCs are derived from the aorta-gonado-
mesonephros region (AGM)2-6. Recently the placenta has been identified as a further source 
of adult HSCs7,8. At E11 the mouse fetal liver becomes the main organ of hematopoiesis, later 
replaced by the bone marrow.
 HSC differentiation involves co-ordinated and changing transcription, often by 
functionally conserved genes. For example, in mammals such a set of transcription factors 
(including Gata2, Tal1, Lmo2, Gata1 and Runx1/Aml-1) is required for the differentiation of 
HSCs9. 
 Often the binding sites for transcription factor complexes are located at great distance 
from the genes that they control. In the human β-globin locus the interacting binding sites and 
genes are spread over a distance of 100kb. A three-dimensional structure resulting from long 
range interactions, the Active Chromatin Hub, has recently been demonstrated10-13. We anticipate 
that (novel) classes of proteins will establish such 3D structures by mediating interactions of 
protein complexes bound to distal regulatory elements. An example of a long range interaction 
protein is Chip/Ldb114, a protein that can interact with the insulator protein Su(Hw)15. Initially 
isolated in a screen for proteins that bind LIM domains16, orthologs of Ldb1 have now been 
identified in a range of other species. Ldb1, a ubiquitously expressed nuclear protein, does not 
bind DNA but appears to participate in transcriptional control by acting as a co-factor for other 
proteins. It binds LIM-homeodomain (LIM-HD) and LIM-only (LMO) proteins via the C-terminal 
LIM Interaction Domain (LID)15,17 and homodimerises via a Self Interaction Domain (SID) in 
the N-terminus and the Other Interaction Domain (OID)15. It is part of a protein complex in 
murine erythroid cells composed of the hematopoietic transcription factors Lmo2, Tal1, Gata1 
and E2A18 binding to a GATA-E box motif. This complex binds to the LCR and β globin promoter 
of murine erythroleukemic (MEL) cells19, to the erythoid specific glycophorin A promoter20 and to 
multiple sites in the α-globin locus during erythroid differentiation21.
Correct transcriptional regulation by Ldb1 has been shown to be the result of an 
equilibrium of interactions between Ldb1 and its different binding partners. For example, in 
D. melanogaster Chip/Ldb1 and Apterous interact forming a functional complex where the 
relative levels of the two proteins are critical . This interaction can be modulated by dLMO, 
another interacting factor24. Consistent with its interaction with a broad range of transcription 
factors involved in development, the Ldb1 knockout mouse dies between E9.5 and E10.5 of 
a series of developmental defects, including no hematopoieisis25 and A. Hostert unpublished. 
The latter partly resembles the knockout phenotypes of the hematopoietic transcription factors 
Lmo2 and Tal1 26-29.
In order to understand the role of Ldb1 in erythroid transcriptional interactions, we 
performed a biochemical screen to identify its binding partners. Using our in vivo biotinylation 
approach30,31 we describe a number of novel partners. We show that Ldb1 forms complexes 
that change composition during MEL cell differentiation and that these complexes are bound 
to the target genes in vivo. We show that Ldb1 and its binding partners are co-expressed in 
situ at early stages of development of the hematopoietic system in the mouse embryo and that 
the novel erythroid binding partners are required for development of the definitive but not the 
primitive hematopoetic system of zebrafish embryos.
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Materials and Methods
Ldb1 cDNA and bio-Ldb1 construct cloning
Ldb1 cDNA was cloned from D14.5 FvB fetal liver RNA (Trizol, Life Technologies) by RT-
PCR (SuperScriptII RT, Invitrogen; Pfu Pol, Promega) into the EcoRI site of pBluescript (pBS) 
(construct AH-3). 
ATG less Ldb-1 cDNA was amplified and cloned between the BamHI and NotI sites of pBS. 
The bio-tag was cloned directly in front of the ATG-less cDNAtagged cDNA was isolated as a 
XhoI–NotI fragment and cloned into the SalI and NotI sites of pEV-Neo (de Boer et al., 2003) to 
give construct pEV-Neo-bio-Ldb1.
MEL cell transfection and culture
C88 cells were cultured and induced for differentiation as described. C88BirA cells  were 
transfected by electroporation with ScaI-linearised pEV-Neo-bioLdb1, cultured in 96 well plates 
containing medium with 1µg/ml puromycin and 0.8mg/ml neomycin to select single clones.
Nuclear extract preparation
Small scale nuclear extract preparation of MEL cell cultures (30-50ml) was prepared according 
to Andrews and Faller78. Nuclear extracts of larger cultures (5,5 to 9l) were prepared as 
described.
Strepatavidin Pulldown and Mass spectrometry
Strepatavidin coated Dynabeads M-280 (Dynal) were blocked for one hour with chicken serum 
albumin/PBS (200ng/µl). The salt and detergent concentrations of nuclear extract samples of 5-
6mg from induced C88BirA/bio-Ldb1 cells or 15mg from non-induced C88BirA/bio-Ldb1 cells were adjusted 
to 200mM KCl and 0.3% NP40 with 10mM KCl buffer (10mM KCl, 10mM HEPES-KOH, 1,5mM 
MgCl2, 25% glycerol, 0,75% NP40, 2mM PMSF) prior to overnight incubation with blocked 
beads at 4°C. The beads were washed 6 times 5 min each in washing solution (150/200mM 
KCl, 10mM HEPES-KOH pH 7.9, 1.5mM MgCl2, 0.2mM EDTA, 0.3% NP40, 0.2mM PMSF) at 
RT. Pulled down proteins were processed and analyzed by mass spectrometry as described. 
Immunoprecipitations and Western blot analysis
Immunoprecipitations were performed as described, Western blots as in. Bio-Ldb1 was detected 
using a 1/10000 dilution of Streptavidin-Horeseraddish peroxidase (HRP) conjugate (NEN).
Antibodies
Monoclonal rat antibodies against Mtgr1 and Lyl1 were produced by Absea. Antibody against 
E2-2 was obtained from Abcam (ab2233), all others from Santa Cruz Biotechnology: α-Ldb1 
(sc-11198), α-Lmo4 (sc-11121, sc-22833), α-Eto-2 (sc-9741), α-Runx1 (sc-8563), α-Cdk9 (sc-
484), α-HEB (sc-357), α-E2A (sc-349), α-Gata1-N6 (sc-265).
Chromatinimmunoprecipitations
Fixation, lysis of cells and sonication of chromatin were performed as described. 
Primers for real time-PCR were as in. Primers for the Gata1 HS and negative control sequences 
were:
Gata1 HS-3.5 Rev: CCGGGTTGAAGCGTCTTCT
Gata1 HS-3.5 For: TCAGGGAAGGATCCAAGGAA
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Gata1 Negrev: TGCCGCTTGCCTTTGTAAG
Gata1 Negfor: CACTAGCAGCTGGGTGGGTTA
Immunohistochemistry
E9.5 FvB mouse embryos were fixed in 2% paraformaldehyde/PBS for 2hrs at RT. After overnight 
equilibration in 20% Sucrose/PBS at 4OC embryos were orientated, quick frozen in Tissue Tek 
(Sakura Finetek).
Immunohistochemistry was essentially carried out as described in 32. All animal 
experiments were carried out according to the Dutch Welfare of Animals Act.
Zebrafish maintenance and Morpholino oligo injections
WT zebrafish were kept and staged according to . ATG morpholinos (Gene-Tools) were derived 
from the genebank cDNA of ldb1 (NM_131313, 5’-GCCCACGTCTCGGTCCAGCATGGTG-3’), 
tcf4 (NM_131259, 5’-AGCTGCGGCATTTTTCCCGAGGAGC-3’), e12 (X76997, 5’-GGTGCCC
ACCGTCGCCATCCTGATC-3’), cdk9 (BC055634, 5’-CGACGCCATCGTAGTATTTGGACAT-
3’), lmo4 (NM_177984, 5’-AGCTTTCCACACGACTGTTCACCAT-3’). For identification of the 
zebrafish Eto family homologues xblastn searches of the EST database using the murine protein 
sequences of Eto-2, Eto and Mtgr1 were performed. ATG-MOs were designed against the 
hypothetical translational start sites in EST AF164710 (5’- AACATGACGGTTGGAACTCTGGTT-
3’), the orthologue of Eto-2 and EST CD053087 (5’-GACCGGGCATGGCAGGAACCTTCT-3’) 
that showed similarity to the least conserved ETO family member Mtgr1. 
All morpholinos were dissolved in water to a concentration of 1mM and injected at three doses 
(0.1nl, 0.5nl and 1.2nl) into zebrafish embryos at the 2-8 cell stage. As an injection control 
rhodamin-dextrane was added to a concentration of 10% vol/vol before use. 
Whole mount in situ hybridization
Digoxigenin-UTP (Roche) labeled antisense and sense RNA probes against the zebrafish 
orthologues of embryonic beta globin, βE1  and runx1 (M. Gering) were synthesized from 
linearised plasmids using T3 and T7 RNA polymerases. In situ hybridization was performed 
as described by . Probes were detected by incubation with alkaline phophatase (AP) coupled 
anti-Digoxigenin antibody (Roche) and color reaction with Fast Red (Roche) for α-E1 and BM 
Purple (Roche) for runx1.
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Results
Generation of bio-Ldb1 cells
In order to identify Ldb1 interacting partners, C88BirA MEL cells expressing the 
Escherichia coli BirA protein-biotin ligase30 were stably transfected with pEV-Neo-bio-Ldb1. 
Induction of  MEL cells to differentiate upregulates β-globin. Since BirA and bio-Ldb1 are under 
the control of human β-globin LCR sequences, these C88BirA/bioLdb1 cells also upregulate the 
biotin ligase and bio-tagged Ldb1 upon induction (Figure 1 A).
Sixteen C88BIR/bioLdb1 clones were isolated and induced to differentiate. Nuclear extracts were 
tested for presence of the fusion protein using an α-Ldb1 antibody and Streptavidin-HRP 
 (Figure 1B). Non-induced clone #3F4 expresses low levels of bio-Ldb1 and, upon induction, 
upregulates it to levels comparable to endogenous Ldb1 (Figure 1C). This allowed us to compare 
Ldb1 complexes before and after terminal differentiation.
Identification of Ldb1 interaction partners
Nuclear extracts prepared from non-induced and induced #3F4 cells were incubated 
with streptavidin coated paramagnetic beads and separated by PAGE30,31 (Figure 1D). Proteins 
were trypsin digested, eluted and analysed by mass spectrometry (LC-MSMS). Table 1 shows 
the pulled down proteins when washed at the same level of stringency (150mM salt). An 
Figure 1 Ldb1 biotinylation and streptavidin pulldown.
A. Schematic representation of bio-Ldb1. The 23 amino acid sequence recognized by BirA and a triple 
Haemagglutinin tag are fused in tandem to the amino-terminal end of the ATG-less Ldb-. B. Expression 
of Ldb1 and bio-Ldb1 in nuclear extracts of induced C88BirA/bio-Ldb1, C88-/BirA and C88-/- cells. Eight of 16 
transfectants are shown. Three clones (lanes 3-5) did not express bio-Ldb1, lane 9 not loaded. Clone #3F4, 
(arrow) was chosen for further experiments. Lanes on the right are C88-/BirA and C88-/- controls. C. Ldb1 
and bio-Ldb1 expression in equal amounts (see Coomassie stained gel) of nuclear extracts of non-induced 
(-) and induced (+) #3F4 cells. Expression of endogenous Ldb1 is reduced in induced cells. D. PAGE of 
proteins bound to bio-Ldb1; PD: pulled down proteins; NE: untreated nuclear extract. Pull downs of non-
induced and induced cell extracts washed at lower stringency conditions are shown.
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additional pulldown with nuclear extract from induced #3F4 cells was performed under higher 
stringency washing conditions (200mM) with very similar results. 
The screen for interacting proteins was validated by the fact that known Ldb1 partners 
(Lmo2, Tal1, Gata1 and E2A)18 were readily identified. We also found 3 proteins of the Ssdp 
family, members of which interact with Ldb1 in HeLa cells and in Drososphila33-35. In addition, 
a substantial number of novel (potential) interaction partners of different functional classes 
was found, including transcription (co)factors, cell cycle proteins, chromatin remodelling and 
DNA repair proteins. In agreement with our previous results30,31, a number of endogenously 
biotinylated proteins and background proteins were also identified (data not shown). 
Some of the previously identified binding partners of Ldb1 (Tal1, E2A), the bHLH 
Table I
Proteins pulled down C88-/BirA Nonind. Ind. Ind.
lo str. lo str. hi str.
Transcription factors
LIM only proteins
Lmo2 - + - +
Lmo4 - - + +
Zinc finger proteins
Gata1 - - + +
Basic helix-loop-helix
Tal1 - + + +
E2A - + + +
Lyl1 - + + +
HEB - + + +
E2-2* - + + +
ETO-family
Eto-2 - + + +
Mtgr1 - + - +
Runt domain
Runx1 - - + +
SSDP
Ssdp2 - + + +
Ssdp3 - + + +
RIKENcDNA1210001E11(Ssdp4) - + + +
Cell cycle proteins/kinase
Cdk9 - + - -
Table 1: Proteins identified by LC-MSMS in bio-ldb1 pulldown experiments.  
The lower amount of identified proteins and their corresponding peptides in the lower stringency pulldown 
experiment of induced cells (ind.1) is due to the lower amount of input for the LC-MSMS analysis. Proteins 
marked with an asterisk were not tested in immunoprecipiations.
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Figure 2 Analysis of Ldb1 interacting 
protein complexes.
A. Protein levels of Eto-2, Cdk9 
and Lmo4 change with induction of MEL 
cell differentiation. Western Blot analysis of 
non-induced (U) and induced (I) MEL cell 
nuclear extracts. Input lanes indicate levels of 
tested proteins in untreated nuclear extracts 
diluted to the same concentration as in the 
IP experiments. Proteins immunoprecipitating 
with Ldb1 (IP lane) and supernatant (Sup) are 
shown and labeled accordingly. The isoforms 
of E2A and Cdk9 and bio-Ldb1 are indicated. 
B. Changes in protein levels are 
reflected in the amounts in which they 
interact with Ldb1. Extracts were incubated 
with α-Ldb1 antibodies and equal amounts 
of immunoprecipitated (IP) and Supernatant 
(Sup) loaded. Less Eto-2 but more Lmo4 
co-precipitate with Ldb1. Even though 
upregulated, Cdk9 (55kD form) does not 
interact with Ldb1 in induced cells. The IgG 
controls were performed with nuclear extracts 
of noninduced (not shown) and induced 
(shown here) bio-Ldb1 cells with a non-
specific, isotype matched antibody.
proteins HEB, E2-2, Lyl1 and the novel interacting protein Eto-2 were detected in all three 
analyses. Eto-2, an ortholog of the D. melanogaster gene nervy, was the most abundant protein 
in two of the three LC-MSMS outputs. Mtgr1, another member of the ETO protein family, was 
also found identified by MS analysis of non-induced and induced cell extracts. Additionally, 
Ssdp2, Ssdp3 and a protein homologous to human Ssdp4 were identified in all MS analyses, 
but not analysed further. The known partner Lmo2, present in extracts from non-induced and 
induced cells (Figure 2), was only detected in one of the induced nuclear extracts. Lmo4, Gata1 
and Runx1 were present in the MS analyses of induced cells only, although it should be noted 
that Gata1 may be absent due to the fact that only very few peptides are detectable in our 
MS analysis 31. In contrast to the proteins mentioned above, the cell cycle protein Cdk9 was 
only found in nuclear extracts of non-induced cells. Proteins of different chromatin remodeling 
complexes were also identified only in induced cell extracts. With the exception of BRG/brm-
associated factor 53A none of these were found under both stringency washing conditions. 
To determine the expression levels of the binding partners found in the MS analysis, 
western blots of equal amounts of nuclear extracts of noninduced and induced MEL cells were 
carried out. This showed that the levels of all binding partners except for the newly identified 
interacting proteins Eto-2, Cdk9 and Lmo4, did not change significantly (Fig.2A, input lanes). 
Lmo4 and Cdk9 increased with induction whereas there was considerably less Eto-2 in induced 
extracts (Figure 2A, input Lmo4, Cdk9 and Eto-2 panels). Interestingly the much less abundant 
55kD isoform of Cdk936 is upregulated with induction, whilst the 41kD isoform of Cdk9 is present 
at the same levels in non-induced and induced extracts (Figure 2A, input Cdk9 panels); a 
phenomenon also seen in differentiating macrophages37. 
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Identification of different complexes
To confirm the interactions found in the MS analysis, immunoprecipitations of equal 
amounts of nuclear extracts from induced and non-induced C88 (not shown) and #3F4 cells 
(Figure 2) were performed with an α-Ldb1 antibody. The α-Ldb1 antibody depleted the extracts 
of non-induced cells almost completely of endogenous and bio-Ldb1, whereas a very low 
amount (<5%) remained in the supernatant of the induced cell extract (Figure 2B, Ldb1 panel). 
Lmo2, Tal1, the two E2A isoforms E12 and E47, HEB and Gata1, precipitated equally with Ldb1 
before and after induction (not shown). Consistent with its lower level in induced cell extract, 
less Eto-2 precipitated with Ldb1 from induced cell extracts when compared to that of non-
induced cells (Figure 2B, Eto-2 panels). Mtgr1, the other identified Eto-family member, was also 
enriched to a lesser extent in induced cells (Figure 2B, Mtgr1 panels). As expected, more Lmo4 
precipitated with Ldb1 in induced cells when compared to non-induced cells (Figure 2B, Lmo4 
panels), while the amount of co-precipitated Lmo2 did not change (not shown). These results 
suggest that the newly identified partner Lmo4 may play a more important role at later stages 
of erythroid differentiation. Most notably however, the two isoforms of Cdk9 immunoprecipiated 
with Ldb1 only in non-induced cells (Figure 2B, Cdk9 panels). Since Cdk9 is involved in cell 
cycle progression38, the interaction between Ldb1 and Cdk9, which appears to be exclusive 
to noninduced, proliferating MEL cells, may link the formation of a complex containing Ldb1 
and Cdk9 to the maintenance of the proliferative state (see also below). Although their level is 
unchanged , there was less co-precipitation of E2-2 and Lyl1 with either α-Ldb1 (Figure 2B) or 
α-Eto-2 (not shown) in induced cells.
In order to gain a better understanding of some of the Ldb1 containing complexes and 
to determine whether Ldb1 binding partners bind to Ldb1 in the absence of Eto-2 and vice versa 
we performed sequential IP experiments: We first depleted nuclear extracts of either Ldb1 or 
Eto-2 with their respective antibodies and then incubated the supernatants with α-Eto-2 and 
α-Ldb1 respectively (Fig. 3). IPs were then analysed for Ldb1 interacting proteins identified and 
validated in the single IP experiments (not shown and see Figure 3). It should be noted that we 
have not set out to characterise all the possible complexes that may be formed by every single 
Ldb1 interacting partner identified in our MS analysis, a task which is outside the scope of this 
paper.
As noted above, the α-Ldb1 antibody (almost) completely depletes Ldb1 protein from 
the extract (Figure 2B and 3 Ldb1 panel). A precipitation with α-Eto-2 antibody brings down 
high amounts of Ldb1, indicating that a high proportion of complexes contain both Ldb1 and 
Eto-2. However, α-Eto-2 did not deplete the extract of Ldb1 protein since more Ldb1 protein 
is precipitated with α-Ldb1 from the α-Eto-2 treated supernatant (Figure 3 - Ldb1 panel). 
Conversely, precipitation of Ldb1 with α-Ldb1 antibody brings down large amounts of Eto-2 
(Figure 2B, 3 - Eto-2 panels) but does not deplete Eto-2 completely from the extract since there 
is more Eto-2 left in the supernatant that can be precipitated with α-Eto-2 antibody (Figure 3 
– Eto-2 panels). Taken together, these results suggest that there are at least three complexes, 
one containing both Eto-2 and Ldb1, one that contains Ldb1 but not Eto-2 and one that contains 
Eto-2 but not Ldb1 (suppl. Figure 1).
To investigate the binding behaviour of Cdk9, the only protein that does not interact 
with Ldb1 upon induction of differentiation, we tested the sequential IPs for the presence of Cdk9 
protein. α-Ldb1 antibody precipitated Cdk9 with a substantial amount left in the supernatant 
which was not precipitable by α-Eto-2 antibody (Figure 3 – Cdk9 panels). In reverse, incubation 
of nuclear extracts with α-Eto-2 antibody also precipitated Cdk9 only partially, the remainder 
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also not being bound to Ldb1 (Figure 3 – Cdk9 panels). We conclude that Cdk9 requires both 
Ldb1 and Eto-2 for its interaction with either of the two proteins. E2-2 and Lyl1 exhibited a 
similar interaction behaviour (Figure3). with the exception that Lyl1 is also bound to Ldb1 alone 
(suppl. Figure 1).
To test whether the Ldb1-Lmo2 interaction requires Eto-2, we first depleted Eto-2 
from the extract and then carried out a Ldb1 IP testing for Lmo2 (Figure 3– Lmo2 panels): 
α-Eto-2 brought down only some Lmo2. Since all of Lmo2 is in complex with Ldb1 (see above) 
we conclude that there is a complex containing Lmo2-Ldb1-Eto-2 and that the remaining Lmo2 
left in the supernatant after Eto-2 depletion is bound to Ldb1 but not Eto-2. Lmo4 basically 
behaves similarly but shows an important quantitative difference. There is little Lmo4 before 
differentiation which increases several fold after induction of differentiation (figure 2B). 
 The two isoforms of E2A show a different binding behaviour with regards to Ldb1 
and Eto-2: Both the larger E47 and smaller E12 isoforms are precipitated equally by Ldb1, 
albeit incompletely. The remaining E47, but not E12 is bound by Eto-2 (Figure 3 – E2A panels). 
Conversely, α-Eto-2 completely depletes the extracts of the E47 isoform but binds only some 
E12 (Figure 3 – E2A panels). Some of this remaining E12 is precipitable by Ldb1. Taking into 
account the Ldb-1/E2A data from above this indicates the presence of a complex containing 
Ldb1/Eto-2/E47/E12, two further complexes composed of at least Eto-2/E47 or Ldb1/E12 and 
“free” E12 that can participate in other complex formation.
Mtgr1 was the second member of the Eto family identified in our MS analysis. α-Ldb1 
antibody precipitates some Mtgr1, but not all, with a substantial amount left in the supernatant 
that is all precipitated with an α-Eto-2 antibody (Figure 3 – Mtgr1 panels). Precipitation with 
Figure 3. Sequential immunprecipitations to investigate Ldb1 and Eto-2 containing 
complexes. 
Nuclear extracts of noninduced bio-Ldb1 cells were first depleted of either Ldb1 or Eto-2 with their 
respective antibodies. The supernatants were then incubated with α-Eto-2 or α-Ldb1, respectively. The 
second supernatant was also loaded to determine which proteins do not interact with either Eto-2 or Ldb1. 
IgG lanes are control IPs carried out with a non-specific, isotype matched antibody. 
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α-Eto-2 antibody however completely depletes Mtgr1 from the nuclear extracts indicating that 
all Mtgr1 is complexed with Eto-2 (Figure 3 – Mtgr1 panels). We conclude that there are at least 
two complexes containing Mtgr1: Firstly, one complex containing Mtgr1/Eto-2/Ldb1 and that the 
Mtgr1/Ldb1 interaction requires Eto-2. Secondly, a further complex containing Mtgr1/Eto-2 but 
not Ldb1.
Tal1 also forms several complexes, with and without either Ldb1 or Eto-2. α-Ldb1 
antibody precipitates most but not all Tal1 from the nuclear extract, part of the remaining Tal1 
is pulled down with Eto-2 (Figure 3 – Tal1 panels). Testing first with α-Eto-2 shows that Eto-2 
brings down Tal1 but not all, some of which is precipitable with an α-Ldb1 antibody (Figure 3 
– Tal1 panels). This indicates that there are at least four Tal1 containing complexes: Eto-2/Tal1/
Ldb1, Ldb1/Tal1 Eto-2/Tal1 and “free” Tal1.
HEB also forms complexes that contain either Ldb1 and/or Eto-2. Both α-Ldb1 and 
α-Eto-2 precipitate large amounts of HEB indicating that HEB forms complexes with Ldb1 or 
Eto-2, and probably a complex containing all three of these proteins. A second precipitation 
with either α-Eto-2 or α-Ldb1 respectively precipitates more HEB, but again not completely, 
with small amounts remaining in the supernatant after this second immunoprecipitation step 
(Figure 2C – A and B HEB panels). Therefore, HEB forms at least three complexes: HEB/Ldb1, 
HEB/Eto-2 and “free” HEB and possibly HEB/Ldb1/Eto-2. When an α-HEB IP is carried out it 
does precipitate all the partners (suppl. Table 1), including Lyl1, Cdk9 and E2-2, suggesting that 
it is part of a large Ldb1/Eto-2 complex (suppl. Figure 1) or perhaps a smaller one containing 
Ldb1 and Eto-2. 
Finally, Gata1, a transcription factor which we have previously shown to participate in 
a multitude of complexes39, also forms separate complexes with either Eto-2 or Ldb1. Treatment 
of extracts with α-Ldb1 antibody brings down small amounts of Gata1 with the majority of Gata1 
left in the supernatant. Further precipitation with α-Eto-2 provides evidence of an Eto-2-Gata1 
interaction separate from Ldb1 (Figure 3 – Gata1 panels). In reverse, and in accordance with 
the previous IP, α-Eto-2 antibody precipitates Gata1 but incompletely. Very little Gata1 is then 
precipitable with an α-Ldb1 antibody indicating that possibly most of the Eto-2/Gata1 complex 
also contains Ldb1 (Figure 3 - Gata1 panels). We conclude that Gata1 forms at least four 
complexes: Gata1/Ldb1, Gata1/Eto-2, Gata1/Ldb1/Eto-2 and “free” Gata1, which we know is 
participating in other complexes.
 Single IP’s using antibodies for the Ldb1 interacting proteins confirmed all the pairwise 
interactions described above (not shown).
Although it is difficult to distinguish the complexes from each other, the data strongly 
suggest that there are several subcomplexes formed by Ldb1 and its interaction partners that 
can form larger, functional complexes (possibly via the homodimersation of Ldb1). Taking these 
data together we can distinguish two large subcomplexes with either Ldb1 or Eto-2 and one 
large complex containing both Ldb1 and Eto-2 (suppl. Figure 1). Upon differentiation association 
with Cdk9 is lost and the level of Eto-2 is substantially decreased, while the amount of Lmo4 
is increased several fold. The reduction in association is also reflected in the reduced co-
imunoprecipiation of E2-2 and Lyl1 with α-Ldb1 and α-Eto-2 in induced cells. In addition these 
complexes appear to interact with Runx1, but we have as yet not been able to characterize this 
interaction due to the poor quality of antibody.
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Chromatin immunoprecipitations
To confirm Eto-2 and Ldb1 are bound to chromatin at specific regulatory sites we 
carried out chromatin immunoprecipitations using a number of erythroid genes: Gata1, GPA, 
Myb, Myc and Eklf for which the binding of Gata1 complexes is known (Figure 4)31,40. Among 
the Gata1 gene regulatory regions the HS-3.5 is known to bind the Gata1/Tal1/Ldb1 complex, 
whereas the DNaseI hypersensitive site in the gene (Gata1 IE) does not41. The GATA-E box 
sites in the GPA and Eklf promoters are also known targets of Gata1/Ldb120,31. The c-myb 
and c-myc genes were tested because they bind a Gata1/Gfi-1b complex31. In all cases we 
find an enrichment for Gata1 (as expected) when compared to non GATA site negative control 
fragments (not shown; 31). In contrast, Eto-2 and Ldb1 were bound to Gata1, Eklf and GPA 
(Figure 3), but not to c-myc and c-myb (not shown). The ratio of Eto-2/Ldb1 binding to the three 
elements decreases during differentiation in MEL cells (Figure 3) in accordance with the fact that 
there is less Ldb1/Eto-2 complex (see Figure 2). Gata1, GPA and Eklf proteins are expressed 
late in erythroid differentiation (the -3.5 HS of the Gata1 gene also regulates Gata1 expression 
in megakaryocytic cells42,43 whereas c-myc and c-myb are downregulated. The decrease of 
Eto-2 levels in late erythroid cells suggests that Eto-2 adds a repressive function to the Gata1/
Tal1/Ldb1 complex to repress late erythroid genes early during differentiation. In contrast Eto-2 
would not be essential for Gfi-1b repressed genes such as c-myb and c-myc31. 
Eto-2, Cdk9 and Lmo4 are required for definitive hematopoiesis in a zebrafish 
model system.
Ldb1 and its constitutive binding partners Lmo2 and Tal1 are essential for embryonic 
blood formation29,44,45. We next asked whether the newly identified Ldb1 interacting partners E2A, 
Cdk9, Eto-2, Lmo4 and Mtgr1 are required for hematopoietic development. Since the genetic 
regulation of embryonic and definitive hematopoiesis is highly conserved between zebrafish 
Figure 4: ChIP of ldb-1 and Eto-2. Top: Localisation of the upstream Hypersensitive sites 
in the Eklf, Gata1 and glycophorin promoter.
Middle row: Bar graphs of the relative enrichment of sequences immunoprecipitated by Eto-2 (grey), Ldb1 
(light grey) and the IgG control (dark grey) in non-induced MEL cells. All values were normalised to a 
GAPDH control. Bottom row: Same as middle row for induced MEL cells.
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and mammals, we tested the role of these proteins by ATG-Morpholino (ATG-MO) mediated 
inhibition of mRNA translation in zebrafish embryos46. In zebrafish, primitive erythrocytes 
expressing embryonic hemoglobin derive from the intraembryonic intermediate cell mass (ICM) 
and start circulating at 24 hours post fertilisation (hpf). Shortly thereafter, with development 
of the definitive hematopoietic system, ventrally located flk1 positive precursors of the dorsal 
aorta start to express runx1. Runx1 is also expressed in primitive erythrocytes, the olfactory 
epithelium, Rohon-Beard neurons47 and the anterior paraxial mesoderm. 
ATG-MOs targeted against the zebrafish orthologues of Cdk9, Eto-2, Lmo4, Ldb1, and E12 
were injected at three increasing doses into 2-8 cell stage embryos. To test the effects of these 
morpholinos on the embryonic and definitive hematopoeitic system we analysed embryos after 
onset of blood circulation by in situ hybridisation with probes against embryonic β-globin and 
runx1, respectively (Figure 5). 
Ldb1-MO injected embryos displayed variable phenotypes at all three doses, including 
deformation of the body axis, dysmorphic somites, abnormal tail morphology, hematopoietic 
defects resembling that of the mouse (A. Hostert, unpublished) and necrosis in the brain (not 
shown). The severity of defects increased with increasing dose of injected Ldb1-MO. As a 
negative control, we used a morpholino targeted against the zebrafish orthologue of Tcf7/2. 
Figure 5 Analysis of zebrafish embryos after morpholino injections. 
All pictures were taken at the same magnification. Top panels: non injected WT control embryos (30hpf) 
stained for embryonic β-globin (left column) and runx1 (right column). The intermediate cell mass (ICM), 
dorsal aorta (DA), primitive erythrocytes (Pr.Ery.), anterior paraxial mesoderm (APM.) and olfactory 
epithelium (OE.) are indicated. The globin signal is red, runx1 signal is blue. The second row of panels are 
representative embryos injected with 1pmol eto-2-MO (32hpf), the third row with 1pmol cdk9-MO (28hpf), 
the fourth row with 1 pmol lmo4-MO (30hpf) and the fifth row with 0.5pmol of the control tcf4-MO (30hpf).
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Tcf7/2 is not expressed in hematopoietic tissues and when deleted has a specific effect outside 
the mouse hematopoietic system, i.e. only in the mouse in the intestinal epithelium (Korinek et 
al., 1998). As expected, no effects of the z-tcf4-MO on the hematopoietic system were observed 
in the injected zebrafish at any dose, but embryos injected with the highest dose displayed 
some slight tail abnormalities.
The cdk9-MO had no effect on embryonic β-globin expression and expression of 
runx1 in the primitive erythrocytes located in the posterior ICM, the olfactory epithelium and 
the anterior paraxial mesoderm. However, it had a severe effect on definitive erythopoiesis. 
0.5 pmol cdk9-MO showed a clear reduction of runx1 signal in the dorsal aorta precursor 
population (n=10/18) which decreased further in embryos injected with 1 pmol (n=8/10). 
Surprisingly the effect appears to be specific to the hematopoietic system although cdk9 is 
expressed in many tissues48.
Embryos injected with the eto-2-MO had a similar but distinct phenotype. The reduction 
of runx1 expression in embryos injected with 0.5 pmol (n=13/16) and 1 pmol of eto-2 MO (n=5/7) 
was more severe when compared to the cdk9-MO: runx1 in the dorsal aorta was either almost or 
completely abolished. In addition, and different from the cdk-9-MO embryos, runx1 expression 
in primitive erythrocytes was severely reduced or completely absent. Embryonic β-globin 
expression was normal in all eto-2-MO injected embryos, however, some primitive erythrocytes 
in the caudal region were located laterally to the midline as opposed to their location in wild 
type embryos. This is similar to the effect observed when sonic hedgehog signaling is inhibited, 
again suggesting that eto-2 may play a role in the response to extracellullar signals. Embryos 
treated with the eto-2 MO were also reduced in size. Injection of the highest dose of the mtgr1-
MO did not affect embryonic hematopoiesis. Some reduction of runx1 expression in dorsal aorta 
precursor cells was observed (not shown).
Embryos treated with the lmo4-MO were comparable to cdk9 and eto-2. Expression of 
embryonic γ-globin was normal, whereas reduced levels of runx1 were observed in the dorsal 
aorta at 0.5 pmol MO (n=8/13) and decreased further with lmo4-MO injected at 1 pmol. In 
addition, some of the treated embryos appeared to have brain or neural tube abnormalities, 
which are the cause of perinatal death of the correponding knock out mouse49-51. These mice 
showed no defects in the hematopoietic system, however, only half of the homozygous Lmo4 null 
mutants were born. The other half died around E9 of gestation, possibly due to a hematopoietic 
phenotype.
We conclude that the newly identified Ldb1 interaction partners eto-2, cdk9 and lmo4 
are essential for definitive erythropoiesis, whereas Mtgr1 plays a less critical role It is noteworthy 
in this context that Eto-2 (in zebrafish, this paper) and most of its constitutive binding partners, 
namely HEB and E47 (in mouse52) and Mtgr1 (in zebrafish, this paper), are not required for 
embryonic hematopoiesis. 
Ldb1 interacting partners are expressed in the same cells in the para-aortic 
splanchnopleura of the early mouse embryo. 
The results obtained for the novel Ldb1 interaction partners in the zebrafish suggest 
that they would be expressed in the early mouse embryo at stages prior to the “birth” of the 
definitive hematopoietic stem cells in the AGM1. We therefore performed immunohistochemistry 
and immunofluoresence on E9.5 embryo sections (Figure 6). Immunohistochemical 
analysis with α-Ldb1, α-E2A, α-Lmo2, α-Gata1, α-Eto-2 and α-Cdk9 showed that all 
are expressed in the para-aortic splanchnopleura (P-Sp), the region destined to 
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contribute to the AGM (Figure 6A, B). 
To further determine the expression pattern of the interacting proteins and to confirm 
that cells within the P-Sp co-express these proteins, we performed in situ immunofluorescence 
experiments on the cryosections. We found that cells positive for Gata1 also expressed Eto-2 
and Ldb-1 (Figure 6C). Cells expressing Ldb-1 were also positive for Runx1 (Figure 6C), E2A 
and Lmo2 (not shown). The observation that the newly identified interaction partners of Ldb1 
are co-expressed with Ldb1, Gata1, E2A and Lmo2 in the pre-AGM cells of the P-Sp strongly 
suggests that they form a complex that may be essential for the induction of the definitive 
hematopoietic system. The fact that Eto-2 is predominantly in the cytoplasmic  at that stage 
(Figure 6C, Column 3 Panels Eto-2 and Merge) suggests that it may respond to extra-cellullar 
signals at the pre-hematopoietic stage. At later stages (fetal liver) it is abundant in the nucleus 
but its cytoplasmic expression is very weak. (not shown).
Figure 6 Ldb1 interacting partners are expressed in the P-Sp. 
A. Hematoxylin stained 10µm transversal cryosection of a D9.5 FvB embryo. The area of the P-Sp is 
indicated by the box. B. High magnification (1000 X) of the areas such as shown in (A). Expression of 
Cdk9, E2A, Ldb-1, Lmo2 and Gata1 was detected with specific antibodies and visualised with DAB. IgG 
panel shows the background staining with an unspecific IgG antibody. C. Immunfluorescence analysis of 
E9.5 embryos with α-Eto-2, α-Ldb1, α-Runx1 and α-Gata1 antibodies. Specific staining is seen for both 
Eto-2 (Green) and Gata1 (Red) antibodies, compared to the IgG control. Third column of panels show an 
enlargement of part of the section shown in the second column. Merge is a superposition of images of the 
Eto-2 and Gata1 detection. The third column shows cells that express both Eto-2 and Gata1 appear as 
yellow. The fourth column shows that Ldb-1 (Green) and Gata1 (red) expressing cells are located in the 
dorsal aorta (DA) region; cells positive for Ldb1 are also positive for Gata1. Ldb1 (Green) and Runx-1 (Red) 
expression overlap in E9.5 embryos. 
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Discussion
Ldb1 forms dynamic complexes during erythroid differentiation
By using a systems biology approach we identified all known and new binding partners 
of Ldb1 and determined their importance for hematopoietic development. The important 
implication of this work is that the analysis of proteins co-expressed and interacting with each 
other in a late mature cell type are already implicated at the earliest stages of (in this case blood) 
development.
The Ldb1 proteome has a number of interesting interactions: 1. with Eto-2 (and Mtgr1). 
2. with a large number of different bHLH proteins. 3. with Cdk9 and 4. with the Ssdp proteins 
although this latter interaction was not analysed further. Recently we have shown that Gata1 
forms at least five clearly identifiable protein complexes31. We did not observe such distinct 
complexes for Ldb1. Clearly Ldb1 forms a core complex with the known partners Gata1, Tal1, 
Lmo2 and E2A and the newly identified partner Eto-2 (Figure 6). Eto-2 also forms complexes 
with E2A and Tal1 without Ldb1. In the sequential IPs we can distinguish between the preferential 
binding partners of Eto-2 and Ldb1 and deduce the existence of a higher order complex whose 
formation is favored in proliferating cells. At the same time it is difficult to separate groups 
of interacting proteins from each other by IPs, especially if a protein interacts in different 
combinations. Hence we are in the process of purifying the different complexes. With induction, 
levels of Eto-2 decrease and formation of the large complex is lower (Figure 7). Cdk9, which 
has been linked to cell cycle progression38, would no longer be part of the complex. This may 
explain why the cells stop proliferating upon differentiation. At the same time the levels of Lmo4 
increase, possibly replacing Lmo2/Eto-2 and leading to an activation of transcription of genes 
expressed after terminal differentiation.
 Noteworthy is the presence of a large number of DNA binding proteins within the 
complex, particularly the presence of at least five bHLH proteins and the zinc finger transcription 
factor Gata1. It is possible that such a complex may very well be involved in the establishment 
and/or facilitation of long range interactions, processes in which Ldb1 has been implicated 57. 
Figure 7 Model of Ldb1 complexes. Based on the interaction of Ldb1 and Eto-2 and their 
respective binding partners.
The horizontal arrows indicate that the balance of interaction is towards the large complex in proliferating 
non-induced cells. Upon the induction of differentiation and termination of proliferation the level of Eto-2 
drops while the level of Lmo4 rises, hence the equilibrium would shift towards the smaller complexes. The 
presence of several DNA binding proteins in a single complex may explain the role of Ldb1 as a facilitator 
of long range interactions.
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Specifically, in D. melanogaster Chip was identified in a screen for factors involved in the long 
range gene activation of the cut gene. Chip was proposed to bridge the Pannier (GATA) and 
Achaete/Scute (bHLH) complexes causing the intervening DNA to loop out bringing DNA control 
elements into close proximity . The erythroid Ldb-1-Lmo2-Tal1-E2A-Gata1 complex may have a 
similar role. It was recently shown that the complex binds to multiple sites in the α-globin locus21. 
We envisage that these complexes interact and promote long range interactions also in other 
gene loci, eg. in the β-globin locus ACH10.
The Eto family members Eto-2 and Mtgr1 are thought to be repressors by binding 
the NCor/Sin3A/HDAC1 complex . Eto-2 was the most abundant protein in the MS analysis, 
suggesting it is a direct (and crucial) binding partner of Ldb1 (confirmed by immunoprecipitations). 
We also observed that Eto-2 and its family member Mtgr1 interact with each other. Moreover 
Eto-2 appears to be the bridging factor for Ldb1 to interact with Mtgr1 (Fig. 2). Eto proteins and 
the D. melanogaster orthologue nervy have four highly conserved protein interaction domains . 
The DNA binding of the Eto-2 complexes we describe probably occurs through its bHLH binding 
partners and/or Gata1.
Interestingly, with induction Eto-2 and the Eto-2/Ldb1 complex decrease, while the level 
of Lmo4 increases. Thus the level of the large Ldb1-Eto-2 complex drops to be replaced by one 
with Lmo4. Complementary results were obtained by Goardon et al. (personal communication) 
through characterization of Tal1 complexes. As indicated by the ChIP experiments the repressive 
role of Eto-2 may very well explain how late erythroid genes become activated. An alternative 
or complementary explanation may be post-translational protein modifications of the Eto-2 
complex members, a possibilty that can not be excluded at present.
A good candidate to carry out modifications and change specific interactions is Cdk9. 
This CDC2 ortholog  precipitated differentially with Ldb1 in proliferating and differentiating MEL 
cells. The invariance of the main isoform independent of the cell cycle stage has been reported. 
Cdk9 is thought to have two functions: Regulating RNA polymerase II by phosphorylating its C-
terminal domain66-71. Secondly, regulating the cell cycle. A “knockdown” of the D. melanogaster 
orthologue of Cdk9 causes an arrest at the G1 to S transition , congruent with the in vitro data 
that the human Cdk9 orthologue phosphorylates Rb . Interestingly, Gata1 has been found to 
interact with Rb in vitro . We detect an interaction between Cdk9 and Ldb1 only in non-induced, 
proliferating MEL cells, suggesting Ldb1 and its partners might be involved in transcriptional 
control of the cell cycle through the dual function of Cdk9. Putative target genes could be E2F 
family members expressed in hematopoietic cells. Cdk9 also interacts with BRG1 and STAT3 to 
activate transcription of the cell cycle inhibitor p21waf1  suggesting Cdk9 has different functions 
in the cell cycle depending on its partners. In this context it is interesting that we detect Eto-2 
protein in the cytoplasm of hematopoietic stem cell precursors (Figure 4) and of developing 
neurons (N. Meier, unpublished). Eto-2 may respond to extracellular signals by translocating 
from the cytoplasm into the nucleus, whilst it is downregulated in terminally differentiating cells. 
This suggests that Eto-2 plays a key role in the birth of the definitive HSCs and is required for 
the subsequent phases of expansion of the different lineages. It then needs to be downregulated 
to allow the activation of late genes such as Eklf for terminal differentiation.
Late erythroid differentiation complexes and early hematopoiesis
It is remarkable that the analysis of interacting proteomes of Gata1  and Ldb1 (this 
paper) in late erythroid cells has resulted in the identification of a number of proteins essential 
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for early hematopoiesis (as found in the zebrafish experiments), in particular Lmo4, Cdk9 and 
Eto-2. 
Lmo4 expression in mice has been detected at E9 from the caudal region of the dorsal 
and lateral paraxial mesoderm up to the direct vicinity of the dorsal aorta, suggesting that Lmo4 
could play a role in HSC formation . It is also upregulated in late T cell differentiation  similar 
to what is observed in MEL cells. In Xenopus Xlmo4 and Gata-2 act synergistically in ventral 
mesoderm formation. However an Xlmo4-MO did not prevent ventral mesoderm formation 
. In zebrafish Lmo4 is expressed at gastrulation but not during ventral mesoderm formation 
. In accordance with this, we found embryonic hematopoiesis in lmo4-MO treated zebrafish 
embryos to be normal. We show the expression of lmo4 at later stages to be important for the 
formation of definitive HSCs in zebrafish. Whether the same phenotype is observed in mice 
remains to be determined. 
MO mediated repression of eto-2 had the most drastic phenotype in zebrafish – 
absence of runx1 expression in embryonic erythrocytes and lack of definitive hematopoiesis, 
suggesting it is essential for runx-1 expression. Cdk9-MO treated fish lacked definitive cells. 
However in embryonic cells runx1 expression was detected, suggesting it does not regulate 
runx-1 directly.
The fact that these factors are already co-expressed in the same cells in the murine 
P-Sp before the generation of the definitive HSCs in the AGM  suggests that they are also 
essential for definitive hematopoiesis in the mouse. Eto-2 and Cdk9 may be more important in 
this process than Gata1, because loss of Gata1 is not deleterious to these very early stages (with 
cytoplasmic Eto-2). This in turn suggests that Tal1, Ldb1 and Lmo2 are dominant at this stage. 
Because all of the Ldb1 bound Gata1 is complexed with Eto-2, we postulate that when Eto-2 
translocates from the cytoplasm to the nucleus, the balance of interactions is changed causing 
the transition to a more proliferative Gata1 driven phase followed by terminal differentiation. 
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Supplementary Figure 1: Ldb-1 forms independant complexes in erythroid cells.
Proteins tested in sequential immunodepletion are depicted on the left.
Chapter 6:
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After the complete sequencing of the human genome as well as the genomes of other 
species, the focus of the molecular biology has shifted towards the study of gene function and of 
the protein complement of the cell, the proteome. Comparison of the sequenced genomes has 
revealed a small difference in gene numbers between organisms. For example, the Drosophila 
and human genomes contain 12,000 and 25,000 genes, respectively. This difference in gene 
numbers increases the complexity of the proteome of the organisms. In studying proteome 
complexity, or proteomics, powerful but also simple biochemical techniques are required for 
protein complex isolation and identification, for example in elucidating transcriptional regulation 
in higher vertebrates. Efficient protein isolation from crude extracts requires simple, high-affinity 
purification techniques. In addition, sensitive mass spectrometry methods that identify peptide 
sequences have become an integral part of protein complex identification strategies. 
Biotinylation tagging
In this thesis, we demonstrated that biotinylation tagging is a very efficient approach to 
isolate and characterize protein complexes. We applied this technique in mammalian cells to 
isolate, in one step, several protein complexes even of low abundance. As described in this 
thesis, GATA-1 and Ldb1 complexes were isolated in erythroid cells. One of the main advantages 
of the single step biotin/streptavidin purification system is the very high affinity binding of 
biotin to avidin. This reduces the risk of protein partners dissociating from complexes during 
manipulations as is often found with conventional multi-step protein purification protocols. In 
addition, this method allows a more direct and rational approach for protein complex purification 
in describing most of the partners (repressing and activating), compared to previous studies 
describing similar functions but fragmented in different approaches in several studies, as it 
was shown for TAL-1 for example1,2. Biotinylation tagging also potentially offers an advantage 
in ChIP experiments due to a higher enrichment compared to antibodies, presumably due its 
very high affinity for streptavidin (E. Katsantoni, E. de Boer and K. Kolodziej, pers. comm. and 
Viens 2003). In addition, the use of biotinylation tagging/streptavidin in ChIP could alleviate 
the variability observed in these assays using different antibodies. Furthermore, biotinylation 
tagging of specific transcription factors can also be applied in ChIP-on-chip approaches 
(i.e. using ChIPed DNA to hybridize to genomic arrays), with the aim of identifying transcriptional 
gene target networks. Thus, biotinylation tagging has the potential to serve as a uniform 
platform for characterizing the protein complexes as well as gene targets of any given (tagged) 
transcription factor.
Recently, biotinylation tagging was also successfully used in diverse applications on a 
genome-wide scale. For example, a biotin-tagged H3.3 histone variant was used to describe the 
dynamics of its incorporation in chromatin3. In addition to its use in isolating nuclear proteins, the 
cell surface protein epidermal growth factor receptor (EGFR) was also shown to be efficiently 
biotinylated4. This approach therefore can be used to isolate cell populations. Another biological 
application of biotin-tagging a cell surface protein is based on the use of streptavidin-labeled 
quantum dots (QD). QD are nano-particles that allow protein visualization in vivo5. Furthermore, 
another large-scale application of the biotinylation tagging system is to isolate all proteins that 
are covalently modified in vivo by ubiquitin or SUMO by biotin-tagging these modifiers.  
Lastly, the biotinylation tagging method has been improved at different levels. Higher 
expression of the bacterial BirA biotin ligase in mammalian cells was obtained after mammalian 
codon optimization6. Along the same lines, a shorter sequence of the peptide tag has been 
used successfully7, thus reducing the risk of interference with functionality of the protein, even 
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though we have not seen so far any differences in the properties of tagged GATA-1 or Ldb1. The 
application of biotinylation tagging in the characterization of transcription factor complexes in 
erythroid cells, and particularly for GATA-1, has provided novel insight as to the molecular basis 
of their functions, as discussed further below. 
What’s new with GATA-1 function: regulation of transcription programs
Several lines of evidence have implicated GATA-1 as a key regulator of megakaryocytic/
erythroid lineage (Meg/E) differentiation and of their associated transcription programs8-10. 
This has been demonstrated by the ectopic expression of GATA-1 in progenitor and non-
Meg/E cells11,12. Significantly, GATA-1 expression in primary multipotential progenitors such as 
hematopoietic stem cells (HSC), common lymphoid progenitor (CLP) and common myeloid 
progenitor (CMP) was shown to induce expression of a subset of megakaryocytic and erythroid 
genes13. The activation of the Meg/E program was accompanied by the suppression of 
alternative lineage-affiliated programs. For example, CLP reprogramming by GATA-1 towards 
a Meg/E fate was characterized by the repression of genes associated with the lymphoid 
transcription program13. GATA-1 has also been shown to directly repress the GATA-2 gene 
in terminal erythroid differentiation14. Considering the essential GATA-2 functions in HSC and 
progenitor proliferation15, this finding implicates GATA-1 in the repression of early multipotential 
transcription programs. Taken together, these observations suggest that GATA-1 functions during 
differentiation to concomitantly activate the Meg/E program and repress transcription programs 
associated with hematopoietic multipotentiality and alternative (non-Meg/E) lineages.
FOG-1 has been implicated as a key co-factor in these GATA-1 functions. FOG-1 
 functions were revealed by gene knockout studies, but also by the ectopic expression of 
FOG-1 in in vitro differentiated eosinophilic cells where FOG-1 is not normally expressed. Thus, 
FOG-1 expression led to the reprogramming of these cells towards an earlier, less differentiated 
state with the concomitant repression of eosinophilic markers such as EOS47 or MBP16,17. 
Considering the important GATA-1 functions in eosinophilic differentiation18, it is of interest 
that the expression of FOG-1 in these cells appears to dominantly divert GATA-1 away from 
its normal functions. In addition, the repression of the GATA-2 gene has also been shown to 
require an interaction between GATA-1 and FOG-1. Thus FOG-1 is implicated as an important 
co-factor in the suppression of early transcription programs19. 
Our data on the GATA-1/FOG-1/MeCP1 complex provide additional insight as to the 
molecular basis of the GATA-1/FOG-1 functions. We showed that the recruitment by GATA-1 and 
FOG-1 of the MeCP1 repressive complex to the GATA-2 locus is responsible for its repression 
in terminal erythroid differentiation (Chapter 4). In addition, the detection by ChIP assays of the 
GATA-1/FOG-1/MeCP1 complex bound in vivo to repressed genes associated with non-Meg/E 
lineages, such as the eosinophilic MBP and IL-5Rα and the myeloid PU.1 genes, implicate this 
complex in the silencing of non-Meg/E lineage programs. Thus, we have identified the MeCP1 
complex as an important partner in mediating the repressive GATA-1 and FOG-1 functions in 
erythroid differentiation and we suggest that the GATA-1/FOG-1/MeCP1 complex plays a major 
role in the suppression of multipotential and alternative lineage transcription programs, which 
represent an integral part of GATA-1 function (see also below). In providing more definitive 
evidence for a role for the MeCP1 complex in erythropoiesis, (or for any other newly identified 
protein partner, for that matter) one would need to carry out gene knockdown or conditional 
knockout experiments. In fact, we did employ RNAi to knockdown selected components of the 
MeCP1 complex, such as Mi2β, MTA2 and others. However, this approach proved inconclusive 
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since cells transfected with these constructs either died or showed no effect (A. Swiatek, 
J. Campbell and J. Strouboulis, pers. communication). We also analyzed fetal liver cells from 
MBD2 knockout embryos for defects in erythroid cell differentiation and maturation. MBD2 
knockout mice are essentially viable and fertile20. We did not detect any significant differences 
in erythroid proliferation or differentiation between wild type, heterozygous and homozygous 
MBD2 knockout embryos (data not shown). However, it should be noted that MBD2 knockout 
mice still express a truncated form of the MBD2 protein, suggesting that the remaining protein 
product could still be functional. Since MBD3 has been previously shown to play key roles in the 
assembly and properties of the MeCP1/NuRD complex21 and the MBD3 gene knockout is early 
embryonic lethal20, suggesting essential functions in development, we are now investigating a 
conditional knockout of the MBD3 gene for defects in erythropoiesis. Another approach that 
was used successfully to ascribe functions in hematopoiesis of newly identified partners of 
key transcription factors was based on the use of morpholinos for Ldb1 and its partners in 
Zebrafish (Chapter 5). This approach is based on the inhibition of mRNA translation in Zebrafish 
embryos. However, this may not be suitable in the functional analysis of more general co-factors 
or complexes, such as MeCP1/NuRD, due to pleiotropic effects (i.e. morpholinos or antisense). 
Nevertheless, ChIP assays combined with the characterization of protein complexes provide 
invaluable insight into transcription factor function.
The observation that the ectopic expression of FOG-1 by itself in progenitors such 
as HSCs, CLPs and CMPs, does not induce a Meg/E program13 suggests that FOG-1 is found 
downstream of GATA-1 in eliciting the aforementioned repressive functions. This is supported 
by the observations on the ectopic FOG-1 expression and reprogramming of the GATA-1-
expressing eosinophilic cells17 and, more importantly, by the observation that GATA-1 expression 
in CLPs leads to an increase in FOG-1 expression. In agreement with these observations, it 
was recently shown that the FOG-1 promoter was indeed bound by GATA-1 in erythroid cells 
in vivo22. Thus, a key event in Meg/E differentiation would be the upregulation/stabilization of 
GATA-1 expression, which upregulates the expression of FOG-1 that in turn synergies with 
GATA-1 in repressive or activating functions complexes.
The stable binding of the GATA-1/FOG-1/MeCP1 complex to known repressed genes in 
differentiated erythroid cells implies that these genes are actively suppressed, even after the cell 
has made a fate decision to become erythroid. We can extrapolate that this complex stays bound 
to target genes during cell differentiation. These observations provide a clear demonstration of 
how GATA-1 regulates gene expression at the chromatin level and suggest that even after 
chromatin remodeling (i.e. closing down) has occurred, the transcription factor remains bound 
to DNA. Data from Kim and colleagues have also shown that Ikaros, an essential transcription 
factor for lymphocyte development, interacts with the NuRD complex in differentiated T cells 
and propose that the complex remains stably bound to DNA throughout the cell cycle23. In 
addition, previous observations on the repressed GATA-2 locus showed that GATA-1 and 
FOG-1 remained bound even after a wave of histone deacetylation had occurred across the 
locus14. These observations suggest that the shutting down of alternative lineage transcription 
programs may not be irreversible in differentiated hematopoietic cells. Thus, cell reprogramming 
could be explained if the “resident” transcription factor/chromatin remodeling complexes are 
competed off the genes by ectopically expressed key transcription factors and co-factors. For 
example, in eosinophils, where GATA-1 interacts with C/EBPβ and FOG-1 is not expressed, 
the forced expression of FOG-1 inhibits expression of eosinophilic genes17. The expression of 
FOG-1 displaces the preformed GATA-1 complexes in eosinophils, implying that the interaction 
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between FOG-1 and GATA-1 must be dominant. In light of our data, we hypothesize that 
GATA-1 interacts in eosinophils with ectopic FOG-1 and associates with MeCP1 to (initially) 
repress the eosinophilic program and promote Meg/E differentiation. It would therefore be 
of interest to look at the FOG-1/MeCP1 occupancy of the EOS47 and MBP promoters in 
eosinophilic cells following FOG-1 expression. It would also be interesting to investigate the 
mechanism by which FOG-1 remains silent in eosinophils. Considering that GATA-1 binds to 
the FOG-1 promoter in erythroid cells22 we would speculate that GATA-1 also mediates FOG-1 
repression in eosinophils, perhaps through its interactions with C/EBP factors. This could be 
tested by ChIP experiments in the FOG-1 locus in eosinophils isolated from mice.
What’s new with GATA-1 function: activation versus repression
The characterization of GATA-1 complexes provides a clear example of how 
a key transcription factor can carry out both repressive and activating functions. The 
GATA-1/FOG-1 interactions provide an interesting case in point. For example, whereas we have 
provided clear examples of the repressive functions of the GATA-1/FOG-1/MeCP1 complex, 
some of the activating functions of GATA-1 could take place in the context of GATA-1/FOG-1 
interactions that are independent of the MeCP1 complex. ChIP assays have previously shown 
GATA-1/FOG-1 to bind in vivo to active genes such as the α-globin locus and the GATA-1 
gene itself19,24. Several reports have shown that disruption of the GATA-1 and FOG-1 interaction 
down-regulates erythroid gene expression such as α and β globin, Band 3, DC11 and HD210,22,25. 
During erythropoiesis, the β-major gene is activated only after protein synthesis of FOG-1 and 
not immediately upon onset of GATA-1 expression22. In addition, the authors show a direct 
binding of GATA-1 to the FOG-1 locus. These data show that some of the activating functions 
of GATA-1 in erythroid cells require FOG-1. So we can also imagine a GATA-1/FOG-1 complex 
involved in activating genes that dictate a specific cell fate, with GATA-1 playing a dominant 
role. Importantly, this complex would be active in the same cells in parallel to the repressive 
GATA-1/FOG-1/MeCP1 complex. Given the FOG-1 size fractionation profile on a superose 6 
column (Chapter 3), we can expect additional protein partners in a GATA-1/FOG-1 complex that 
would synergize in transcriptional activating functions. Significantly, we (Chapter 3) and Blobel 
and colleagues have shown that only the large isoform of FOG-1 interacts with MeCP1, thus 
providing a mechanism for the formation of repressive or activating GATA-1/FOG-1 complexes26 
(see also below).
In addition to the GATA-1/FOG-1 activating complex, we have provided an example of 
a different activating GATA-1 complex in association with TAL-1/Ldb1 binding to the enhancer 
of the EKLF gene, the expression of which is essential for erythropoiesis and globin gene 
activation27. Several lines of evidence have previously shown GATA-1 to be part of a pentameric 
complex containing TAL-1, Ldb1, Lmo2 and E2A28. We have not investigated the other partners 
of the pentameric complex, but it is possible that Ldb1, E2A and Lmo2 are also present on 
the EKLF enhancer. However, it is also of note that expression of a TAL-1 mutant unable to 
bind DNA in erythroid cells does not affect expression of genes such as EKLF or GATA-129. It 
would thus be of interest to determine whether EKLF is activated in the erythroid specific TAL-1 
knockout. 
A critical question arising from these studies is how these complexes that contain 
shared protein partners can exist at the same time in the cell, and how they are regulated? 
DNA sequence at regulatory elements, specific protein partners and protein posttranslational 
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modifications (PTMs) are the three key regulatory levels that can determine the formation and 
binding of a protein complex and its effects on transcription. Our work provides examples of how 
DNA sequences and specific protein partners can regulate the function of a protein complex. For 
example, ChIP analysis of the GATA-2 locus showed binding of two distinct GATA-1 complexes, 
one that contains the repressive MeCP1 complex binding to the -2.8 kb region and another 
GATA-1 complex binding to the -3.9 kb region that does not include MeCP1 (30 and Chapter 4). 
Interestingly, the -2.8kb and -3.9kb GATA-1 binding sites are DNase I hypersensitive when the 
GATA-2 locus is active, but once GATA-1 binds (and represses GATA-2) the -2.8kb site loses 
DNase I sensitivity. The -3.9kb HS remains sensitive. This suggests that the binding of MeCP1 
to the -2.8 kb modifies the chromatin structure into a closed, less sensitive conformation, also 
characterized by a wave of histone deacetylation14. Taken together, these data support a model 
whereby GATA-1 can interact in the context of two different complexes binding at the same time 
on different sites in the same locus. 
DNA sequence analysis of the GATA-2 locus revealed that sequences adjacent to the 
-2.8kb region (that binds GATA-1/FOG-1/MeCP1) and to the -3.9kb region (that binds GATA-1) 
differ in consensus binding sites. For example, the -3.9kb region contains multiple SP1 binding 
sites. Interestingly, it was shown that SP1 binding sites were necessary to enhance transcription 
of genes such as TAL-1 and c-kit31,32. In addition, Sp1 binding motifs occur frequently together 
with GATA motifs in hematopoietic regulatory elements and GATA-1 has been reported to 
interact directly with Sp1 by EMSA and co-transfections33. These observations suggest that 
SP1 binds with GATA-1 at the -3.9kb element, thus preventing the binding/spreading of the 
GATA-1/FOG-1/MeCP1 complex. This is supported by the observations of Bresnick and 
colleagues who showed that during GATA-2 repression by GATA-1 the levels of histone H3 
acetylation were greatly reduced at the -2.8kb region, whereas deacetylation at the -3.9kb region 
was more moderate14. To provide insight into the regulation of the different GATA-1 complexes 
binding to the GATA-2 locus, mutations of either of the GATA binding sites at -3.9kb and 
-2.8kb should be made, or these sequences should be swapped and assayed for their effects on 
GATA-2 expression.
Another example of the importance of DNA sequence in the regulation of protein 
complexes binding is the GATA-1 locus itself. GATA-1 was shown to activate its own transcription34. 
However, the down regulation of GATA-1 expression was shown to be necessary for terminal 
erythroid differentiation35. ChIP analysis of the GATA-1 regulatory sequences showed that the 
DNase I HS located at the -3.5 kb region of the GATA-1 locus is bound by the pentameric 
complex including GATA-1 and TAL-1. Whereas GATA-1 binds also to the erythroid IE promoter 
and the HS located at the +3.5 kb region, the TAL-1 complex was not detected36. This shows 
that different protein complexes regulate the GATA-1 locus at the same time, highlighting again 
the importance of the combination of interacting partners to define the expression pattern of a 
gene. Thus, the underlying DNA sequences are likely to be an important determining factor in 
the binding specificity of the GATA-1 protein complexes. 
A second level for regulating protein complex formation can be through the proteins 
themselves. Our work from GATA-1 and Ldb1 complexes purification provide several examples. 
FOG-1 is detected as two isoforms of about 110 and 140 kDa. We and the Blobel group 
showed that only the larger FOG-1 isoform that contains a N-terminal 45aa domain interacts 
with the MeCP1complex, suggesting that it is sufficient for binding the NuRD/MeCP1 complex 
(Chapter 3 and 26). In addition, a similar mechanism was observed in the formation of Ldb1 
complexes, in which Eto-2, a novel Ldb1 partner, preferentially interacts with the larger isoform 
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of E47 (Chapter 5) which could influence transcriptional activation. 
The presence or absence of a protein partner in the complex could also influence 
the activity of the complex. Data obtained from the Ldb1 purification demonstrate that 
Ldb1 forms multiprotein complexes with Cdk9 in non-induced MEL cells but not in 
induced MEL cells. Similarly, Ldb1 forms protein complexes with Eto2, which include 
GATA-1. However, the ratio of Eto-2 in Ldb1 complexes changes during erythroid 
differentiation, suggesting that Ldb1 complexes are dynamic during differentiation. As the 
Eto-2/Ldb1 ratio decreases in complexes bound to activated genes, we suggest that 
Eto-2 is having a repressing function on TAL-1 target genes that diminishes with erythroid 
differentiation.
A third regulatory level relies on PTMs that could influence transcription factor complex 
formation. GATA-1, and a number of other transcription factors, have been shown to be modified 
by acetylation, phosphorylation and sumoylation. For example, acetylation of GATA-1 by 
CBP/P300 was linked to increased transcription activity37,38. However, the molecular mechanism 
remains an open question. While Boyes and colleagues have shown that acetylation of chicken 
GATA-1 increased its affinity for binding to DNA, Hung and colleagues found no such increase 
with acetylated murine GATA-139. Nonetheless posttranslational modifications can affect the 
properties of proteins by most likely altering their three-dimensional conformation, and thus 
subsequently influencing the binding of other protein partners. For example, phosphorylation 
of serine 26 and 178 in the GATA-1 protein is critical for interactions of GATA-1 with Lmo240. In 
addition, GATA-1 was shown to be sumoylated in mammalian cells41. However, no correlation 
between GATA-1 sumoylation and GATA-1 function has yet been found. Nevertheless, interaction 
with PIASy ligase was shown to repress GATA-1 transcriptional activity, albeit independently of 
sumoylation41.
A striking observation from our studies on the characterization of GATA-1 and Ldb1 
complexes in erythroid cells is the higher abundance of repressive complexes compared to 
activating complexes. This observation suggests that activating complexes would be more labile. 
Recent studies have linked ubiquitination-mediated degradation of transcriptional activators 
to their activating functions42. This suggests a very fast turnover of the activating proteins. 
However, this mechanism alone cannot explain our results. We could not identify the co-factors 
of the activating transcription factor complexes, but we did detect by ChIP of formaldehyde 
crosslinked chromatin a stable binding of the activating factors, suggesting that the transcription 
factors are not degraded. Taken together, these results suggest a higher degree of complexity 
in the regulation gene activation, for which the mechanism(s) remain to be explained.
What’s new with GATA-1 function: a key regulator of cell 
cycle progression
GATA-1 binds to retinoblastoma and regulates expression of cell cycle related genes 
such as c-myb and c-myc43,44. During cell cycle progression, c-Myc promotes the G1/S phase 
transition by inducing cyclin E-CDK2, which results in an increase in active E2F transcription 
complexes that promote cell cycle progression. Conversely, repression of c-myc gene expression 
is required for G1 arrest45,46. The binding of GATA-1 with Gfi-1b to the c-myc and c-myb 
promoters provides clues as to how GATA-1 suppresses cell proliferation in differentiating MEL 
cells through G1 arrest, and explains part of the GATA-1 function in terminal differentiation. Our 
data agree with recent microarray data obtained in G1E-ER4 cells suggesting that the induced 
GATA-1 expression represses the c-myc and c-myb genes in terminal erythroid differentiation10,44. 
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In addition, genes coding for cyclin-dependent kinases (cdk), such as cdk2, 4 and 6 that are 
functionally associated with cell cycle progression, were inhibited by GATA-1 expression, 
whereas expression of kinases inhibitors such as p18 and p27 were induced44. Our data also 
provide insight as to Gfi-1b functions, since Gfi-1b was also shown to regulate the cell cycle in 
myeloid cells47. Our data also provide clues as to how GATA-1 overexpression leads to a failure 
in the G1 arrest in erythroid cells43. We speculate that GATA-1 overexpressing mice and cells 
exhibit high level of expression of the c-myc and c-myb genes, that would lead to the failure of 
G1 arrest. Interestingly, the forced expression of Gfi-1b in myeloid cells blocks G1 arrest and 
prevents the down-regulation of c-myc and c-myb thus inhibiting myeloid cell differentiation47. In 
the light of previous and our results, we propose that GATA-1 exerts two levels of regulation of 
the cell cycle, one by suppressing c-myc and c-myb genes by direct binding to their promoters, 
and a second by direct binding to Rb. 
The mechanism by which GATA-1 and Gfi-1b mediate repression is unclear. 
Gfi-1b contains a N-terminal SNAG domain that has been implicated in recruiting the chromatin 
modifying Sin3A/HDAC1 repressive complex48. In addition, deletion of the SNAG domain 
abolishes Gfi-1b-induced erythroid maturation as well as myeloid differentiation, showing that 
it is an essential functional domain47,49. Thus, it is possible that the GATA-1/Gfi-1b complex 
we purified contains additional co-factors that modulate their repressing function, e.g. at the 
chromatin structure level. However, due to the low abundance of the GATA-1/Gfi-1b complex 
we were not able to identify them. It is possible that part of the GATA-1 complexes we identified 
interacting with HDACs may also involve Gfi-1b. These interactions would be in addition to the 
GATA-1 interactions with MeCP1. In fact, the superose 6 gel filtration profiles of Gfi-1b and 
GATA-1 support this hypothesis, as Gfi-1b and GATA-1 are eluted in a higher molecular weight 
range than expected for a complex formed only by GATA-1/Gfi-1b. This would provide evidence 
for another large protein complex involving GATA-1 in gene repressing function.
GATA-1 and GATA-2
The N-terminal zinc finger (NF) is the main GATA-1 protein-protein interaction domain 
(Our work and 10,26,39). In contrast to the DNA binding C-terminal zinc finger domain (CF), the 
NF domain is not as well conserved between the different members of the GATA family of 
transcription factors. Thus, differences in NF sequences could be responsible for differentially 
mediating interactions with protein partners that are specific to individual GATA factors. This 
may account for the fact that the expression of the hematopoietic GATA-2 transcription factor 
only partially rescues the GATA-1 low phenotype50. Rescue experiments in GATA-1.05 mice with 
GATA-2 expressed under the 3.9kb regulatory sequences of GATA-1 (shown to be sufficient 
to drive similar pattern of expression as wild type GATA-1) showed a rescue of embryonic 
lethality. However, mice developed severe anemia in the adult age50. To provide insight into 
the lack of the complete rescue by GATA-2 of the GATA-1 null phenotype, the GATA-2 protein 
complex was purified from erythroid cells using biotinylation tagging (H. Braun, unpublished 
data). Analysis of isolated complexes showed that GATA-2 interacts with some, but not all, 
of the GATA-1 partners. Whereas GATA-2 was found to interact with FOG-1 and members of 
the MeCP1/NuRD complex, transcription factors such as TAL-1, Ldb1, Lmo2 and Gfi-1b were 
absent from the GATA-2 pull-down. A number of novel GATA-2 partners were also identified 
which do not overlap with GATA-1. Thus, GATA-1 and GATA-2 interact with overlapping but also 
distinct partners. This can in part explain why GATA-2 does not completely compensate for loss 
of GATA-1 in mice. Our data support the notion that GATA-2 and GATA-1 have at least some 
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overlapping functions.
Analysis of mice expressing either a GATA-1 mutant unable to bind FOG-1, or a 
combination of GATA-1 and GATA-2 mutants that are unable to bind FOG-1 show different 
degree of severity in megakaryocytic defects51. If both factors cannot interact with FOG-1, 
the megakaryocytic lineage is completely absent, whereas in the presence of GATA-2 only 
the maturation of megakaryocytes is impaired. In conclusion, although GATA-1 and GATA-2 
recognize a similar DNA binding sequence and share partly overlapping expression profiles, 
they play unique as well as overlapping roles in vivo reflected by this protein interactions. 
GATA-1 complex interactions: re-examination of knockout phenotypes
Our findings on the distinct GATA-1 complexes give some insight on the phenotypes 
observed with the knockouts of key GATA-1 interacting partners, such as FOG-1, Gfi-1b, 
TAL-1 and Ldb1. One striking observation that emerges from the analysis of the knockouts 
models for GATA-1, FOG-1, Gfi-1b and TAL-1 is the close similarity they present in erythroid 
and megakaryocytic differentiation9,52-55. However, some phenotypic differences suggest that 
these transcription factors possess specific functions in erythropoiesis. We have suggested a 
direct function for GATA-1 in the suppression of cell proliferation based on our findings that a 
GATA-1/Gfi-1b complex binds to the repressed c-myc and c-myb genes in differentiated 
erythroid cells. The GATA-1 gene knockout leads to a complete block of erythroid maturation 
at the pro-erythroblast stage due to apoptosis, whereas erythroid progenitors in Gfi-1b mutants 
continue to proliferate8,53,55. We can speculate that in the absence of Gfi-1b protein, the c-myc 
and c-myb genes would not be repressed and erythroid progenitors would therefore continue to 
proliferate. These data would also suggest that Gfi-1b functions in erythropoiesis do not overlap 
with the GATA-1 anti-apoptotic functions. However, it is of note that erythroid progenitors in 
Gfi-1b mutants are blocked at the BFU-E stage. This phenotype resembles that of TAL-1 
conditional knockout that also leads to a block of erythroid differentiation at a similar stage54,56. 
These observations suggest an essential role for Gfi-1b and TAL-1 that is GATA-1 independent 
early in erythroid differentiation. It is also possible that the two transcription factors Gfi-1b and 
TAL-1 are involved, in parallel, in a common pathway, as it was shown that the Drosophila Gfi-1b 
ortholog senseless interacts with bHLH proteins in sensory organ development57. 
FOG-1 knockout embryos exhibit a severe, but partial, block of erythroid differentiation 
at the pro-erythroblast stage. Cells survive for longer time during erythroid maturation as 
compared to the GATA-1 knockout52. It is remarkable that despite the similar phenotypes 
between the Gfi-1b and the FOG-1 knockouts in the erythroid and megakayocytic lineages, we 
have not seen any direct interactions between these two factors in erythroid cells. This raises 
the possibility that FOG-1 and Gfi-1b are involved in distinct but parallel pathways or in common 
pathways. As erythroid defects occur earlier in Gfi-1b mutants than in FOG-1 mutants, we can 
think that FOG-1 is temporally playing a role downstream of Gfi-1b.
Future directions
As a conclusion, we can picture GATA-1 as a orchestra conductor. It interacts with 
many partners recruiting effector molecules for the modification of chromatin structure in the 
proper temporal and spatial gene regulation of several target genes (Figure 1 and 2). The 
regulation of the distribution of the co-factors between GATA-1 complexes remains to be 
understood. However, our data suggest that GATA-1 uses chromatin remodeling complexes 
such as MeCP1 to repress genes early during erythroid differentiation and remain bound 
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at a late stage of terminal erythroid differentiation. Other GATA-1 complexes such as the 
GATA-1/FOG-1 and the GATA-1/Gfi-1b need further characterization to identify the co-factors that 
are involved in the transcriptional activity regulation. We have shown that the GATA-1/FOG-1/
MeCP1 complex was able to repress in erythroid cells eosinophilic and myeloid lineage-affiliated 
genes. It would be interesting to investigate the regulation of more classes of genes in erythroid 
differentiation (e.g. the repression of megakaryocytic genes) to know whether the function of the 
GATA-1/FOG-1/MeCP1 complex would be broader than the one we propose in our study. In 
addition, as GATA-1 is also expressed in megakaryocytic cells with FOG-1, it would be interesting 
to know whether the GATA-1/FOG-1/MeCP1 complex exists in megakaryocytes and whether it 
represses erythroid genes. We would also speculate that in megakaryocytic cells eosinophilic 
and myeloid programs would also have to be switched off in a similar way as we have proposed 
in erythroid cells. 
GATA-1/FOG-1 interactions are very important in Meg/E differentiation. Thus, a very 
interesting question is how does GATA-1 regulate the differentiation of megakaryocytic versus 
erythroid cells from the Meg/E progenitors, taking into account the considerable overlap in 
GATA-1 interactions (i.e. with FOG-1 or Gfi-1b) between these two lineages. This point raises 
the question as to what are the differences in GATA-1/FOG-1 and GATA-1/Gfi-1b complexes 
between erythroid and megakaryocytic cells, stressing again the importance of identifying 
protein partners in order to understand transcriptional regulation. In order to address these 
points, the GATA-1 complex purification in megakaryocytes using the biotinylation tagging 
method is presently under way (P. Vyas, Oxford). 
In order to provide a broader picture of the protein network in hematopoiesis, a larger 
number of transcription factors and co-factors need to be tagged. We can therefore anticipate 
the reconstitution of a map of protein-protein inter-connections as has been described in 
yeast58. In addition to the distinct GATA-1 complexes in erythroid cells, purification of the protein 
complexes of the GATA-1 partner Ldb1 has also revealed the presence of distinct complexes 
with or without GATA-1 (Figure 1). These data expand on our knowledge of transcription factor 
Figure 1: GATA-1 and Ldb-1 protein partners in erythroid cells.
Proteins partners (white circles) of biotinylated GATA-1 and Ldb-1 (grey circles) form distinct protein 
complexes. In addition, they are involved in other protein-protein interactions that are GATA-1 or Ldb1 
independent (non-overlapping circles).
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complexes and provide more clues as to how transcription factors interact in hematopoiesis. 
For example, purification of FOG-1 protein complexes would give a better understanding of 
the FOG-1 functions that are GATA-1 independent, in erythroid but also megakaryocytic cells. 
FOG-1 was described to interact with TACC3 (Transforming Acidic Coiled Coil)59. This protein 
was not found in our GATA-1 purification, suggesting that FOG-1, like Ldb1, interacts with 
proteins independently of GATA-1. 
The dynamics of protein complexes are an important aspect in the regulation of 
gene expression. We have seen that Ldb1 can form different complexes at different stages 
of erythroid differentiation. Similarly, we have preliminary results showing that GATA-1 
complexes are also dynamic during erythroid cell differentiation. Thus, it would be interesting 
to purify GATA-1 complexes at an earlier stage of differentiation to identify potentially novel 
GATA-1 partners. It is also interesting to determine the relative abundance of GATA-1 complexes 
for example between non-differentiated and differentiated MEL cells to identify function of 
GATA-1 at an earlier stage of erythroid differentiation. To do so, GATA-1 associated proteins 
isolated from MEL cells at the two different stages of differentiation can be mixed after labeling 
one of the two populations of proteins and the proteins analyzed by Mass Spectrometry. 
A   similar approach based on Isotope-coded Affinity Tag (ICAT) has already been used to purify 
NF-E2/p45 protein complexes60.
Lastly, we can envisage developing a ChIP-on-chip approach based on the biotinylation 
method to address the question of gene target network regulated by the different transcription 
factor complexes. For instance, DNA sequences bound by GATA-1 and Ldb1 can be isolated 
form ChIPed material and hybridized with DNA promoter arrays to determine the sequences 
that are common and distinct to the two factors, thus providing more insight on their molecular 
functions in hematopoiesis.
Figure 2: GATA-1 protein regulates several target genes in erythroid cells.
EKLF, FOG-1, TAL-1 and GATA-1 gene expression are activated by the transcription factor GATA-1. In 
contrast, GATA-2, c-Myc, c-Myb and MBP gene expression are suppressed. GATA-2 activates also GATA-1 
gene.
GATA-1 gata-2
mbp
c-myc/c-myb
tal-1
fog-1
eklf
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Isolation of transcription factor complexes by in 
vivo biotinylation tagging and direct binding to 
streptavidin beads 
Abstract
 Efficient tagging methodologies 
are an integral aspect of protein complex 
characterization by proteomic approaches. 
Due to biotin’s very high affinity for avidin and 
streptavidin, biotinylation tagging offers an 
attractive approach for the efficient purification 
of protein complexes. The very high affinity 
of the biotin/(strept)avidin system also offers 
the potential for the single-step capture of 
lower abundance protein complexes, such 
as transcription factor complexes. The 
identification of short peptide tags that are 
efficiently biotinylated by the bacterial BirA 
biotin ligase, led to an approach for the 
single-step purification of transcription factor 
complexes by specific in vivo biotinylation 
tagging. A short sequence tag fused N-
terminally to the transcription factor of 
interest is very efficiently biotinylated by 
BirA co-expressed in the same cells, as was 
demonstrated by the tagging of the essential 
hematopoietic transcription factor GATA-1. The 
direct binding to streptavidin of biotinylated 
GATA-1 in nuclear extracts resulted in the 
single-step capture of the tagged factor and 
associated proteins, which were eluted and 
identified by mass spectrometry. This led to 
the characterization of several distinct GATA-
1 complexes with other transcription factors 
and chromatin remodeling co-factors, which 
are involved in activation and repression of 
gene targets. Thus, BirA-mediated tagging 
is an efficient approach for the direct capture 
and characterization of transcription factor 
complexes.
Key words: biotinylation tagging; BirA; 
transcription factors; chromatin; mass 
spectrometry; size fractionation; GATA-1
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Introduction
 
 Completion of the sequencing of an 
ever-increasing number of genomes has led 
to a shift of focus towards the characterization 
of the protein complement of cells, i.e. the 
proteome. A key aspect of proteomic analysis 
is the development of simple methodologies 
for the efficient isolation of protein complexes 
for peptide analysis and identification by 
powerful mass spectrometric approaches. 
This is particularly challenging for the analysis 
of nuclear proteins involved in transcriptional 
regulation such as transcription factors and 
their chromatin associated co-factors due to 
their relatively lower abundance, the different 
parallel functions that they execute (e.g. 
activation and repression involving different 
partners) and the often transient nature of their 
interactions. Transcription factor purification 
approaches involving several pre-purification 
steps are laborious and costly and most likely 
result in the isolation of only the most abundant 
of the protein complexes formed by the factor. 
We describe here the application of in vivo 
biotinylation tagging as a simple approach for 
the efficient direct purification of transcription 
factor complexes from crude nuclear extracts 
(1). 
Biotin is a naturally occurring cofactor 
essential for certain metabolic enzymes such 
as carboxylases. Specific protein-biotin ligases 
are responsible for covalently attaching biotin to 
these enzymes. The key to using biotinylation 
lies in the fact that biotinylated substrates can 
be bound very tightly by the naturally occurring 
proteins avidin and streptavidin (Kd = 10
-15), a 
fact that has been widely exploited in many 
affinity-based biochemical applications. In 
addition, in vivo biotinylation tagging offers a 
number of advantages for protein purification 
purposes. Firstly, there are few naturally 
biotinylated proteins (mostly cytoplasmic and 
mitochondrial) ensuring that non-specific 
background binding remains low. Secondly, 
the very high affinity of (strept)avidin for biotin 
allows high stringencies to be employed during 
purification without fear of losing binding of the 
tagged protein.
The biotinylation tagging approach 
described here is based on previous work 
on the screening of a combinatorial synthetic 
peptide library for efficient biotinylation by the 
bacterial BirA biotin ligase (2). This led to the 
identification of a number of short sequence 
tags that can be very efficiently biotinylated 
in vitro (2, 3). Such tags were subsequently 
utilized for the efficient in vivo biotinylation 
of tagged proteins in bacterial cells through 
the co-expression of BirA (4, 5). We have 
applied this approach in mammalian cells 
and demonstrated its efficiency in specifically 
biotinylating nuclear proteins in cultured 
cells and transgenic mice through the co-
expression of the BirA biotin ligase together 
with the tagged protein (Figure 1A) (1). Our 
work is focused primarily on the biotinylation 
tagging of hematopoietic transcription 
factors in erythroid cells. Most of our work 
to date has been carried out with GATA-1, a 
critical transcription factor for erythroid cell 
differentiation. We have been able to very 
efficiently biotinylate GATA-1 in cultured mouse 
erythroleukemic cells (Figure 1B and C; (1)) 
leading to the isolation and characterization of 
GATA-1 protein complexes by direct binding 
of nuclear extracts to streptavidin beads. 
Using this approach we identified a number of 
GATA-1 complexes, containing other essential 
hematopoietic transcription factors (FOG-1, 
Gfi-1b and TAL-1) and chromatin remodeling 
and modification complexes (MeCP1 and ACF/
WCRF). These complexes were implicated in 
the transcriptional activation and repression 
of different subsets of target genes (6). Thus, 
biotinylation tagging has proven to be a very 
efficient method for the single-step purification 
and characterization of transcription factor 
complexes. It should also be noted that we 
have no evidence so far that biotinylation 
tagging adversely affects the physiological 
properties of the tagged protein (1).
In this chapter we describe protocols 
for the binding of nuclear extracts expressing 
a specific biotin-tagged protein to streptavidin 
beads and the preparation of the eluted material 
for analysis by mass spectrometry. We do not 
provide protocols for the stable transfection 
of cultured cells as these will vary depending 
on the cell line/type used in each case. We 
routinely prepare large scale nuclear extracts 
from a few liters of cultured cells, we test for the 
presence of the biotin tagged protein in high 
molecular weight complex(es) by gel filtration 
using a Superose 6 column and then carry out 
the binding of the tagged factor to streptavidin 
paramagnetic beads. We normally check the 
efficiency of the biotin tagging and the binding 
to streptavidin beads by testing the nuclear 
extract (input), the bound material (eluate) 
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and the flowthrough (unbound) by Western 
blotting using first an antibody against the 
tagged protein followed, by streptavidin-HRP 
conjugate on the same blot. In this way the 
fraction of the tagged protein that becomes 
biotinylated in vivo and subsequently 
captured by the streptavidin beads can be 
determined. As shown in Figure 1, for GATA-1 
the biotinylation efficiency and capture by the 
beads is nearly 100%. The proteins eluted from 
the beads are fractionated by SDS-PAGE, the 
gel is stained and photographed (Figure 4). 
The gel lane with the fractionated proteins 
is excised and cut into small pieces (or gel 
plugs) along its entire length. The gel plugs 
are then processed for protein identification 
by mass spectrometry. The following sections 
describe in detail all of these techniques. We 
also provide an overview of the background 
binding in experiments using nuclear extracts 
and the specific enrichment observed when 
purifying biotin tagged transcription factors 
(Figure 4). Lastly, we provide protocols for the 
size fractionation of nuclear extracts using a 
preparative Superose 6 column and for the 
cleavage of proteins bound to streptavidin 
beads using TEV protease (Figure 3). 
Both approaches are presented with the 
aim of reducing the background in protein 
purification by biotinylation tagging. Given 
the increase in the potential applications of 
biotinylation tagging for protein purification, 
the description of such protocols may prove a 
useful resource.
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Materials
2.1 Cell culture
1. Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Cambrex Bio Science, Belgium), 
supplemented with 10 % Fetal Bovine 
Serum (FBS, Hyclone, Belgium).
2. Penicillin (used at 100u/ml final 
concentration) and streptomycin (used 
at 100µg/ml final concentration), stored 
at –20oC (100x stock from Cambrex Bio 
Science, Belgium).
3. 100% Dimethylsulfoxide (DMSO, Merck, 
Germany), used at 2% final concentration.
4. Neomycin (Gibco-BRL, UK), stock 
prepared as 100mg/ml in phosphate 
buffered saline (PBS, see below), filter-
sterilized, aliquoted, stored at –20oC and 
used at 400µg/ml final concentration.
5. Puromycin (Sigma, St. Louis, MO), 1000x 
stock aliquoted and stored as above and 
added to 1µg/ml final concentration.
2.2 Nuclear extract preparation
1. Dulbecco’s Phosphate Buffered Saline 
(PBS, Cambrex Bio Science, Belgium)
2. Protease inhibitors: Complete (Roche, 
Germany). Use 1 tablet for 50ml of 
solution
3. Cell resuspension buffer: 2.2 M sucrose in 
10 mM HEPES-KOH, pH 7.9, 25 mM KCl, 
0.15 mM Spermine, 0.5 mM Spermidine, 1 
mM EDTA (with protease inhibitors added 
as above).
4. Standard household blender with rotating 
blades for homogenizing cells. 
5. Nuclear lysis buffer: 10 mM HEPES, 
pH 7.9, 100 mM KCl, 3 mM MgCl2, 0.1 
mM EDTA, 20% glycerol (with protease 
inhibitors added as above).
6. Coomassie Plus Assay reagent (Pierce, 
IL).
7. Protein standards:  dilutions of 0, 100, 200, 
300, 400 and 500 µg/ml of chicken egg 
albumin (Sigma-Aldrich, MO) in ddH2O 
prepared from a 20 mg/ml stock solution. 
10 µl of each standard diluted in 1 ml (final 
volume) of ddH2O is used for obtaining a 
standard curve.
8. Spectrophotometer: Ultraspec II (LKB 
Biochrom), cuvettes (Sterna, Germany).
9. Conductivity meter: Philips PW 9526.
10. Standards for determining salt 
concentration: 100, 200 300, 400 mM 
KCl diluted in ddH2O from a 1M KCl stock 
solution. 10 µl of each standard are diluted 
in 1 ml (final volume) of ddH2O for obtaining 
a standard curve.
2.3 Size fractionation by Superose 6 gel 
filtration
1. Superose 6 analytical grade column: HR 
10/30 with a total bed volume of 24 ml. 
Preparative grade column: XK 50/600 
with a bed height of 30.3 cm, total bed 
volume of 589 mL, both purchased form 
Amersham Biosciences (UK). Range 
of separation of 5,000 to 5,000,000 Da. 
20% ethanol is used as preservative. The 
column is connected to an AKTA FLPC 
system (Amersham Biosciences).
2. Gel filtration calibration kit: dextran blue 
and high molecular weight standards 
(Amersham Biosciences, UK).
3. Column running buffer: 20mM HEPES, 
0.5mM EGTA, 1mM MgCl2, 200mM KCl, 
10% glycerol. All buffers used for gel 
filtration column should be filtered prior to 
use.
4. 100% Trichloroacetic acid (TCA, Sigma-
Aldrich, MO).
2.4 SDS-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE)
1. Pre-cast NuPAGE 4-12% Bis-Tris gel 
(Invitrogen, UK).
2. Gel electrophoresis buffer: 1 X MOPS 
buffer diluted from 20 X stock solution and 
NuPAGE antioxidant (both from Invitrogen, 
UK).
3. Sample loading buffer, final concentration: 
62.5 mM Tris-HCl pH 6.8, 25% glycerol 
(v/v from 100% stock, Sigma-Aldrich, St. 
Louis, MO), 2% SDS (v/v from 20% stock 
in ddH2O), 0.01% bromophenol bl (w/v, 
Sigma-Aldrich, St. Louis, MO), 5 % β-
mercaptoethanol (v/v, 100% stock, Merck, 
Germany). Can be prepared as a 4X stock 
solution.
4. Broad range pre-stained SDS-PAGE 
molecular weight standards (BioRad, 
Hercules, CA).
5. SimplyBlue Safestain gel staining solution 
(Invitrogen, UK).
2.5 Western blotting
1. ProTran nitrocellulose membrane 
(Schleicher & Schuell, Germany).
2. Gel-blotting paper (Schleicher & Schuell, 
Germany).
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3. Blotting buffer: 25 mM Tris (made directly 
from the solid), 192 mM Glycine (made 
directly from the solid), 20% methanol.
4. Tris-Buffered Saline (TBS): 10 mM Tris-
HCl, pH 7.4, 150 mM NaCl. Can be 
prepared as a 10X stock and stored at 
room temperature.
5. Blocking buffer: 5% Bovine Serum Albumin 
(BSA, Roche, Germany) in 1X TBS, 
prepared fresh.
6. Washing buffer 1x TBS adjusted to 0.5M 
NaCl (using a 5M NaCl stock solution), 
0.3% Triton X-100 (Sigma-Aldrich, MO).
7. Primary and secondary antibody dilution: 
in blocking buffer with 0.2% NP-40.
8. Secondary antibodies: anti-rabbit (1/50000 
dilution), anti-mouse (1/15000 dilution) 
from Amersham Biosciences (UK), anti-
rat (1/3000 dilution) and anti goat (1/4000 
dilution) from DakoCytomation (Denmark). 
All antibodies are purchased as horseradish 
peroxidase (HRP) conjugates.
9. Enhanced Chemiluminescence (ECL) kit 
(Amersham Biosciences, UK).
10. Bio-Max MR film (Kodak, Rochester, NY).
2.6 Streptavidin binding
1. Streptavidin paramagnetic beads 
(Dynabeads M280, Dynal, Sweden).
2. Chicken Egg Albumin (Sigma-Aldrich, 
MO).
3. Binding buffer: 1X TBS, 0.3% 0.3% NP-40 
(Nonidet-40, Sigma-Aldrich, MO). 
4. HENG buffer: 10 mM HEPES-KOH, pH 
9, 1.5 mM MgCl2, 0.25 mM EDTA, 20 
% glycerol, 1mM PMSF (phenyl methyl 
sulfonyl fluoride, prepared as a 100x stock 
in ethanol and stored at –20oC). 
5. Wash buffer: HENG buffer with 250 mM 
KCl and 0.3% NP-40.
6. Elution buffer: 1X sample loading buffer.
7. Magnets: Dynal MPC-1 and MPC-S 
magnets, for large and small volumes 
respectively (Dynal, Sweden).
2.7 TEV protease cleavage
1. Nuclear extract dilution buffer: 20mM Tris-
HCl pH7.5, 0.45% NP-40.
2. Tobacco Etch Virus (TEV) protease 
(AcTEV Protease, Invitrogen, Scotland).
2.8 Sample preparation for mass 
spectrometry
1. Trypsin, sequencing grade (Roche, 
Germany). 10x stock made by dissolving 
lyophilized powder in 1mM HCl to 100ng/
µl final concentration. 
2. 50mM Ammonium bicarbonate (Sigma-
Aldrich, MO). Dissolved in ddH2O and filter 
sterilized.
3. 100% Acetonitrile (Sigma-Aldrich, MO).
4. 100% Formic acid (Sigma-Aldrich, MO).
5. Gel slice destaining solution: 25mM 
ammonium bicarbonate in 50% acetonitrile 
prepared by mixing equal volumes of the 
stock solutions given above.
6. 50mM iodoacetamide (Sigma-Aldrich, 
MO) prepared in 50mM ammonium 
bicarbonate.
7. 6.5mM DTT (dithiothreitol, (Sigma-Aldrich, 
MO) prepared in 50mM ammonium 
bicarbonate.
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3. Methods
3.1 Cell culture
1. Mouse Erythroleukemia (MEL) cells 
are Friend virus transformed erythroid 
progenitors arrested at the proerythroblast 
stage of differentiation (7). MEL cells are 
cultured in DMEM supplemented with 
10% FBS at 37°C and 5% CO2. Cells are 
grown to a maximum of 2x106 cells/ml and 
routinely split to a density of 5x104 cells/
ml. Cells appear to be semi-adherent and 
rounded with a smooth surface (see Note 
1). 
2. For induction, cells are diluted to 5x105 
cells/ml and cultured in DMEM with 2% 
DMSO (v/v) for at least 3 days. Cells 
become smaller but remain round and 
when pelleted appear pink/red due to 
hemoglobinization. 
3.2 Nuclear extract preparation
1. Cells are harvested in 1 liter centrifuge 
bottles by centrifugation at 640 x g for 40 
min at 4°C in a Beckman J4 centrifuge and 
washed once with 100 ml of ice-cold PBS. 
Resuspended cells are transferred into 
50ml Falcon tubes and re-pelleted in an 
Eppendorf 5810R benchtop centrifuge at 
2540 x g for 10 min at 4oC. The supernatant 
is discarded.
2. The cell pellet is gently resuspended 
by pipetting up and down in 200 ml of 
cell resuspension buffer with protease 
inhibitors added. Cells are equilibrated to 
the new osmotic conditions for 20 min on 
ice.
3. Cells are lysed in a blender using a single 
30 second pulse at setting 3 (see Note 2). 
Excessive foaming should be avoided. 
4. Lysis efficiency is checked under the 
microscope by staining a 10 µl aliquot 
with an equal volume of Unna stain 
(Methylgreen-Pyronin). Nuclei appear 
blue whereas intact cells appear with a 
blue nucleus surrounded by a non-stained 
cytoplasm. Optimal lysis should result in 
more than 90% of the nuclei appearing 
free of cytoplasm. 
5. Nuclei are pelleted by ultracentrifugation at 
141,000 x g using the SW28 rotor for 2 h at 
4°C. A clean white pellet corresponding to 
the nuclei should be visible at the bottom 
of the tube. The top layer (cellular debris/
cytoplasm) is discarded.
6. Nuclei are resuspended in 15 ml of nuclear 
lysis buffer and proteins are extracted by 
the drop wise addition of a 3.3M KCl solution 
with gentle agitation on ice, until the final 
concentration is ~350-400mM (see Note 
3). Nuclear lysis and protein extraction are 
allowed to proceed by incubating on ice 
for 20 min. Two phases should be visible: 
one is clear and represents the soluble 
nuclear extract fraction whereas the other 
phase appears viscous and represents 
the insoluble fraction of mostly chromatin 
fragments. 
7. Insoluble material is removed by 
ultracentrifugation at 300,000 x g using 
the SW50.1 rotor for 1 h at 4°C. The 
supernatant (soluble nuclear extract, 
approximately 17-18ml) is aliquoted in 1-
5ml aliquots. 
8. A small aliquot is used to measure protein 
concentration using the Bradford method. 
First, a standard curve is obtained by adding 
200µl of Bradford reagent to 800 µl of each 
of the chicken egg albumin standards, 
incubating for 5 min at room temperature 
and measuring the absorbance at 595nm 
in a spectrophotometer. The absorbance 
of dilutions of the aliquot of the nuclear 
extract are measured in the same way. 
The concentration of the nuclear extract 
is determined using the standard curve, 
taking the dilution of the sample into 
account. 
9. The salt concentration of the solution is 
determined by measuring the conductance 
of the sample with a conductivity meter. 
First, a calibration curve of conductance 
is obtained using the KCl dilutions as 
standards. The conductivity of a diluted 
aliquot of the nuclear extract is then 
measured and its approximate salt 
concentration is estimated using the 
calibration curve.
10. Nuclear extracts are snap frozen in liquid 
nitrogen and stored at –70°C (see Note 
4).
3.3 Analytical Superose 6 gel filtration (see 
Note 5)
1. An aliquot of nuclear extract is thawed on 
ice and centrifuged for 5 min at full speed 
using a microcentrifuge at 4°C. The volume 
of extract loaded on the column should not 
exceed 1% of the column volume.
2. The pump and the column are equilibrated 
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with column running buffer. The running 
program is set up as follows: 100 µl/min 
flow rate; sample volume loop 200µl; 
fraction volume 500 µl; elution length 1 
column volume of running buffer; alarm 
pressure set at 0.5 MPa (see Notes 6 and 
7). After each run the column is washed 
with 2 column volumes of running buffer.
3. The calibration standards are run through 
the column to establish the elution volume 
of protein complexes and of free protein 
monomers (see Notes 8-10).
4. Collected fractions are concentrated by 
trichloroacetic acid precipitation (TCA), 
as follows: 125 µl of cold 100 % TCA are 
added to each 500 µl fraction, mixed well 
and incubated on ice for 30 min.
5. Proteins are pelleted by centrifugation at 
full speed in a microcentrifuge at 40C for 
20 min.
6. The supernatants are discarded and the 
pellets washed with at least 500µl 1% ice 
cold TCA (in ddH2O) and re-centrifuged as 
above.
7. The supernatants are discarded again 
and the pellets are washed with ice-cold 
acetone and re-centrifuged as above.
8. The pellets are air dried (on ice) and re-
suspended in 50 µl of sample loading buffer 
(see Note 11). The fractionation patterns of 
specific proteins are determined by SDS-
PAGE and Western blotting, as described 
below. An example of a GATA-1 Superose 
6 fractionation profile of nuclear extracts 
from MEL cells expressing biotin-tagged 
GATA-1, is shown in Figure 2. From this, it 
is clear that both endogenous and tagged 
GATA-1 elute in high molecular weight 
(>670kDa) fractions. The fractionation 
profile of tagged GATA-1 follows that of the 
endogenous GATA-1 protein.
3.4 Preparative gel filtration by Superose 6
1. Steps 1 and 3 are as above.
2. Running program: 4ml/min flow rate; 
sample volume loop 5ml; fraction volume 
10ml; elution length 1.5 column volumes; 
alarm pressure set at 0.65Mpa (see Note 
12).
3. Fractions are collected in 15 ml Falcon 
tubes and used for precipitation (see 
below) or for binding to streptavidin beads 
(section 3.6).
4. Proteins are precipitated with 20% TCA 
(2.5 ml of 100 % TCA are added to every 
10ml fraction) and kept on ice for 1h. The 
tubes are centrifuged in an Eppendorf 
5810R benchtop centrifuge at maximum 
speed (2540 x g) for 20 min at 4°C. The 
pellet is subsequently washed with ice-
cold 1% TCA (in ddH2O). At this step the 
pellet can be carefully resuspended and 
transferred into microfuge tubes. The 
samples are re-pelleted by spinning as 
above, or in a microfuge for 20 min, full 
speed at 4ºC. The pellets are washed 
with ice-cold acetone, centrifuged again 
as above and air dried on ice. The protein 
pellets are finally resuspended in 50µl of 
sample loading buffer and denatured by 
boiling before loading on an SDS-PAGE 
gel (section 3.8). 
3.5 Binding to streptavidin beads
1. 5-10mg of nuclear extract is thawed 
on ice and diluted to 150mM KCl final 
concentration by the dropwise addition of 
ice-cold HENG with gentle shaking (see 
Note 13). NP-40 is adjusted to a 0.3% final 
concentration.
2. We routinely use 200 µl of resuspended 
streptavidin beads per 5mg of nuclear 
extract. The beads are blocked with 
200ng/ml chicken egg albumin (CEA) in 
a 1ml final volume (made up with HENG 
buffer), for 1 hour at room temperature on 
a rotating platform.
3. The beads are immobilized using a 
magnetic rack and the blocking solution is 
removed. The beads are then resuspended 
in the diluted nuclear extract and incubated 
on a rotating platform 4°C for 2 hours to 
overnight. 
4. The beads are immobilized on ice using 
the magnetic rack. The supernatant, 
corresponding to the unbound fraction or 
flowthrough, is collected and saved.
5. The beads are washed in 1 ml of washing 
buffer as follows: 2 quick rinses followed 
by 3 washes, 10 min each at room 
temperature on a rotating platform.
6. After the last wash, the beads are 
resuspended in 50 µl of sample buffer. 
Bound proteins are eluted by boiling the 
beads for 5 min.
7. The eluted material is fractionated by SDS-
PAGE and processed for analysis by mass 
spectrometry as described below.
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3.6 Binding of preparative Superose 6 
fractions to streptavidin beads
1. After determining the fractionation profile 
of the protein(s) of interest by SDS-PAGE 
and Western blotting (as below), the peak 
fractions are pooled in a suitable sterile 
container (we conveniently use a sterilized 
glass measuring cylinder). All work is 
carried out on ice or in the cold room.
2. KCl and NP-40 concentrations are 
adjusted to 150mM and 0.3%, respectively 
(as above) with gentle mixing.
3. The diluted fractions are divided equally into 
separate 50ml Falcon tubes, so that tubes 
are not more than ¾ full, and resuspended 
streptavidin M280 beads (equilibrated and 
blocked as above) are added followed by 
overnight incubation at 4oC on a rotating 
platform. We use approximately 10µl of 
streptavidin M280 beads for every 10ml 
fraction.
4. The beads are immobilized using the 
Dynal MPC-1 magnet and the supernatant 
corresponding to the unbound fraction 
is removed and saved. The immobilized 
beads from each tube are resuspended in 
washing buffer and pooled by transferring 
to a microfuge tube.
5. The beads are washed 4-5 times at room 
temperature in 1ml washing buffer for 5-10 
min each.
6. The bound proteins are eluted by boiling 
the beads in sample buffer (50µl of sample 
buffer per 20µl of immobilized beads). The 
eluted material is fractionated by SDS-
PAGE and processed for analysis by mass 
spectrometry as described below.
3.7 TEV protease cleavage
With the aim of reducing the non-specific 
background observed in streptavidin binding 
experiments, we developed a modified 
version of the biotin tag for the N-terminal 
tagging of fusion proteins. This tag consists 
of a shorter (14aa) amino acid sequence than 
the one previously used but which is also 
very efficiently biotinylated by the BirA biotin 
ligase (3). The biotin tag sequence is followed 
by a 7aa cleavage site for the highly specific 
TEV-protease (Tobacco Etch Virus protease) 
(Figure 3A). In this way, the biotinylated 
protein and associated complexes can be 
specifically released from the streptavidin 
beads by cleaving off with the TEV protease 
(Figure 3B and C).
1. Immediately after the washing steps 
(step 5, section 3.5) the streptavidin 
paramagnetic beads are resuspended in 
1xTBS/0.3% NP-40 buffer (95µl of buffer 
for every 50µl of resuspended beads used 
in the outset of the experiment). 
2. 5-10% (v/v) of TEV-protease is added 
to the resuspended beads followed by 
incubation for 1-3h at 16oC with shaking 
(see Note 14).
3. The supernatant can be collected (it 
should contain the cleaved protein) and, 
if necessary, can be concentrated by TCA 
precipitation, as above.
4. The efficiency of protease cleavage can 
be monitored by testing an aliquot of the 
supernatant by SDS-PAGE and Western 
blotting (Figure 3B and C). The material 
that remains bound to the beads after TEV 
protease cleavage can be eluted by boiling 
in sample buffer and tested by SDS-
PAGE. Successful cleavage results in 
the loss of the biotin-tag (as visualized by 
Streptavidin-HRP, Figure 3C) accompanied 
by a downshift in the size of the tagged 
protein thus resulting in faster migration by 
SDS-PAGE (as visualized by the tagged 
protein-specific antibody, Figure 3B).
3.8 SDS-PAGE
We preferably use NuPAGE pre-cast gels 
since they give clear and reproducible 
results in terms of resolution and sharpness 
of the protein bands. This if of particular 
importance if the gel is to be processed for 
mass spectrometry. There is also the added 
advantage of using gradient precast gels (e.g. 
4-12%) for resolving proteins in a wide range 
of molecular weights. We use the Invitrogen 
electrophoresis system for running the 
NuPAGE gels.
1. Pre-cast gels are removed from the plastic 
envelope and rinsed in ddH2O. The sticker 
near the bottom of the gel and the comb 
are removed carefully. 
2. 800 ml of 1X MOPS electrophoresis buffer 
are prepared.
3. The gel is placed in the electrophoresis 
system (Invitrogen). The outside chamber 
is filled with 600 ml of 1X MOPS. 
4. 500 µl of antioxidant are added to the 
remaining 200 ml of the 1X MOPS buffer, 
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mixed and used to fill the inner chamber. 
5. The wells of the gel are rinsed twice with 
the running buffer.
6. The samples in sample loading buffer are 
boiled for 5 min to denature the proteins 
and loaded directly onto the gel. 5-10 µg 
of nuclear extract are loaded per lane.
7. The gel is electrophoresed at 200V 
constant voltage for 60-75 min.
3.9 Western blotting
Samples that have been separated by SDS-
PAGE are electrophoretically transferred onto 
nitrocellulose membrane by “wet blotting”. 
For protein transfer we use the Trans-Blot 
electrophoretic transfer cell (Bio-Rad, CA).
1. Four gel-blotting papers are cut to the size 
of the gel. A “sandwich” is set up consisting 
of a sponge, 2 pieces of blotting paper, 
the gel, the membrane, another 2 pieces 
of blotting paper and a sponge (see Note 
15). The membrane is pre-wetted in water 
followed by transfer buffer.
2. The “sandwich” is placed in the transfer 
tank containing transfer buffer pre-chilled 
at 40C, such that the membrane is between 
the gel and the anode. 
3. Blotting is carried out under constant 
amperage at 390 mA for 70 min in the cold 
room (see Note 16).
4. At the end of the transfer, the “sandwich” is 
disassembled and the membrane is rinsed 
in 1x TBS / 0.05% NP-40 (see Note 17).
5. The membrane is blocked at room 
temperature in freshly prepared blocking 
buffer for 1 hour on a rocking platform.
6. The blocking buffer is discarded, replaced 
by the primary antibody (in this case 
anti-GATA-1 N6 antibody diluted 1:5000) 
in blocking buffer / 0.2 % NP-40 and 
incubated overnight at 4°C on a rotating 
wheel.
7. The primary antibody is removed and the 
membrane washed three times with 50 ml 
of washing buffer, 15 min each wash at 
room temperature (see Note 18).
8. A freshly prepared secondary antibody (in 
this case anti-rat diluted 1:3000 in blocking 
buffer) is added to the membrane and 
incubated for one hour at room temperature 
on a rocking platform.
9. The secondary antibody is discarded 
and the membrane is washed as in step 
8, followed by one wash for 5 min in 
1xTBS/0.05% NP-40.
10. The membrane is lifted out of the wash 
buffer and excess liquid is removed by 
touching it on a clean tissue and placed in 
a clean tray such as a plastic weigh boat. 
11. 3 ml of ECL solution (per filter) is 
prepared according to the manufacturer’s 
instructions and immediately added to the 
membrane and shaken gently for 1 min to 
ensure an even coverage of the membrane 
by the liquid.
12. Excess liquid is again removed by 
touching the membrane on a clean tissue. 
The membrane is wrapped in cling wrap 
and exposed to film in an autoradiography 
cassette in a dark room, as soon as 
possible.
3.10 Preparation of samples for mass 
spectrometry (see Note 19)
The procedures described below are for the 
analysis by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) using a Q-Tof 
Ultima API mass spectrometer. The treatment 
of samples may vary depending on the type 
of analysis and the instrument used. It is best 
to consult with the mass spectrometry facility 
where the analysis is to be carried out for the 
processing of samples.
1. Following electrophoresis by SDS-PAGE 
the gel is stained overnight with Colloidal 
Blue, according to the manufacturer’s 
instructions.
2. The gel is destained in several changes 
of ddH2O until the background (i.e. the 
non-protein containing part of the gel) is 
completely destained. This usually takes 
several hours (i.e. more than 12 hours).
3. The destained gel is photographed 
to provide a record of the purification 
experiment.
4. 20-25 microfuge tubes are rinsed in 60% 
acetonitrile.
5. The entire lane is cut out lengthwise and 
divided into at least 20 gel slices. Each gel 
slice is placed in a separate tube.
6. Each gel slice is destained in 100µl of 
destaining solution (25mM ammonium 
bicarbonate in 50% acetonitrile) for 20-
30min. This step is repeated until the 
gel slice becomes completely destained 
(usually 3-4 times). Alternatively, gel slices 
can be destained overnight at 4oC.
7. Each gel slice is dehydrated in 100µl of 
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100% acetonitrile for 5-10min at room 
temperature. The plug become hard and 
white at this step.
8. The gel slices are reduced with freshly 
prepared 6.5mM DTT solution for 45-
60min at 37oC.
9. The solution is discarded and proteins in 
the gel slices are alkylated by adding 100µl 
of 54 mM iodoacetamide solution and 
incubating for 60min at room temperature 
in the dark.
10. The solution is discarded and the gel slices 
are washed in 100µl of gel slice destaining 
solution for 15 min at room temperature. 
This step is repeated once more.
11. The washing solution is discarded and 
the gel slices are dried in 100µl of 100% 
acetonitrile for 10min. The solution is again 
discarded and the gel slices are dried at 
room temperature.
12. Proteins are in-gel digested in 15µl of 10 ng/
µl modified trypsin at (diluted from the 100x 
stock in 50 mM ammonium bicarbonate) 
for 30 min on ice (see Note 20). 15 µl of 
50 mM ammonium bicarbonate are added 
to the samples followed by overnight 
incubation at 37°C.
13. Samples are equilibrated to room 
temperature. 30µl of 2% acetonitrile in 
0.1% formic acid are added to the samples 
and incubated at room temperature for 15 
min. The samples are then vortexed briefly 
and sonicated for 1 minute. 
14. The supernatants are collected in separate 
tubes and the remaining gel slices are 
treated with 30µl of 50% acetonitrile 
in 0.1% formic acid and incubated as 
above. Samples are again vortexed and 
sonicated as above and the supernatants 
are collected and pooled with the 
corresponding supernatants from step 14.
15. The samples are vacuum dried in a vacuum 
centrifuge for 45-60 minutes until they are 
dry.
16. The eluted peptides are now ready for 
analysis by mass spectrometry.
Figure 4A shows an example of a preparative 
binding of nuclear extracts from MEL cells 
expressing biotinylated GATA-1 (lane 3) and 
control extracts from cells expressing the BirA 
biotin ligase only (lane 5). The control binding 
experiment shows that background consists of 
a few strongly stained bands against a backdrop 
of more faintly staining bands. Analysis by 
mass spectrometry identified the strongly 
staining bands as corresponding to naturally 
biotinylated proteins such as carboxylases 
(1). The bulk of the remaining background 
proteins corresponded to abundant nuclear 
proteins such as splicing factors, proteins 
involved in ribosome biogenesis etc. (Figure 
4B). The low background binding (<1% of the 
total) of transcription factors and chromatin 
remodeling and modification proteins is of 
note (Figure 4B). By contrast, analysis of the 
GATA-1 purification gel slice shows a large 
increase in the binding of transcription factors 
and chromatin remodeling and modification 
proteins, thus indicating specific co-purification 
with biotin-tagged GATA-1 (Figure 4C) (6). 
A number of these interactions have been 
validated by independent immunoprecipitation 
experiments using nuclear extracts from non-
transfected MEL cells and shown to include 
essential hematopoietic transcription factors 
such as FOG-1, TAL-1 and Gfi-1b in addition 
to chromatin remodeling complexes such as 
MeCP1 and WCRF/ACF (6). In addition, the 
analysis of the GATA-1 binding experiment 
identified abundant chromatin associated 
proteins, such as topoisomerases, as 
background due to their indirect co-purification 
with GATA-1 by virtue of their association with 
chromatin. Thus, we have defined background 
in these experiments as consisting primarily 
of naturally biotinylated proteins, abundant 
nuclear proteins associated with RNA 
metabolism and ribosome biogenesis and 
abundant chromatin associated proteins that 
are indirectly co-purified with chromatin-bound 
transcription factors.
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4. Future prospects
We have shown that biotinylation 
tagging is highly efficient in cultured cells 
(Figure 1) and transgenic mice (1) and we 
have used this approach to identify a number 
of different complexes formed by the essential 
hematopoietic transcription factor GATA-1 (6). 
Due to its efficiency and ease of application, 
biotinylation tagging offers the prospect of 
rapidly expanding the characterization of 
transcription factor complexes. For example, 
the biotinylation tagging of the hematopoietic 
transcription factor partners of GATA-1 and the 
characterization of their protein complexes will 
lead to the rapid elucidation of the distinct and 
overlapping transcriptional networks these 
factors regulate in hematopoiesis. Similarly, 
the biotinylation tagging of chromatin co-
factors will lead to a better understanding 
of their interactions with tissue-specific 
transcription factors and the molecular basis 
of their functions (i.e. chromatin remodeling 
and modification in activation and repression). 
Furthermore, efforts in reducing the 
background along the lines described here (i.e. 
a pre-purification steps such as gel filtration 
or the use of protease cleavage) will help in 
further expanding the utility of biotinylation 
tagging, for example in preserving the native 
properties of complexes or in determining 
stoichiometries. The utility of biotinylation 
tagging will be further increased through the 
development of additional tools such as the 
recent derivation of a transgenic mouse strain 
that expresses BirA ubiquitously in all tissues 
(8), or the construction of a codon-optimized 
version of BirA for the efficient expression in 
mammalian cells (9). The recent description of 
the biotinylation of cell surface proteins (10) 
should also serve to expand the utility of this 
approach. Lastly, it should be noted that in vivo 
biotinylation tagging can also be employed (e.g. 
instead of antibodies) in all other applications 
involving an affinity purification or detection 
step, such as immunofluorescence (1), 
immunoprecipitations (1, 11) and chromatin 
immnoprecipitation (ChIP) assays (1, 12).
5. Notes
1. We routinely screen 12-20 stable 
transfected MEL cell clones by SDS-PAGE 
in order to select a clone that expresses 
the tagged protein at no more than 50% 
of the expression level of the endogenous 
protein. This is in order to ensure that the 
physiological interactions and functions 
of the protein of interest are not disturbed 
as a result of the overexpression of the 
tagged protein.
2. The specific lysis conditions will depend 
on the make of blender employed. It 
is recommended that conditions are 
optimized for cell density, length of lysis 
time and speed setting of the blender.
3. The final salt concentration is critical for 
the extraction of nuclear proteins. 
4. We routinely obtain around 100 mg of 
nuclear extract from 4 liters of MEL cell 
culture at a density of 2x106 cells/ml.
5. There are a large variety of column 
matrices commercially available for 
gel filtration, with each matrix having 
different optimal separation ranges and 
physicochemical properties (e.g. ability to 
withstand high pressure in the column). 
Thus, the choice of matrix will depend 
on the desired range of fractionation 
and the liquid chromatography operating 
system available to the user (e.g. FPLC or 
HPLC).
6. Users must also refer to the manufacturer’s 
instructions and training for use of the 
column and the FPLC apparatus.
7. The resolution efficiency of new columns, 
expressed as the number of theoretical 
plates per meter of column under normal 
running conditions, should be tested first. 
This can be done by injecting a sample 
of acetone (5mg/mL) in ddH2O water. 
Indicative efficiency for the analytical grade 
column is 11100 theoretical plates/m.
8. While loading the extract, care must be 
taken that no air bubbles enter the loop. Air 
bubbles as well as cell debris can damage 
the column bed.
9. Once a new column is installed, the void 
(V0) volume is determined by the peak of 
elution of dextran blue. In order to further 
calibrate the column, a mixture of at least 
two proteins of known molecular weight 
should also be injected. Recommended 
standards: bovine serum albumin 
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(67kDa), thyroglobulin (669kDa), aldolase 
(158kDa).
10. If there is any suspicion that the column 
bed has been damaged, it is best to run 
the calibration standards again.
11. If the blue color of the sample loading 
buffer turns yellow, it is due to the protein 
sample being acidic which will also affect 
migration of the sample during SDS-PAGE. 
A few microliters of Tris-HCl pH9.0 are 
usually sufficient to neutralize the sample.
12. To avoid pressure build up the run can be 
started at a flow rate of 1ml/min. It is also 
better to inject the sample with the lower 
flow rate.
13. The concentration of 150mM KCl is critical 
for the efficient binding of biotinylated 
proteins to streptavidin beads. We have 
found that even modest increases in salt 
concentration severely affect binding 
efficiency.
14. Protease cleavage also works well with 
shorter incubation times (5-30min) and a 
broader temperature range (4-37oC).
15. Avoid handling membrane directly, use 
gloves and forceps.
16. Under these transfer conditions, the 
temperature of the buffer can rise 
significantly and frothing may occur. This 
does not affect the transfer.
17. The gel can be stained after blotting in 
order to visualize residual proteins as a 
test for the efficiency of transfer as well 
as an indication of the amount of protein 
loaded per lane.
18. The primary antibody can be stored 
and re-used. Sodium azide is added to 
the antibody solution to a 0.02% final 
concentration and stored at 40C (sodium 
azide stock: 10% w/v in ddH2O. Caution: 
sodium azide is highly toxic.
19. In order to reduce the risk of contaminating 
the samples for mass spectrometry, 
particularly with keratins, work is carried 
out in a hood wearing double gloves, a lab 
coat and always using sterile plasticware.
20. The volume of trypsin solution added will 
depend on the size of the gel slice. The 
volumes given above are for appr. 4x2mm 
gel slices. At this stage, gel slices should 
swell and little solution should remain 
visible.
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Figure 1: (A) Scheme for the specific biotinylation of tagged GATA-1 by BirA biotin ligase 
in mouse erythroleukemic (MEL) cells.
The sequence of the 23aa peptide tag fused to the N-terminus of GATA-1 is shown. The asterisk indicates 
the lysine residue that becomes specifically biotinylated by BirA. Speckled boxes indicate the positions of 
the two GATA-1 Zinc-fingers. (B) Biotinylation of tagged GATA-1 in MEL cells. Left panel: Western blot with 
an anti-GATA-1antibody to detect endogenous and tagged GATA-1 proteins. Right panel: Western blot 
of the same extracts with streptavidin-HRP conjugate to detect biotinylated GATA-1. Biotinylated GATA-1 
(asterisk) is clearly visible in the right panel only in the lane of the double transfected cells. (C) Efficiency of 
GATA-1 biotinylation and binding to streptavidin beads. Left panel: Western blot using anti-GATA-1 antibody 
to detect binding of tagged GATA-1 to streptavidin beads Input and unbound material are shown in lanes 
1 and 3. Right panel: the same filter stripped and re-probed with streptavidin-HRP to detect the binding of 
biotinylated GATA-1 to streptavidin beads (lane 5). Lane 6 shows that very little tagged GATA-1 remains 
unbound by streptavidin. In: Input (nuclear extract); El: Eluted material; Un: Unbound material. Reproduced 
with permission from (1). Copyright (2003) National Academy of Sciences, USA.
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Figure 3: TEV protease cleavage of bioGATA-2 bound to streptavidin beads.
Panel (A): sequence and translation of the shorter biotinylation tag and the TEV protease cleavage 
site. Panels (B) and (C): Lane 1: nuclear extract from MEL cells expressing tagged GATA-2 (there is no 
endogenous GATA-2 expressed in MEL cells). Lane 2: biotinylated GATA-2 (bioGATA-2) bound to the beads. 
Lane 3: TEV protease cleavage of bound GATA-2. (A) Detection with anti-GATA-2 antibody. (B) Detection of 
the blot shown in panel A with streptavidin-HRP. TEV-cleavage of bioGATA-2 results in a downshift in size 
of the protein and loss of the biotin-tag (compare lanes 2 and 3 in panels A and B, respectively). Remaining 
uncleaved bioGATA-2 is indicated with an asterisk in panel B.
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Figure 4: (A) Colloidal Blue-stained gel of a binding experiment of crude nuclear extracts 
to streptavidin beads.
Lane 1: Marker (M). Lane 2: input nuclear extract from tagged GATA-1/BirA double transfected cells. Lane 3: 
proteins eluted after binding to streptavidin beads. Lane 4: input nuclear extract from BirA transfected cells. 
Lane 5: proteins eluted after binding to streptavidin beads. Arrow in lane 3 indicates protein band containing 
biotinylated GATA-1, as determined by mass spectrometry. (B) Classification according to Gene Ontology 
criteria of proteins identified by mass spectrometry from the control experiment using extracts from cells 
expressing BirA (around 500 peptide sequences were identified). This represents the background binding. 
(C) Classification according to Gene Ontology criteria of proteins identified by mass spectrometry using 
extracts from cells expressing biotin tagged GATA-1 (more than 1000 peptide sequences were identified). A 
significant increase in the identification of chromatin remodelling proteins and transcription factors is clearly 
notable compared to the control experiment shown in (B). Fig. 4A reproduced with permission from (1). 
Copyright (2003) National Academy of Sciences, USA.
Summary
Samenvatting
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We have adapted an in vivo biotinylation tagging method in mammalian cells in order to 
characterize interacting partners of the essential transcription factors GATA-1 and Ldb-1, with the 
aim of understanding the molecular mechanisms that these proteins regulate in erythroid cells. 
Using GATA-1 as a paradigm, we showed that biotin-tagged proteins can be pulled-down in a 
single purification step by binding to streptavidin beads, and their interacting partners identified 
by mass spectrometry. The biotinylation tagging technique was shown to be highly specific and 
very efficient as almost 100% of the tagged protein was biotinylated in mouse erythroleukemic 
(MEL) cells. Importantly, this method was also shown to work efficiently in transgenic mice. The 
identification of GATA-1 and of Ldb-1/Tal-1 partners led to the characterization of large protein 
complexes, containing transcription factors and/or co-factors, which carry out activating or 
repressing functions. For both transcription factors we identified a number of previously known 
partners, thus validating our purification approach, as well as novel interacting partners, such as 
the MeCP1 and ACF/WCRF complexes and the Gfi-1b transcription factor for GATA-1, or Eto-2 
and cdk9 for Ldb1. Significantly, we showed GATA-1 to be part of at least five distinct complexes 
in differentiated MEL cells, all identified through the single step binding to streptavidin.
 More specifically, GATA-1 interacts with the repressive MeCP1 complex, the interaction 
being mediated by FOG-1, a well-known GATA-1 co-factor. The GATA-1/FOG-1/MeCP1 
complex was shown to carry histone deacetylase activity and to repress transcriptional activity 
in a transfection assay. Importantly, we showed that the GATA-2 gene, which is essential for 
early stages of hematopoiesis, is specifically repressed by the GATA-1/FOG-1/MeCP1 complex 
in differentiating erythroid cells. The promoters of the eosinophilic MBP and IL-5Rα genes 
or of the myeloid PU.1 gene also showed enrichment for a similar GATA-1/FOG-1/MeCP1 
complex binding. Interestingly, in the case of the MBP gene, we found GATA-1 binding to the 
same promoter in eosinophils, where it is known to act as an activator together with C/EBP 
proteins. Taken together, these data suggest a role for the GATA-1/FOG-1/MeCP1 complex in 
the repression of early hematopoietic potential or of alternative cell fates in terminal erythroid 
differentiation. 
 GATA-1 forms a second complex with (at least) Gfi-1b, which was found to bind weakly 
to promoters of genes involved in cell proliferation, such as c-Myc and c-Myb. Microarray 
expression analysis of differentiating erythroid cells expressing an inducible form of GATA-1 has 
shown these genes to be repressed upon induction of GATA-1 expression, thus linking GATA-1 
to cell cycle regulation in erythroid differentiation(Welch et al., 2004). A third GATA-1 complex 
involves the known association with the TAL-1 and Ldb1 transcription factors. This complex 
binds stably to the enhancer of the active EKLF erythroid gene, which contains E-box and GATA 
motifs. Finally, we also show GATA-1 to form a fourth distinct complex with FOG-1 independently 
of MeCP1 and a fifth complex with the chromatin remodeling ACF/WCRF complex.
In addition, we also purified from non-induced and induced MEL cells the complex 
for Ldb1, which is a ubiquitously expressed partner of the hematopoietic GATA-1 and TAL-1 
transcription factors. Interestingly, purification of Ldb-1 in differentiated MEL cells revealed the 
presence of the pentameric complex that has been previously described and which included 
GATA-1, TAL-1, Ldb1, E2A and Lmo2. Novel partners were also identified and included 
Eto-2, Cdk9 and Lmo-4. Our work also suggested that Eto-2 provides a repressive role for 
TAL-1 target genes, and that repression is relieved by changes in the ratio of Eto-2/Ldb1 in the 
complex during erythroid differentiation. Ldb1 was also shown to form complexes independently 
of GATA-1. These data suggest that GATA-1 and Ldb1, in addition to their common functions 
via the complex GATA-1/TAL-1/Ldb-1, also carry different functions independently of each other 
in erythropoiesis. 
Our data on GATA-1 and Ldb1 document the functional importance of transcription 
factors, co-factors and chromatin remodeling/modifying complexes and how antagonistic active 
or repressive functions of a single transcription factor can take place at the same time in the 
cell.
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We hebben een in vivo biotinylatie tagging methode geschikt gemaakt  voor 
zoogdiercellen om partners te kunnen karakteriseren van de essentiële transcriptiefactoren 
GATA-1 en Ldb-1, met het doel de moleculaire mechanismen te begrijpen die deze eiwitten in 
erytroïde cellen reguleren.We gebruiken GATA-1 als model en laten zien  dat eiwitten met een 
biotine tag in één stap uit de oplossing kunnen worden gevist door binding aan streptavidinbollen 
en dat de samenwerkende partners door middel van massaspectometrie geanalyseerd kunnen 
worden. De biotinylatie tagging methode blijkt zeer specifiek en efficiënt want bijna 100% van de 
getagde eiwitten  werd gebiotinyleerd in MEL (mouse erythro leukemic) cellen . Bovendien  werkt 
deze methode ook efficient in transgene muizen. De identificatie van de GATA-1 en Ldb-1/Tal-1 
partners heeft geleid tot de karakterisering van van grote eiwitcomplexen met transcriptiefactoren 
en/of co-factoren, die activerend of represserend werken. Voor beide transcriptiefactoren hebben 
we een aantal bekende partners gevonden, hetgeen onze zuiveringsmethode valideert, alsook 
onbekende partners zoals de MeCP1 en ACF/WCRF complexen en de Gfi-1b trancriptiefactor 
voor GATA-1 , of Eto-2 en cdk9 voor Ldb-1. Het is opvallend dat we laten zien dat GATA-1 
tenminste deel uitmaakt van vijf verschillende complexen , allemaal geïdentificeerd  door een 
enkele binding aan streptavidinebollen.
 Bij nadere beschouwing zien we dat GATA-1 een  interactie aangaat met het repressieve 
MeCP-1 complex, bewerkstelligd door FOG-1, een bekende cofactor  van GATA-1. Het GATA-
1/FOG-1/MeCP1 complex vertoont histon deacetylase activiteit en remt transcriptie in een 
transfectieproef . Bovendien laten we zien dat de expressie van het GATA-2 gen , belangrijk 
voor de vroege stadia van hematopoiese, specifiek wordt onderdrukt door het GATA-1/ 
FOG-1/MeCP1 complex in differentiërende erytroïde cellen. De promoters van de eosinofiele 
genen MBP en IL-5R ∝ of van het myoloïde PU.1 gen laten ook verrijking zien van een soortgelijke 
GATA-1/FOG-1/MeCP1 complex binding. Interessant is dat we, in het geval van het MBP gen, 
GATA-1 binding vinden aan dezelfde promoter  in eosinofiele cellen, waar het samen met 
C/EBP eiwitten een activator is. Samengenomen suggereren deze data een rol voor het GATA-1/
FOG-1/MeCP1 complex in de repressie van vroeg hematopoietisch potentieel of in alternatieve 
bestemmingen van cellen in terminale erytroïde differentiatie.
 GATA-1 vormt een tweede complex met (tenminste) Gfi-1b, dat zwak bindt aan 
promoters van genen die betrokken zijn bij celproliferatie, zoals c-Myc en c-Myb. Microarray 
expressie analyse van differentiërende erytroïde cellen die een induceerbare vorm van GATA-1 
tot expressie brengen, toont  repressie van deze genen aan na inductie van GATA-1 expressie. 
Dit laat zien dat  GATA-1 een functie heeft bij de regulatie van de celcyclus in erytroïde 
differentiatie(Welch et al., 2004). Bij een derde GATA-1 complex  is er sprake van betrokkenheid 
met de transcriptie factoren TAL-1 en Ldb-1. Dit complex bind stabiel aan de enhancer van het 
actieve erytroïde gen EKLF, die een E-box en GATA motieven bevat. Tenslotte tonen we een 
,ander, vierde complex samen met FOG-1 maar onafhankelijk van MeCP1 aan en een vijfde 
complex samen met het chromatin remodeling  complex ACF/WCRF.
 Tevens hebben we, uit niet geïnduceerde en geïnduceerde MEL cellen, het complex 
voor Ldb-1  gezuiverd . Dit is een alomtegenwoordige partner van de hematopoiëtische 
transcriptiefactoren GATA-1 en TAL-1. De zuivering van Ldb-1 uit gedifferentiëerde MEL cellen 
laat het pentamere complex zien met GATA-1, TAL-1, Ldb-1, E2A en Lmo-4. Bovendien werden 
nieuwe partners gevonden  waaronder  Eto-2, Cdk9 and Lmo-4. Ons werk suggereert dat Eto-2 
een negatieve functie heeft  voor genen die een target voor TAL-1 zijn, en dat repressie wordt 
opgeheven door veranderingen in de verhouding tussen Eto-2 en Lbd-1 in het complex tijdens 
de erytroïde differentiatie. We laten ook zien dat Ldb-1 complexen vormt waarbij GATA-niet 
betrokken is. Deze resultaten suggereren dat GATA-1 en Ldb-1, behalve  hun gezamenlijke 
functie via het complex GATA-1/TAL-1/Ldb-1, onafhankelijk van elkaar ook andere functies 
hebben in erythropoiëse.
       Onze gegevens over GATA-1 en Lbd-1 bevestigen het functionele belang van transcriptie 
factoren, co-factoren en chromatin remodeling/modifying complexen en hoe tegenstrijdige 
activerende of repressieve functies van een  enkele transcriptiefactor gelijktijdig in de cel kunnen 
plaatsvinden.
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